



OFFICE OF THE CHANCELLOR

SCHOOL OF ALLIED HEALTH PROFESSIONS
SCHOOL OF DENTISTRY
SCHOOL OF GRADUATE STUDIES
SCHOOL OF NURSING
SCHOOL OF MEDICINE IN NEW ORLEANS
SCHOOL OF PUBLIC HEALTH

March 26, 2013

Dr. William L. Jenkins
Interim President
Louisiana State University System
3810 West Lakeshore Drive
Baton Rouge, LA 70808

Dear Dr. Jenkins:

Please find enclosed the LSU Health Sciences Center at New Orleans' 2013 Granting Resources and Autonomy for Diplomas (GRAD) Act Annual Report. The narratives and attachments submitted support the data presented in the GRAD Act online reporting system. I am in full support of the information and statistics provided to the Board of Regents.

Should you have any further questions regarding this data, please contact Dr. Joseph Moerschbaecher, Vice Chancellor for Academic Affairs, at 504-568-4804.

Sincerely,

A handwritten signature in cursive script that reads "L. Hollier, MD".

Larry H. Hollier, MD
Chancellor

cc: Joseph M. Moerschbaecher, III, Ph.D., Vice Chancellor for Academic Affairs

Enclosures

**LSU HEALTH SCIENCES CENTER—NEW ORLEANS
2013 GRAD ACT ANNUAL REPORT
TABLE OF CONTENTS**

<u>SUBJECT</u>	<u>PAGE(S)</u>
Performance Objective 1: Student Success	1-5
1.a. Achieve Graduation Rates & Productivity Consistent with Peers	1
a.i. 1 st to 2 nd Year Retention Rate	1
a.iv. Same Institution Graduation Rates	2
a.x. Median Professional School Entrance Exam	2
1.b. Increase Percentage of Program Completers	2-3
1.c. Develop High School Partnerships (N/A)	3
1.d. Increase Licensure Exam Passage Rates	4-5
 Performance Objective 2: Articulation & Transfer (N/A)	 6
 Performance Objective 3: Workforce & Economic Development	 7-12
3.a. Eliminate Low-Completer Programs	7-8
3.b. Increase Use of Technology for Distance Learning	8-9
3.c. Increase Research Productivity in Key Economic Development Industries	9-11
3.d. Increase Number of Students Placed in Jobs & Post-Graduate Training	11-12
 Performance Objective 4: Institutional Efficiency & Accountability	 13-14
4.a. Eliminate Remedial Education Course Offerings (N/A)	13
4.b. Eliminate Associate Degree Programs (N/A)	13
4.c. Adhere to a Schedule to Increase Non-Resident Tuition Amounts	13-14
4.d. Designate Centers of Excellence	14
 Section 5	 15-19
a. Number of Students by Classification	15
b. Number of Instructional Staff Members	15
c. Average Class Student-to-Instructor Ratio	15
d. Average Number of Students per Instructor	15

e. Number of Non-Instructional Staff Members in LSUHSC-NO Schools.....	15-16
f. Number of Staff in Administrative Areas.....	16
g. Organizational Chart.....	Attachment 2
h. Salaries of All Personnel Identified in Organizational Chart.....	16-19
i. Cost Performance Analysis.....	19
i. Total Operating Budget.....	19
ii. Average Yearly Cost of Attendance (N/A).....	19
iii. Average Time to Degree Completion (N/A).....	19
iv. Average Cost per Degree Awarded (N/A).....	19
v. Average Cost per Non-Completer (N/A).....	19
vi. All Institution Expenditures for Most Recent Academic Year.....	19

Attachments

(1) List of Active Research & Development Awards/Contracts.....	11 pages
(2) LSUHSC-NO Organizational Chart.....	1 page

**LSU HEALTH SCIENCES CENTER—NEW ORLEANS
2013 GRAD ACT ANNUAL REPORT
PERFORMANCE OBJECTIVE NARRATIVES**

1. STUDENT SUCCESS

a. Implement policies established by the institution's management board to achieve cohort graduation rate and graduation productivity goals that are consistent with institutional peers.

LSU Health Sciences Center—New Orleans (LSUHSC-NO) utilizes the LSU System Performance Metrics Process (implemented in January 2010), which provides campus leadership and the Board of Supervisors a mechanism for evaluating annual institutional performance. Metrics data allow institutions to discuss descriptive metrics and performance measures within the context of their mission, including, amongst others, measures related to retention, graduation, licensure, and pass rates, degrees, and credentialing. These metrics are collected and reported on an annual basis, and they represent a significant analysis and measuring tool for the Louisiana State University System and its institutions.

a.i. 1st to 2nd Year Retention Rate:

LSUHSC-NO School	Baseline (2008-2009)	2009-2010	2010-2011	2011-2012
School of Allied Health Professions	97% (159/164)	95% (156/164)	87% (143/165)	95% (161/170)
School of Dentistry—Dentistry	97% (58/60)	98% (64/65)	99% (64/65)	99% (64/65)
School of Dentistry—Dental Hygiene	100% (41/41)	100% (41/41)	98% (41/42)	94% (34/36)
School of Dentistry—Dental Lab Tech*	100% (4/4)**	100% (4/4)**	91% (10/11)**	83% (5/6)**
School of Graduate Studies*	89% (17/19)	89% (17/19)	75% (12/16)	85% (11/13)*
School of Medicine	99% (187/189)	97% (183/188)	97% (195/202)	95% (188/198)
School of Nursing	93% (310/334)	82% (235/286)	91% (301/331)	89% (307/346)
School of Public Health	100% (24/24)	94% (22/24)	92% (24/26)	98% (42/43)

*** NOTE: LSUHSC-NO requests a waiver in benchmarking of Schools with cohorts of 25 or fewer students, as the smallest of numeric fluctuations can cause misleading percentile drops.**

**** Dental Lab Technology program numbers were reported for the (since discontinued) Bachelor's degree program in 08-09 and 09-10, and for the Associate's degree program in 10-11 and 11-12.**

All Schools in the HSC-NO met or exceeded GRAD Act Year 3 retention goals, with the exception of 3 programs. The Dental Hygiene (DHY) program experienced a 4% decline in retention, as two students were excused from the program for academic reasons; this, however, reflects a large percentage decline due to small cohort numbers. Prior to Fall 2010 the Baton Rouge DHY program was discontinued, which decreased the overall DHY cohort from 42 to 36 (30 New Orleans students and 6 Lafayette students). The Dental Lab Technology (DLT) program saw an 8% decline in retention from Year 2 to Year 3; however, this was caused by the loss of only one student, as the cohort is so small. Overall cohort numbers are down due to the DLT BS program being discontinued by the Louisiana Board of Regents, with the last students accepted into the BS program in 2009-2010/graduating in 2012. The School of Graduate Studies continues to see a decline in student enrollment and completion due to ongoing budget cuts, which have decreased the amount of money available for stipend support and tuition waivers. It is expected that the number of enrollees and completers in this School will continue to wane in the future, as sustained decreases in funding have resulted in fewer spaces becoming available for interested applicants, who rely heavily on this funding to continue their studies. **For these reasons, LSUHSC-NO again requests a waiver in benchmarking of Schools with a cohort at or below 25 students.**

a.iv. Same Institution Graduation Rate:

During the 2011-2012 academic year, LSUHSC-NO’s same institution graduation rates fluctuated just slightly from Year 2 reporting, and all Schools met or exceeded Year 3 GRAD Act targets.

LSUHSC-NO School	Baseline (2008-2009)	2009-2010	2010-2011	2011-2012
School of Allied Health Professions	93% (86/92)	92% (85/92)	94% (143/152)	93% (152/164)
School of Dentistry—Dentistry	95% (57/60)	100% (60/60)	100% (53/53)	98% (59/60)
School of Dentistry—Dental Hygiene	100% (40/40)	100% (40/40)	100% (40/40)	98% (41/42)
School of Dentistry—Dental Lab Tech	100% (7/7)	100% (7/7)	100% (9/9)	100% (10/10)
School of Graduate Studies*	N/A	N/A	N/A	N/A*
School of Medicine	94% (166/176)	95% (167/176)	95% (164/173)	96% (171/179)
School of Nursing*	N/A	N/A	N/A	N/A*
School of Public Health	91% (11/12)	83% (10/12)	96% (24/25)	100% (24/24)

* Due to small class sizes and various acceptable lengths of study, graduation rates for the Schools of Graduate Studies and Nursing cannot be calculated.

a.x. Median Professional School Entrance Exam:

Each school within LSUHSC-NO establishes its own requirements for professional school entrance exams. All applicants to the School of Dentistry must take the Dental Admissions Test (DAT) sponsored by the American Dental Association, with a minimum acceptable score of 16. Applicants to the School of Nursing’s BSN program are required to take the HESI Admissions Assessment Exam A from Evolve Testing & Remediation; a minimum score is not published. The School of Public Health utilizes the GRE, which changed its format and scoring in the spring of 2011; the School currently accepts students based on ranking, not raw scores.

LSUHSC-NO School	Baseline (2008-2009)	2009-2010	2010-2011	2011-2012
School of Dentistry—Dentistry	18.9	18.9	18.9	18.9
School of Nursing*	80.25	80.25	83.3*	83.9*
School of Public Health**	1078	1115	1092	297**

* SoN Baseline & Year 1 scores were from the TEAS entrance exam; the entrance exam changed in Fall 2010 to HESI A2.

** NOTE: ETS changed its GRE scoring scale from 1606 maximum in the old test to 346 maximum in new test.

b. Increase the percentage of program completers at all levels each year.

<i>Percent change in completers by award level, from baseline year</i>				
LSUHSC-NO School	2008-2009	2009-2010	2010-2011	2011-2012
School of Allied Health Professions				
BACHELOR’S	Baseline: 30	+13% (34)	+27% (38)	+37% (41)
MASTER’S	Baseline: 47	+32% (62)	+43% (67)	+83% (86)
PROFESSIONAL	Baseline: 23	+52% (35)	+104% (47)	+126% (52)
School of Dentistry—Dentistry				
PROFESSIONAL	Baseline: 59	+2% (60)	-10% (53)	-2% (58)
School of Dentistry—Dental Hygiene				
BACHELOR’S	Baseline: 41	+5% (43)	-2% (40)	-17% (34)
School of Dentistry—Dental Lab Tech				
ASSOCIATE’S	Baseline: 4	+/-0% (4)	+175% (11)	+25% (5)
School of Graduate Studies**				
MASTER’S	Baseline: 2	+/-0% (2)	N/A*	-50% (1)*
DOCTORAL	Baseline: 31	-23% (24)	-39% (19)*	-52% (15)*

School of Medicine PROFESSIONAL	Baseline: 187	+2% (190)	-2% (184)	-4% (179)
School of Nursing BACHELOR'S	Baseline: 176	+/-0% (176)	+11% (196)	+26% (222)
MASTER'S	Baseline: 51	+/-0% (51)	+45% (74)	+86% (95)
DOCTORAL	Baseline: 2	+/-0% (2)	+/-0% (2)	+/-0% (2)
School of Public Health** MASTER'S	Baseline: 29	-3% (28)	-10% (26)	-10% (26)
DOCTORAL	Baseline: 3	-100% (0)	-100% (0)	-66% (1)

* NOTE: In 2011, the Biostatistics and Epidemiology programs (formerly housed in the School of Graduate Studies) were moved to the School of Public Health; additionally, all other existing Graduate School MS programs were terminated by the Board of Regents. A proposal is being prepared to establish a single MS/Biomedical Sciences program to fill this gap.

** In reviewing figures for the 2013 GRAD Act report, data for the Schools of Graduate Studies and Public Health was discovered to have been reported inaccurately in prior reports; the data below shows accurate completer rates. Please note that the School of Public Health did not graduate its first Doctoral candidate until 2012.

	2008-2009	2009-2010	2010-2011	2011-2012
School of Graduate Studies MASTER'S	Baseline: 3	-33% (2)	N/A	-66% (1)
DOCTORAL	Baseline: 18	+33% (24)	+11% (20)	-17% (15)
School of Public Health MASTER'S	Baseline: 30	-3% (29)	-17% (25)	-13% (26)
DOCTORAL	Baseline: 0	+/-0% (0)	+/-0% (0)	+100% (1)

In the School of Allied Health Professions, the number of completers has increased at all levels over the past three years. Likewise, the School of Nursing saw another substantial increase in Bachelor's and Master's level completers, and DNS completers remained consistent. Professional completers in the School of Dentistry (DDS) increased from Year 2 (53) to Year 3 (58), but fell 2% below the baseline of 59 in 2011-2012. Because the DDS is a professional degree program, this attrition is due to students needing to delay or discontinue studies for a number of personal and academic situations. Completers in the Dental Hygiene program declined 17% below baseline targets (34/41); this can be attributed to discontinuation of the Baton Rouge DHY program in 2010, which led to a decline in overall program acceptances from 42 to 36 annually. Year 3 completers in the Dental Lab Tech program are 25% over baseline. The completion rate in the School of Graduate Studies has declined over the past three years, as predicted, due to budget cuts that have reduced the amount of funding available for student stipend support and tuition waivers. The School of Medicine graduated 179 students in Year 3, down slightly from prior years due to unusually poor performance by the class on the USMLE Step 2CS exam. Because a number of students were required to repeat the clinical skills (CS) component it placed them off sequence, and this is reflected as a lower completer rate for the academic year. To improve student performance on this component of the licensure exam, the Office of Undergraduate Medical Education, along with support from the Dean, has instituted a training program that has all third year medical students "practicing" patient interviews and physicals using actor patients (objective structured clinical examinations [OSCEs]). Though the number of completers in the School of Public Health was down by just 3 from the baseline year, there was a large percentage decline due to small cohort numbers. MPH graduation numbers were down because fewer students applied to the MPH program, while more applied to the PhD program. Due to subsequent increased enrollment, however, the School expects to graduate 35 MPH, 1 MS, and 4 PhD students in Spring 2013.

c. Develop partnerships with high schools to prepare students for postsecondary education.

N/A

d. Increase passage rates on licensure and certification exams and workforce foundational skills.

Each LSUHSC-NO School sets its own standards for state and national licensure/certification exams.

- The School of Allied Health Professions requires passage of national certification exams for state licensure.
- The School of Dentistry requires all students to challenge the National Board Dental Examination, Part II prior to graduation.
- A certification/licensure exam does not exist for students in the School of Graduate Studies.
- The School of Medicine requires passage of the USMLE prior to graduation.
- Students of the School of Nursing’s undergraduate program must have graduated prior to sitting for their licensure exams.
- Certification is not mandatory for graduates of the School of Public Health, as it is not available to non-CEPH-accredited school graduates and is not required by U.S. Governmental Agencies.

Passage rates, in addition to those included on the GRAD Act online reporting system, are listed below. All Schools met or exceeded established GRAD Act benchmarks.

SCHOOL OF ALLIED HEALTH PROFESSIONS

Year/Program	School Pass Rate	Nat'l Pass Rate
2011-2012: Cardiopulmonary Science	100% (13/13)	68%
2011-2012: Audiology and Speech-Language Pathology	100% (34/34)	72%
2011-2012: Medical Technology	96% (25/26)	81%
2011-2012: Occupational Therapy	95% (35/37)	85%
2011-2012: Physical Therapy	100% (40/40)	N/A
2010-2011: Cardiopulmonary Science	92% (11/12)	67%
2010-2011: Audiology and Speech-Language Pathology	100% (30/30)	88%
2010-2011: Medical Technology	100% (25/25)	82%
2010-2011: Occupational Therapy	100% (31/31)	84%
2010-2011: Physical Therapy	100% (40/40)	88%
2009-2010: Cardiopulmonary Science	90% (9/10)	72%
2009-2010: Audiology and Speech-Language Pathology	100% (22/22)	86%
2009-2010: Medical Technology	95% (18/19)	82%
2009-2010: Occupational Therapy	97% (33/34)	78%
2009-2010: Physical Therapy	100% (29/29)	89%

SoD—PROGRAM IN DENTISTRY*

Percentage Pass Rate: National Board Dental Examination (written)

Year	School Pass Rate	Nat'l Pass Rate
2012	98% (58/59)	Data Unavailable
2011	100% (53/53)	Data Unavailable
2010	100% (60/60)	Data Unavailable

Percentage Pass Rate: Louisiana State Board of Dentistry Licensure Examination (clinical)

Year	School Pass Rate	Nat'l Pass Rate
2012	100% (59/59)	Data Unavailable
2011	98% (52/53)	Data Unavailable
2010	96% (55/57)	Data Unavailable

***NOTES:**

- If a student graduates without successfully completing the National Board Dental Examination (NBDE), Part II, and takes the exam after graduation, the School of Dentistry is not automatically notified of the student's status. The School is only notified if the student elects to have the scores forwarded to the School.
- The School of Dentistry has no report of any graduate(s) in the past eight years (2003-2011) taking a state clinical licensure exam and failing to attain licensure status. To attain clinical licensure, a graduate must have successfully completed the NDBE, Part II. Therefore, all students attaining clinical licensure in the past five years must have successfully completed the NDBE, Part II.
- Clinical exam information included in this report pertains to students/graduates taking the Louisiana State Board Dental Exam at the School of Dentistry. The School does not have results for students who test elsewhere.

SoD—PROGRAM IN DENTAL HYGIENE**Percentage Pass Rate: National Board DH Examination (Written)**

Year	School Pass Rate	Nat'l Pass Rate
2011-2012	100% (34/34)	Data Unavailable
2010-2011	100% (40/40)	Data Unavailable
2009-2010	100% (43/43)	Data Unavailable

Percentage Pass Rate: Dental Hygiene Clinical Licensure Examination (Practical)

Year	School Pass Rate	Nat'l Pass Rate
2011-2012	100% (34/34)	Data Unavailable
2010-2011	100% (40/40)	Data Unavailable
2009-2010	100% (43/43)	Data Unavailable

SCHOOL OF MEDICINE

Year/Test	School Pass Rate	Nat'l Pass Rate
2011-2012: USMLE Step 1*	94% (180/191)	95%
2011-2012: USMLE Step 2CK*	98% (177/180)	97%
2011-2012: USMLE Step 2CS*	90% (157/177)	97%
2010-2011: USMLE Step 1	98% (183/186)	95%
2010-2011: USMLE Step 2CK	99% (181/183)	99%
2010-2011: USMLE Step 2CS	100% (180/180)	99%
2009-2010: USMLE Step 1	95% (164/172)	94%
2009-2010: USMLE Step 2CK	95% (159/167)	96%
2009-2010: USMLE Step 2CS	94% (155/165)	97%

*NOTE: Using the alternative scoring method, the School of Medicine does meet GRAD Act targets, with a 2-year average passage rate of 96% for USMLE Step 1, 98.5% for Step 2CK, and 95% for Step 2CS; compared with the prior 3-year average of 93.3% for Step 1, 96% for Step 2CK, and 95% for Step 2CS. It should also be noted that Year 3 scores were submitted as an aggregate in the online reporting system, which differs from scores reported in years past. When combining 2012 annual exam scores, the SoM exceeds its average target of 93.6% with a combined passage rate of 94%.

SCHOOL OF NURSING

Year/Exam	School Pass Rate	Nat'l Pass Rate
2011-2012: NCLEX	98% (206/210)	87%
2010-2011: NCLEX	98% (175/178)	91%
2009-2010: NCLEX	97% (169/175)	90%

2. ARTICULATION AND TRANSFER—N/A TO LSUHSC

a. Phase in increased admission standards and other necessary policies by the end of the 2012 Fiscal Year in order to increase student retention and graduation rates.

N/A

b. Provide feedback to community colleges and technical college campuses on the performance of associate degree recipients enrolled at the institution.

N/A

c. Develop referral agreements with community colleges and technical college campuses to redirect students who fail to qualify for admission into the institution.

N/A

d. Demonstrate collaboration in implementing articulation and transfer requirements provided in R.S. 17:3161 through 3169.

N/A

3. WORKFORCE AND ECONOMIC DEVELOPMENT

a. Eliminate academic programs offerings that have low student completion rates as identified by the Board of Regents or are not aligned with current or strategic workforce needs of the state, region, or both as identified by the Louisiana Workforce Commission and Louisiana Economic Development.

LSUHSC-NO's review process for identification of low completer programs is similar in each of its six schools. A curriculum committee monitors content and completion rates in each program. The committee, in turn, reports its findings to the Associate Dean of Academic/Student Affairs, who in turn reports findings to the Dean. Any action proposed by the Dean (program initiation, modification, or termination) is brought to the School's Administrative Council for discussion. Following action by the Council and the Dean, the recommendation is forwarded to the Vice Chancellor for Academic Affairs, who in turn recommends action to the Chancellor.

Programs Modified/Eliminated in the 2011-2012 Academic Year

Programs Modified [1]	Nursing/Nursing Practice <i>(new program added)</i>
Programs Eliminated [0]	None

Activities Conducted to Identify/Modify/Initiate Programs Aligned with Strategic Workforce Needs, as defined by Regents utilizing Louisiana Workforce Commission and Louisiana Economic Development published forecasts:

LSUHSC modifies or initiates new programs in response to need and national requirements for accreditation. These efforts help to propel Louisiana's Health Care industry—one of the predominate economic development industries in the state. For example, the School of Allied Health Professions recently launched a new and much-anticipated Physician's Assistant program to meet current health workforce needs of the state. This program enrolled its first class in January 2013.

All new programs require a needs assessment as part of the application process and must be approved by both the LSU Board of Supervisors and Board of Regents. The Southern Association of Colleges and Schools (SACS) must also approve all new programs; new and ongoing programs producing health care providers must be approved by the appropriate accrediting body for that discipline; and these accrediting bodies must also approve changes in class size to ensure that national and regional manpower needs are met.

Additionally, the Dean of the School of Allied Health Professions and LSUHSC-NO's Director of External Relations regularly attend the Louisiana Health Works Meetings to ensure involvement in and receipt of information relative to workforce issues addressed by the statewide council. The Medical Education Commission, chaired by LSUHSC-NO's Dr. Perry Rigby and overseen by Chancellor Dr. Larry Hollier, not only provides a comprehensive view of Graduate Medical Education in Louisiana, but also tracks and plans for the interrelated workload and workforce production needs for health care providers in Louisiana. This group brings together medical education entities including LSU, Tulane, and Ochsner, among others.

Fall enrollment (2,777) for this reporting period was the largest historical enrollment at LSUHSC-NO.

Most Schools within the HSC-NO demonstrated an increase in overall enrollment this reporting period (Allied Health +2% annual, +32% baseline; Medicine +/0% annual, +7% baseline; Nursing +6% annual, +22% baseline; Public Health +15% annual, +26% baseline). Decreased annual enrollment in the School of Dentistry (-4% annual, +2% baseline) was caused by the discontinuation of the Baton Rouge Dental

Hygiene program and the Dental Lab Technician BS degree program. Enrollment decline in the School of Graduate Studies (-4% annual, -14% baseline) can be attributed to a continued decrease in funding available for tuition waivers and student stipends, on which students rely heavily to pursue their studies.

LSUHSC-NO School Enrollment	Baseline (2008-2009)	2009-2010	2010-2011	2011-2012
School of Allied Health Professions	296	351	385	392 (+2% annual, +32% baseline)
School of Dentistry	381	388	404	389 (-4% annual, +2% baseline)
School of Graduate Studies	114	113	102	98 (-4% annual, -14% baseline)
School of Medicine	714	745	763	763 (+/-0% annual, +7% baseline)
School of Nursing	846	958	975	1033 (+6% annual, +22% baseline)
School of Public Health	81	86	89	102 (+15% annual, +26% baseline)

b. Increase use of technology for distance learning to expand educational offerings.

	2008-2009	2009-2010	2010-2011	2011-2012
Number of course sections offered with 50%-99% instruction through distance education	30	30	31	2
Number of students enrolled in courses with 50%-99% instruction through distance education	12	12	40	46
Number of course sections offered through 100% distance education	0	0	0	0
Number of students enrolled in courses with 100% instruction through distance education	0	0	0	0

In prior reporting years, distance education courses were offered through a joint BS program in Dental Hygiene between LSUHSC-NO and the University of Louisiana—Lafayette (dual degree). This program no longer exists and is now administered solely by LSUHSC-NO, onsite; thus, the chart above reflects a significant decline in the number of course sections offered through distance education. Due to the hands-on, clinical learning requirements of most programs at LSUHSC-NO, the only courses offered through distance education in 2011-2012 were two elective courses in the School of Nursing—NURS 4367-Ethical and Legal Issues in Nursing and NURS 4348-Independent Study in Nursing: Disasters.

Outside of distance learning modules, several examples of online student assessment processes deserve mention. Students in the School of Dentistry are required to have a laptop preloaded with textbooks required for their current year of study. Exams and self-assessment guides are also administered via these laptops. In the School of Medicine, virtually all examinations in the first and second year are taken on student laptops over a secure network. Further, DXR, a diagnostic reasoning program, is used in the first two years and is available to students over the same network. This program assesses student performance in the evaluation of individual case studies. Lastly, technology plays a vital role in LSUHSC’s Learning Center, where computer-controlled patient simulators are used to monitor student skills in a

simulated clinical setting. Students from virtually all clinical programs are exposed to this technology in an interdisciplinary learning environment. These labs rank among the top three centers nationally in terms of this technology. More information about the Learning Center can be found at: http://www.medschool.LSUHSC.edu/learning_center.

c. Increase research productivity especially in key economic development industries and technology transfer at institutions to levels consistent with the institution's peers.

Performance Objectives/Elements/Measures		Baseline (2009-2010)	2010-2011	2011-2012
i.	Number of research/instructional faculty (FTE) at the institution during the reporting year	494.30*	573	545.22**
	Percent of above research/instructional faculty (FTE) at the institution holding active research and development grants/contracts	N/A	29.84%	27.88%
ii.	Percent of above research/instructional faculty (FTE) holding active research and development grants/contracts in Louisiana's key economic development industries.	N/A	29.84%	27.88%
iii.	Dollar amount of research and development expenditures, reporting annually, based on a five-year rolling average, by source (federal, industry, institution, other). Include all expenditures from S&E and non-S&E R&D grants/contracts as reported annually to the NSF.	N/A	\$59,613,963	\$58,029,758
iv.	Dollar amount of research and development expenditures in Louisiana's key economic development industries, reported annually, based on a five-year average. These data will be supplemented with the narrative report demonstrating how research activities align with Louisiana's key economic development industries.	N/A	\$59,613,963	\$58,029,758
vi.	Direct research grants and contracts (recorded). <i>Peer group percentile ranking – TARGET: 33rd percentile.</i>	N/A	37 th	37 th

* NOTE: This baseline figure was inaccurately reported in prior years. It should have been set at 609.42, based on the BOR Salary Database for November 2009, EEO Code of 2, Faculty and Primary Functions of Instruction and Research. The number has declined subsequently due to budget cuts and shifting funding to the primary function of Public Service.

** A list of active grant awards and Principal Investigators is provided as Attachment 1.

Louisiana's key economic development industries include but are not limited to key industry sectors identified in the Fostering Innovation through Research in Science and Technology in Louisiana (FIRST Louisiana) plan, as well as LED's Blue Ocean targeted industry sectors. One of the primary industry sectors identified in these plans is Health Care (specialty research hospital; obesity/diabetes research and treatment; pharmaceutical manufacturing; digital media/software development; health care IT). LSUHSC-NO's Dr. Perry Rigby, Dr. Charles Hilton, and Dr. Larry Hollier all participate in the Medical Education Commission (Dr. Rigby serving as Chair), which documents and tracks the nature and scope of all training programs for postdoctoral residents and fellows in Louisiana, highlighting the workload needs and interrelatedness of workforce production by the Health Science Centers. Commission reports

characterize the public/private partnerships at work in the state and their effects on workforce production. Additionally, Drs. Hilton, Rigby, and Dr. James Cairo all participate in the Healthworks Council, which routinely reviews physician needs and production in Louisiana.

Health Care is one of Louisiana’s primary economic development industries. Virtually all academic programs at LSUHSC-NO are aligned with the production of Health Care providers and researchers. A majority of the research at LSUHSC-NO is funded by the National Institutes of Health (NIH). Other sources of research funding include the Department of Defense, Centers for Disease Control and Prevention, National Science Foundation, American Heart Association, and the like. FY12 research expenditures at the HSC-NO were \$57,922,974 as measured by NSF’s Higher Education Research and Development Survey. These externally funded outlays include salaries for numerous technicians and other employees that have a large multiplying effect in stimulating the local economy. The opening of the new Louisiana Cancer Research Center and eventually the new Academic Medical Center will have positive impacts on clinical research and clinical trials. The number of publications produced by students and faculty is a further measure of research and scholarly productivity. In 2012, there were 948 publications from the HSC.

Using the formulation provided by the Board of Regents $\{[(B + 0.5E)/n] * 100 = \text{percentile rank, where } B = \text{number of peers below } x, E = \text{number of peers equal to } x, \text{ and } n = \text{number of peers}\}$, LSUHSC-NO currently ranks in the 37th percentile in its peer group for direct research grants and contracts (recorded).

Peer	2011	
	Amount	Ranking
Louisville	\$ 42,616,320	1
Oklahoma	\$ 40,076,643	2
Arkansas	\$ 39,082,299	3
MC Georgia	\$ 32,147,063	4
Tennessee	\$ 31,232,506	5
Eastern Virginia	\$ 21,679,575	6
Mississippi	\$ 21,042,388	7
LSUHSC New Orleans	\$ 15,978,317	8
West Virginia	\$ 15,743,081	9
Missouri-Columbia	\$ 14,226,206	10
Texas A&M	\$ 10,795,813	11
South Carolina	\$ 6,837,295	12

Performance Objectives/Elements/Measures		Baseline (2008-2009)	Year 1 (2009-2010)	Year 2 (2010-2011)	Year 3 (2011-2012)
V.	Intellectual Property Measure - Patents	21	19	9	5
	Intellectual Property Measure - Disclosures	14	13	3	12
	Intellectual Property Measure - Licenses	3	0	1	0
	Intellectual Property Measure - Options	0	0	0	1
	Intellectual Property Measure - New Companies	0	0	0	1
	Intellectual Property Measure - Surviving Start-Ups	1	1	1	3

The Office of Technology Management at LSUHSC-NO facilitates the institution's research enterprise and brings significant novel intellectual property to the marketplace. Major steps in technology transfer include disclosure of inventions, evaluation, patent prosecution, marketing, and licensing. In addition to the actual technology transfer process, this Office is also charged with negotiating material transfer agreements, confidential disclosure agreements, and inter-institutional agreements. In 2012, adjusted gross licensing income was \$96,124 from 8 licenses.

Academic technology transfer serves to:

- Facilitate the commercialization of research results for the public good;
- Reward, retain, and recruit faculty;
- Induce closer ties to industry; and
- Generate income and promote economic growth.

In mid-2011, the Director of the Office of Technology Management left the position, and the office has since been reorganized; this turnover led to the decline in intellectual property measures (patents, disclosures, and licenses) reflected in the table above (3.c.v.). A new Director took over this office in June 2012, and productivity has already rebounded significantly. Moving forward, the office is currently on track to double the number of disclosures received in 2012, and several license agreements are nearing the end of negotiation. The new Director has been proactive in engaging faculty in an attempt to alleviate their concerns with the previous technology transfer regime; the marked increase in disclosures is direct evidence that faculty have been receptive to this message. The Office of Technology Management is committed to promoting economic development for the GNO region and State of Louisiana.

LSUHSC-NO further collaborates with two major economic development engines in the city. The first is the New Orleans BioInnovation Center (NOBIC), a technology business incubator that aims to stimulate bioscience entrepreneurship in Greater New Orleans. The primary purpose of this facility is to translate research into therapeutic agents, technology, and devices that can be patented and foster economic growth. It is funded, in part, by the Louisiana Department of Economic Development. NOBIC opened in May of 2011 at 1441 Canal Street, housing 65,000 square feet of wet-lab space, stand-alone offices, and meeting/conference spaces. Biotechnology companies developing from LSUHSC-NO and other area institutions are able to lease lab and office in this facility, which is in close proximity to the HSC's campus. More information about NOBIC can be found at: <http://www.neworleansbio.com>.

LSUHSC-NO's participation in the Louisiana Cancer Research Consortium (LCRC) represents a second area of collaborative participation in economic development. The LCRC brings together outstanding basic and clinical researchers to develop a cancer center that features successful prevention and control programs, state-of-the-art basic research and treatment options, and the creation of cancer educational programs for the citizens of Louisiana. The new home and research building of the LCRC opened in June 2012. More information about the LCRC can be found at: <http://www.lcrc.info>.

d. To the extent that information can be obtained, demonstrate progress in increasing the number of students placed in jobs and in increasing the performance of associate degree recipients who transfer to institutions that offer academic undergraduate degrees at the baccalaureate level or higher.

LSUHSC has a very high placement rate of graduates into professional employment and/or post-graduate training. In most Schools at the HSC, nearly 100% of graduates gain employment or achieve acceptance into post-graduate training programs within 12 months of graduation.

Job Placement Rates (w/in 12 months of graduation)	2009-2010	2010-2011	2011-2012
School of Allied Health Professions	95% (104/109)	94% (143/152)	91% (162/179)
School of Dentistry—Program in Dentistry	73% (44/60)	100% (53/53)	74% (43/58)
School of Dentistry—Program in Dental Hygiene	100% (43/43)	100% (40/40)	100% (34/34)
School of Dentistry—Program in Dental Lab Tech	75% (3/4)	100% (9/9)	100% (6/6)
School of Graduate Studies*	100% (24/24)	100% (19/19)	100% (16/16)
School of Medicine*	99% (166/167)	95% (164/173)	98% (176/179)
School of Nursing	100% (148/148)	100% (177/177)	100% (211/211)
School of Public Health	61% (17/28)	62% (16/26)	38% (9/24)

Placement Rates into Post-Graduate Training (w/in 12 months of graduation)	2009-2010	2010-2011	2011-2012
School of Allied Health Professions	N/A	N/A	N/A
School of Dentistry—Program in Dentistry	27% (16/60)	100% (53/53)	17% (10/58)
School of Dentistry—Program in Dental Hygiene	N/A	N/A	N/A
School of Dentistry—Program in Dental Lab Tech	N/A	N/A	N/A
School of Graduate Studies*	100% (24/24)	100% (19/19)	100% (16/16)
School of Medicine*	99% (166/167)	95% (164/173)	98% (176/179)
School of Nursing	N/A	N/A	N/A
School of Public Health	36% (10/28)	23% (6/26)	33% (8/24)

* Because students from the Schools of Graduate Studies and Medicine move on to post-doctoral placements and residency, respectively, these figures are counted as both job placement and post-graduate training simultaneously. This duplication of tracking is consistent with targets established in GRAD Act Appendix D.

The slight drop in the School of Allied Health Professions' 2011-2012 job placement rate was due to individuals either transitioning between jobs, or having not selected an employment opportunity at the time the School surveyed them post-graduation. The School of Dentistry presumes its placement rates are actually higher than those reported; however, information provided for GRAD Act purposes is based on voluntary student responses in exit interviews given after graduation. In the School of Public Health, job placement rates declined in 2011-2012 due to a large proportion of graduates going on for post-graduate studies and training, rather than seeking employment in the poor economy. Further, the School's accrediting agency measures job/post-graduate training placement rates within 12 months of graduation, and most of these students have not yet met that 12-month post-graduation time period.

4. INSTITUTIONAL EFFICIENCY AND ACCOUNTABILITY

a. Eliminate remedial education course offerings and developmental study programs unless such courses or programs cannot be offered at a community college in the same geographical area.

N/A

b. Eliminate associate degree program offerings unless such programs cannot be offered at a community college in the same geographic area or when the Board of Regents has certified educational or workforce needs.

N/A—The only associate degree program at LSUHSC-NO is the school’s Dental Lab Technology program, which is housed in the School of Dentistry and is currently the only facility in the state with the required equipment to maintain such a program.

c. Upon entering the initial performance agreement, adhere to a schedule established by the institution's management board to increase nonresident tuition amounts that are not less than the average tuition amount charged to Louisiana residents attending peer institutions in other Southern Regional Education Board states and monitor the impact of such increases on the institution. However, for each public historically black college or university, the nonresident tuition amounts shall not be less than the average tuition amount charged to Louisiana residents attending public historically black colleges and universities in other Southern Regional Education Board states.

Total Tuition & Fees Charged to Full-Time Non-Resident Students					
LSUHSC-NO School	2008-2009*	2009-2010*	2010-2011	2011-2012	Peer Comparison
School of Allied Health Professions <i>Undergraduate</i> <i>(Fall & Spring Semesters)</i>	\$6,691.00	\$7,195.00	\$7,533.00	\$9,075.00	\$20,631.00
School of Allied Health Professions <i>Graduate (Fall & Spring Semesters)</i>	\$7,304.00	\$7,855.00	\$8,243.00	\$9,957.00	\$19,554.00
School of Allied Health Professions <i>Doctor of Physical Therapy (Annual)</i>	\$13,939.00	\$14,910.00	\$15,853.00	\$19,223.00	\$30,757.00
School of Dentistry <i>Program in Dentistry</i>	\$23,842.00	\$25,640.00	\$26,555.00	\$32,391.00	\$48,512.00
School of Dentistry <i>Dental Hygiene</i> <i>(Fall & Spring Semesters)</i>	\$4,518.00	\$4,856.00	\$5,104.00	\$6,182.00	\$22,104.00
School of Dentistry <i>Dental Lab Tech</i> <i>(Fall & Spring Semesters)</i>	\$4,127.00	\$4,471.00	\$4,701.00	\$5,689.00	N/A
School of Graduate Studies <i>(Fall & Spring Semesters)</i>	\$7,304.00	\$7,855.00	\$8,243.00	\$9,964.00	\$18,242.00
School of Medicine	\$27,545.00	\$29,625.00	\$30,694.00	\$37,463.00	\$49,674.00
School of Nursing <i>Undergraduate</i> <i>(Fall & Spring Semesters)</i>	\$4,867.00	\$5,234.00	\$5,490.00	\$6,627.00	\$19,534.00
School of Nursing <i>Graduate (Fall & Spring Semesters)</i>	\$6,257.00	\$6,728.00	\$7,030.00	\$8,465.00	\$21,510.00
School of Nursing <i>Master of Nursing, Nurse Anesthesia</i> <i>(Annual)</i>	\$12,830.00	\$13,798.00	\$14,587.00	\$17,743.00	\$27,273.00
School of Public Health <i>Master of Public Health (Annual)</i>	\$6,834.00	\$7,315.00	\$7,808.00	\$9,511.00	\$23,558.00

** NOTE: 2008-2009 and 2009-2010 tuition figures were reported inaccurately in LSUHSC-NO's 2012 GRAD Act report. All current and historic figures have been updated and are accurate as of this report.*

Since the applicant pool for LSUHSC-NO is drawn almost entirely from Louisiana residents, there would be virtually no impact on either enrollment or revenue from a non-resident tuition increase in accordance with GRAD Act provisions. Similarly, a tuition increase for Louisiana residents is not anticipated to negatively impact enrollment in the schools of LSUHSC-NO. However, additional revenues that would be realized from such an in-state tuition increase are not expected to offset the anticipated budget reduction for Louisiana higher education.

Effective with the Fall 2010 semester, the LSU Board of Supervisors passed a resolution authorizing the President (pursuant to LA R.S. 17:3351) to increase total non-resident tuition and mandatory fees of each campus by up to 15% of the initial year and by such additional amounts in subsequent years as to assure, within no more than a five-year period, that the total non-resident tuition and mandatory fees are not less than the average total tuition and mandatory fee amount charged to Louisiana residents attending peer institutions (as non-residents) in other Southern Regional Education Board states.

Most, but not all, non-resident students at LSUHSC-NO (Graduate Studies, MD-Ph.D., MS and Ph.D. in Public Health and some Advanced Dental Education) receive tuition exemptions, which mitigate the impact of non-resident tuition increases and limit the net revenue the institution realizes from non-resident tuition increases considerably. With a relatively small overall enrollment, the resident tuition increases help to mitigate the impact of state general fund reductions—though they do not come close to offsetting cuts. Effective with the Fall 2012 semester, LSUHSC-NO increased total non-resident tuition by 15%. Resident tuition was increased by 10% under the GRAD Act for all students, and an additional 5% under Act 297 of 2011 for MD and DDS students. It is LSUHSC-NO's intent to increase total non-resident tuition another 15% effective with the Fall 2013 semester, in accordance with the board resolution cited above. LSUHSC-NO also intends to use its authority under the GRAD Act to increase resident tuition by 10% for all students and another 5% under Act 297 of 2011 for MD and DDS students, effective with the Fall 2013 semester.

d. Designate centers of excellence as defined by the Board of Regents which have received a favorable academic assessment from the Board of Regents and have demonstrated substantial progress toward meeting the following goals:

- **Offering a specialized program that involves partnerships between the institution and business and industry, national laboratories, research centers, and other institutions.**
- **Aligning with current and strategic statewide and regional workforce needs as identified by the Louisiana Workforce Commission and Louisiana Economic Development.**
- **Having a high percentage of graduates or completers each year as compared to the state average percentage of graduates and that of the institution's peers.**
- **Having a high number of graduates or completers who enter productive careers or continue their education in advanced degree programs, whether at the same or other institution.**
- **Having a high level of research productivity and technology transfer.**

N/A—The Board of Regents shall develop a policy for this element. Upon approval of the policy, measures and reporting requirements will be defined. Pending development of these items, institutions are not required to report on this element.

5. ORGANIZATIONAL DATA ATTACHMENT: LSU HEALTH SCIENCES CENTER—NEW ORLEANS

a. Number of Students by Classification

Headcount, undergraduate students and graduate/professional school students enrolled in fall of the reporting year.

LSUHSC-NO FALL 2012 ENROLLMENT	
Undergraduate	911
Graduate	1,877
TOTAL	2,788

Budgeted FTE (full-time equivalent) undergraduate and graduate/professional school students, annual using reporting year fall and prior year spring.

LSUHSC-NO FALL 2012 BUDGETED FTE STUDENTS	
Undergraduate	732
Graduate	1,887
TOTAL	2,619

b. Number of Instructional Staff Members**

Number and FTE instructional faculty for fall of the reporting year.

LSUHSC-NO INSTRUCTIONAL STAFF— FALL 2012	
Instructional Faculty Headcount	602
Instructional Faculty FTE	486.92

c. Average Class Student-to-Instructor Ratio**

Average undergraduate class size at the institution in the fall of the reporting year

LSUHSC-NO STUDENT-TO-INSTRUCTOR RATIO— FALL 2012	
Average Undergraduate Class Size	3:1

d. Average Number of Students per Instructor**

Ratio of FTE students to FTE instructional faculty in the fall of the reporting year.

LSUHSC-NO # OF STUDENTS/INSTRUCTOR— FALL 2012	
Ratio: FTE Students to FTE Instructional Faculty	5

*** PLEASE NOTE: Due to the large discrepancies in class sizes in LSUHSC-NO’s professional programs, which include the entire class for most didactic courses and one-on-one instruction in many clinical settings, this data is not comparable to traditional institutions. As LSUHSC-NO does not report to the Student Credit Hour (SCH) System, it is our recommendation that these items be removed from future GRAD Act reporting requirements.*

e. Number of Non-Instructional Staff Members in Academic Colleges and Departments

Number and FTE non-instructional staff members in the fall of the reporting year, by academic college (or school, if that is the highest level of academic organization for some units).

SCHOOL	HEADCOUNT	FTE
School of Allied Health Professions	18	17.60
School of Dentistry	9	9.00
School of Graduate Studies	0	0.00

School of Medicine	43	42.80
School of Nursing	5	5.00
School of Public Health	12	12.00
TOTAL NON-INSTRUCTIONAL STAFF	87	86.40

f. Number of Staff in Administrative Areas

Number and FTE executive/managerial staff in the fall of the reporting year, as reported in the Employee Salary Data System (EMPSAL) in areas other than the academic colleges/schools, reported by division.

LSUHSC-NO ADMINISTRATIVE STAFF—FALL 2012	
Headcount	97
FTE	96.8

g. Organizational Chart (Down to the Second Level of the Institution below the Chancellor)

Please see Attachment 2.

h. Salaries of All Personnel Identified in Subparagraph (g) Above, incl. Date, Amount, and Type of All Increases in Salary Received since June 30, 2008

POSITION	TOTAL BASE SALARY <i>Reported for Fall '09</i>	SALARY CHANGES SINCE 06/30/2009 <i>Reported for Fall '10</i>	SALARY CHANGES SINCE 06/30/2010 <i>Reported for Fall '11</i>	SALARY CHANGES SINCE 06/30/2011 <i>Reported for Fall '12</i>
Chancellor	\$316,954			
Vice Chancellor for Academic Affairs; Dean, School of Graduate Studies	\$250,591			
Vice Chancellor for Clinical Affairs	\$186,945 <i>100% as of 07/01/08</i>		\$149,556 <i>80% FTE as of 07/01/10</i>	
Vice Chancellor for Community & Security Affairs	\$130,612			
Vice Chancellor for Administration & Finance	\$266,683		\$211,183 <i>7/1/11 Rehired Retiree</i>	VACANT 01/01/12
Assoc. VC for Academic & Multicultural Affairs		\$135,000 <i>Hired 04/01/10</i>		
Assoc. VC for Property & Facilities	\$172,172			
Assoc. VC for Administration & Finance	\$174,021 <i>Salary as Asst. VC</i>			\$207,250 <i>As of 03/01/12 Promotion to Assoc. VC</i>

Assistant VC for Information Technology	\$188,213			\$175,824 <i>As of 05/01/11 New Hire</i>
SCHOOL OF ALLIED HEALTH PROFESSIONS				
Dean, School of Allied Health Professions	\$250,679.04 <i>As of 07/01/08</i>		07/01/10 <i>Moved supp. into base at this rate</i>	
Assoc. Dean for Academic Affairs	\$132,780		VACANT 07/01/11	VACANT 02/01/13 \$94,397* <i>*Acting Asst. Dean</i>
Assistant Dean	\$91,604			
SCHOOL OF DENTISTRY				
Dean, School of Dentistry	\$250,000 <i>Hired 10/01/08</i>			
Assoc. Dean for Academic Affairs	\$163,155			
Assoc. Dean for Research	\$186,221			
Assistant Dean for Clinical Education	\$129,278 <i>As of 07/01/08</i>		\$144,791 <i>As of 07/01/11 Faculty Promotion</i>	\$155,513 <i>As of 08/01/12 Moved supp. into base</i>
Assistant Dean for Fiscal Affairs	\$113,319			
SCHOOL OF GRADUATE STUDIES				
Assoc. Dean, School of Graduate Studies	\$164,809			
SCHOOL OF MEDICINE				
Dean, School of Medicine	\$272,500			\$299,750 <i>As of 12/01/12 External Equity</i>
Assoc. Dean for Academic Affairs	\$188,032			
Assoc. Dean for Admissions	\$228,469			
Assoc. Dean for Alumni Affairs & Development	\$141,057			
Assoc. Dean for Clinical Affairs	\$224,700		VACANT 07/01/11	\$286,000 <i>As of 01/15/13</i>
Assoc. Dean for Community & Minority Health Education	\$183,990		\$202,389 <i>As of 09/01/10 Equity</i>	

Assoc. Dean for Faculty & Institutional Affairs	\$232,552			
Assoc. Dean for Fiscal Affairs	\$234,705			
Assoc. Dean for Health Care Quality & Safety	\$182,434			VACANT 10/06/12
Assoc. Dean for Research	\$203,658			
Assoc. Dean for Student Affairs & Records	\$148,225			
Assistant Dean for Student Affairs & Records				\$140,937
Assistant Dean for Undergraduate Education	\$129,476			
SCHOOL OF NURSING				
Dean, School of Nursing	\$179,760			
Assoc. Dean for Nursing Research, Scholarship, and Science	\$114,688			
Assoc. Dean for Prof Practice, Comm Service, & Adv Nursing Pract	\$116,931 <i>As of 07/01/08</i>			\$130,963 <i>As of 07/01/11 Faculty Promotion</i>
Assoc. Dean for Undergraduate Nursing Programs	\$113,077			\$126,646 <i>As of 07/01/12 Faculty Promotion</i>
Assistant Dean for Business Affairs	\$94,159			
Assistant Dean for Clinical Nursing Education	\$81,420			
Assistant Dean for Student Services	\$98,500			
SCHOOL OF PUBLIC HEALTH				
Dean, School of Public Health	\$273,935 <i>Merit increase eff. 11/01/08</i>			
Assoc. Dean for Academic Affairs	\$180,836			

Assoc. Dean for Research	\$205,000 <i>Hired 09/29/09</i>			
Assistant Dean, Business Affairs	\$120,000			

i. Cost Performance Analysis

i. Total operating budget by function, amount, and percent of total, reported in a manner consistent with the National Association of College and University Business Officers guidelines.

Expenditures by Function:	Amount	% of Total
Instruction	\$ 88,550,376	52.0%
Research	\$ 14,947,015	8.8%
Public Service	\$ 6,607,333	3.9%
Academic Support**	\$ 13,722,900	8.1%
Student Services	\$ 2,484,655	1.5%
Institutional Services	\$ 18,828,523	11.1%
Scholarships/Fellowships	\$ 3,322,089	2.0%
Plant Operations/Maintenance	\$ 21,406,068	12.6%
Total E&G Expenditures	\$ 169,868,957	99.8%
Hospital	\$ -	0.0%
Transfers out of agency	\$ 262,213	0.2%
Athletics	\$ -	0.0%
Other	\$ -	0.0%
Total Expenditures	\$ 170,131,171	100.0%

ii. Average yearly cost of attendance for the reporting year as reported to the United States Department of Education.

N/A

iii. Average time to degree for completion of academic programs at 4-year universities, 2-year colleges, and technical colleges.

N/A

iv. Average cost per degree awarded in the most recent academic year.

N/A

v. Average cost per non-completer in the most recent academic year.

N/A

vi. All expenditures of the institution for that year most recent academic year.

\$444,129,553*

* As reported in the 2011-2012 BoR-3 Report.

ATTACHMENT 1: LSUHSC-NO ACTIVE RESEARCH DEVELOPMENT AWARD/CONTRACT LIST

P.I. Name	Category	Primary Spnr	Direct Sponsor	Ref Awd #	Ref Awd #2	Project Title
Acierno,Marie D.	Fed Subcontract	NIH, National Eye Institute	St. Luke's Roosevelt Institute	1U10 EY017281-01A1	1 U10EY017281-01A1	DATA ACCOUNTABILITY CENTER
Aiyar,Ashok	Federal		NIH, Nat Inst on Allergy & Infec Disease	1 R21AI095859-01		GENE REGULATORY NETWORK FOR PODOCYTE DEVELOPMENT - STIPENDS
Alahari,Suresh K.	Federal		NIH, National Cancer Institute	1R01CA115706-01		Completion of Human Embryo Sections on DVDS
Alahari,Suresh K.	Business		Regulus Therapeutics			Physiological Consequences of Glutamate receptor Modulation
Alahari,Suresh K.	Institution				Cost Share	Completion of Human Embryo sections on DVDS
Aldridge,Kenneth E	Business		Wyeth-Ayerst	ZOSYN 0910X-101193		Neuropeptide Y and the Control of Catecholamine Secretion from the Adrenal Gland
Aldridge,Kenneth E	Business		Astra Zenca Pharmaceuticals	MERREM		Cellular Mechanisms Underlying the Long-term Potentiation of GABA Release
Aldridge,Kenneth E	Business		Bayer Corporation	MXA03-225B		Generate and Characterize Knock-In Mice Harboring DRD2 Ser311Cys Polymorphism
Aldridge,Kenneth E	Business		Biomerieux, Inc	ZGPAC9 AST		Synaptic mechanism underlying amygdala-obesity
Aldridge,Kenneth E	Business		Pfizer Inc	M7001086		CRCN5: PHASE RESETTING PREDICTS SYNCHRONIZATION IN HYBRID HIPPOCAMPAL CIRCUITS
Ali,Juzar	Business		Clinimetrics	InterMune GIMAC-001		Intrinsic Currents Modulate Synaptic Integration in Dopamine Neurons
Amedee,Angela Martin	Fed Subcontract	National Science Foundation	Board of Regents	LEQSF-EPS(2011)-SURE	EPS-1003897	CRCN5: Analysis of Synchronization in Hybrid Neural Circuits
Amedee,Angela Martin	Fed Subcontract	National Science Foundation	Board of Regents	LEQSF-EPS(2011)-SURE	EPS-1003897	Impact of Stress on GluR2 Transcription and Learning-Induced Synaptic Plasticity
Anand,Rene	Private Institutions		Philip Morris USA Inc			DERIVATION OF HEART MUSCLE LINEAGE-IMMORTALIZED CELL LINES
Anthony,Lowell B	Business		Novartis Pharmaceuticals Corporation	PTKAU550		SCF COMPLEX AND THE DROSOPHILA CENTROSOME CYCLE
Anthony,Lowell B	Business		Novartis Pharmaceuticals Corporation	RAD 001C 2325		A NOVEL REGULATOR OF CANCER CELL MIGRATION AND INVASION
Anthony,Lowell B	Business		ImClone	CP-13-0710		GLUCOCORTICOID RECEPTOR REGULATION IN LEUKEMIA
Backes,Wayne L	Federal		NIH, Nat Inst of Environmental Health	2 R01ES004344-16A1		ATP-UBIQUITIN DEPENDENT PROTEOLYSIS
Backes,Wayne L	Fed Subcontract	NIH, Nat Inst of Environmental Health	LSU, Baton Rouge	040800	1P42E013648-01A2	ATP-Ubiquitin Dependent Proteolysis
Backes,Wayne L	Fed Subcontract	NIH, Nat Inst of Environmental Health	LSU, Baton Rouge	040800	1P42E013648-01A2	TRAVEL GRANT-2ND ANNUAL WORLD SUMMIT OF ANTIVIRALS-BEIJING CHINA
Backes,Wayne L	Fed Subcontract	NIH, Nat Inst of Environmental Health	LSU, Baton Rouge	040800	1P42E013648-01A2	IQGAP1 Structure and Function
Backes,Wayne L	Fed Subcontract	NIH, Nat Inst of Environmental Health	LSU, Baton Rouge	040800	1P42E013648-01A2	Chemistry and Energy Transduction in Kinesin Motor Proteins
Backes,Wayne L	Fed Subcontract	NIH, Nat Inst of Environmental Health	LSU, Baton Rouge	61365	P42E013648	Linking neurodegeneration to protein turnover in ataxia telangiectasia
Backes,Wayne L	Fed Subcontract	NIH, Nat Inst of Environmental Health	LSU, Baton Rouge	61365	P42E013648	Therapeutic Effects of Anti-miR-27b in Breast Cancer
Backes,Wayne L	Fed Subcontract	NIH, Nat Inst of Environmental Health	LSU, Baton Rouge	61365	P42E013648	Cell Biology Development of Nutrient Medium for Increased Cell Longevity and Hardware for Cell Culling
Backes,Wayne L	Fed Subcontract	NIH, Nat Inst of Environmental Health	LSU, Baton Rouge	61365	P42E013648	MECHANISMS OF LUNG CARCINOGENESIS INDUCED BY ASBESTOS & CIGARETTE SMOKE
Backes,Wayne L	Institution				Cost Share	THE ROLE OF IL-17 IN RSV-INDUCED MUCUS AND AIRWAY RESPONSIVENESS
Backes,Wayne L	Institution				Cost Share	ALCOHOL, ROS AND MACROPHAGE EPIGENETICS
Bagby,Gregory J	Federal		NIH, National Inst. on Alcohol Abuse	5T32AA007577-07		Alcohol, ROS, and Macrophage Epigenetics
Bagby,Gregory J	Federal		NIH, National Inst. on Alcohol Abuse	NIAAA-AA07577-11		ALCOHOL, ROS AND MACROPHAGE EPIGENETICS
Bagby,Gregory J	Federal		NIH, National Inst. on Alcohol Abuse	NIAAA-AA07577-11		Mechanism of regulation for the oncogenic Pax3-FOXO1 in Alveolar
Balart Jr.,Luis A	Business		Schering Plough Research Institute	P02570		Non-CD4 Host Defense Against P. Carinii Pneumonia
Balart Jr.,Luis A	Business		Roche Laboratories Inc.	ML17756 Protocol		Host Factors in Fungal Allergy and Fibrosis
Balart Jr.,Luis A	Business		Pharmanet, Inc.	RNA003142-302		Alcohol, ROS, and Macrophage Epigenetics
Balart Jr.,Luis A	Business		Vertex Pharmaceutica	VX03-497-205		Alcohol, ROS, and Macrophage Epigenetics
Balart Jr.,Luis A	Business		Roche Laboratories Inc.	ML 18179		Medical Research Opportunities for the Patrick F. Taylor Science and Technology Academy and Taylor Opportunity Program for Students Scholars
Balart Jr.,Luis A	Business		Gilead Sciences Inc	GU-US-174-0102		Genetic Epidemiology of Lung Cancer
Balart Jr.,Luis A	Business		Coley Pharmaceutical	CPG40101		MENTORING A CANCER GENETICS PROGRAM - DR TOMOO IWAKUMA
Barbee,James Gray	Business		Wyeth-Ayerst	0600B-100735		MENTORING A CANCER GENETICS PROGRAM - DR TOMOO IWAKUMA - Mentor
Barbee,James Gray	Business		Merck & Co., Inc.	061-00		A drosophila model to investigate the role of FUS in ALS
Barbee,James Gray	Business		Wyeth-Ayerst	0600B5-354-US		Gamma Delta T Cells are Integral Mediators of Interstitial Pulmonary Fibrosis
Barbee,James Gray	Business		Bristol Myers Squibb	CN138-146-001		T cells and P carinii Pneumonia
Barbee,James Gray	Business		Eli Lilly And Company	FJ1-US-HMDR		Progress Report: Transcription-coupled GAA-TTC expansion in human cells
Barbee,James Gray	Business		Cephalon	C6671/3033/AX/US		Th17 Cytokines and Lung Immunity
Barbee,James Gray	Business		Bristol Myers Squibb	CN138-165-002		LSUHSC Summer Internship Program
Barron,Bruce Allen	Fed Subcontract	NIH, National Eye Institute	Johns Hopkins University	2U10EY08057-11	U10EY08057	LSUHSC Summer Internship Program
Barsley,Robert E	Federal		HHS, Health Resources & Service Admin	1H97HA07512-01		Germ-line Copy Number Variation in high-risk African American families
Bazan,Haydee Elvira P	Federal		NIH, National Eye Institute	1 R01EY019465-01		Mouse xenograft model generation to support in vivo investigations of CARM1 function
Bazan,Haydee Elvira P	Federal		NIH, National Eye Institute	1 R01EY019465-01		Novel Marcolide Th17 Inhibitors
Bazan,Haydee Elvira P	Federal		NIH, National Eye Institute	2 R01EY004928-27		Molecular mechanism of FUS/TLN1 related ALS
Bazan,Haydee Elvira P	Institution				Inst Fund	Alcohol and Pulmonary Immunity to MRSA
Bazan,Nicolas G	Federal		NIH, National Ctr for Research Resourc	2P20 RR016816-06		Alcohol and Pulmonary Immunity to MRSA
Bazan,Nicolas G	Federal		NIH, National Ctr for Research Resourc	2P20 RR016816-06		Testing Lytic Peptides in a Mouse Xenograft model of Uterine Fibroids
Bazan,Nicolas G	Federal		NIH, National Ctr for Research Resourc	2P20 RR016816-06		Determination of Genetic Susceptibility to Lung Cancer in Families from Southern Louisiana
Bazan,Nicolas G	Federal		NIH, National Ctr for Research Resourc	2P20 RR016816-06		Alcohol, Ros and Macrophage Epigenetics
Bazan,Nicolas G	Federal		NIH, National Ctr for Research Resourc	2P20 RR016816-06		Targeting DNA Mismatch Repair in Age-Related Repeat Expansion
Bazan,Nicolas G	Federal		NIH, National Ctr for Research Resourc	2P20 RR016816-06		Short Term Research Training for Medical Students
Bazan,Nicolas G	Federal		NIH, National Ctr for Research Resourc	2P20 RR016816-06		Short Term Research Training for Medical Students
Bazan,Nicolas G	Federal		NIH, National Ctr for Research Resourc	2P20 RR016816-06		Louisiana Sure Program
Bazan,Nicolas G	Federal		NIH, National Ctr for Research Resourc	2P20 RR016816-06		Louisiana Sure Program
Bazan,Nicolas G	Federal		NIH, National Ctr for Research Resourc	2P20 RR016816-06		Medical Student Alcohol Research Internship
Bazan,Nicolas G	Foundation		Foundation Fighting Blindness	TA-NP-0808-0463-LSUN		Research for Nikki Nguyen
Bazan,Nicolas G	Federal		NIH, National Eye Institute	3R01EY05121-25S1		Non-CD4 Host Defense Against P. Carinii Pneumonia. Graduate Student - David Ricks
Bazan,Nicolas G	Federal		NIH, Complementary & Alternative Medicin	1RC2AT005909-01		Graduate Student Contract - Sun Mi Choi
Bazan,Nicolas G	Foundation		Amer Health Assistance Ftdn	Amer Health Asst Fdt		Characterize Reg3g as an immune-base therapy to treat alcohol related life threatening CA-MRSA
Bazan,Nicolas G	Foundation		Amer Health Assistance Ftdn	Amer Health Asst Fdt		SOUTH LOUISIANA INSTITUTE FOR INFECTIOUS DISEASE RESEARCH-EDUCATION
Bazan,Nicolas G	Private Institutions		NIH, Nat Inst of Neurological Disorders	2R01NS046741-07A1		SOUTH LA INSTITUTE INFECTIOUS DISEASE RESEARCH-RESEARCH
Bazan,Nicolas G	Private Institutions		Doheny Eye Institute	1101		SOUTH LA INSTITUTE INFECTIOUS DISEASE RES-COMMERCIALIZATION
Bazan,Nicolas G	Federal		NIH, National Eye Institute	2R01EY005121-26A1		SOUTH LA INSTITUTE INFECTIOUS DISEASE RESEARCH-ADMINISTRATION
Belayev,Ludmila S.	Federal		NIH, Nat Inst of Neurological Disorders	1R01NS065786-01A2		SOUTH LOUISIANA INSTITUTE FOR INFECTIOUS DISEASE RESEARCH-START UP FUNDS-DR LI SHEN
Belayev,Ludmila S.	Federal		NIH, Nat Inst of Neurological Disorders	1R01NS065786-01A2		LOUISIANA VACCINE CENTER AND SOUTH LOUISIANA INSTITUTE FOR INFECTIOUS DISEASE RESEARCH
Bell,Laura J	Business		Genzyme	Genzyme		ANALYSES OF SIGMA FACTOR 28 OF C TRACHOMATIS

ATTACHMENT 1: LSUHSC-NO ACTIVE RESEARCH DEVELOPMENT AWARD/CONTRACT LIST

P.I. Name	Category	Primary Spnser	Direct Sponsor	Ref Awd #	Ref Awd #2	Project Title
Bergsma,Donald R	Business		Parexel International Corp	B7A-MC-MBCM		MECHANISMS OF HERPES VIRUS PROTEINS IN HIJACKING AND SUBVERTING HOST AND CELLULAR RESPONSE PATHWAYS
Bergsma,Donald R	Foundation		Research To Prevent Blindness	Res to Prevent Blind		GRADUATE STUDENT STIPEND-CAROLINE CHAPMAN
Bergsma,Donald R	Fed Subcontract	NIH, National Eye Institute	Johns Hopkins University	U10EY008057	U10 EY008057	GRADUATE STUDENT STIPEND-RYAN CRAIG
Besch,Ceryl Lynn	Fed Subcontract	U.S. Department Of Agriculture	University of Illinois	2009-511110-20173	2009-511110-20173	THE DESIGN, DELIVERY AND DEVELOPMENT OF THERAPEUTIC PEPTIDES: PROJECT 4. DEVELOPMENT OF
Blatz,Markus B	Business		HERAEUS KULZER			Oral Mucosal Immunity in Vulnerable HIV Infected Populations
Block,Michael S	Business		Implant Innovations	2208 Fireball		Characterization and use of a novel AT-hook protein in Leishmania
Boulares,Abdel Hamid	Private Institutions		University of Texas, Galveston	09-033		Analyses of sigma factor 28 of C. trachomatis
Boulares,Abdel Hamid	Foundation		American Cancer Society	RSG-09-279-01-CNE		EBNA1 Functions Required in Burkitt's Lymphomas and Other Immortalized B-Cells
Boulares,Abdel Hamid	Federal		NIH, National Heart Lung & Blood Inst	2R01HL072889-06A2		EBNA1 Functions Required in Burkitt's Lymphomas and Other Immortalized B-Cells
Brantley,Phillip	Federal		NIH, Nat Inst Diabetes & Diges & Kidney	1T35DK093428-01		Defensins in STI-Mediated Enhanced HIV Infectivity
Brantley,Phillip	Federal		NIH, Nat Inst Diabetes & Diges & Kidney	1T35DK093428-01		C. trachomatis increases transmission of HIV: mechanisms in the endocervix
Brennan,Christine S	Federal		NIH, National Cancer Institute	1R15CA151031-01		Isolation, characterization, and culture of domestic cat spermatogonial cells
Breslin,Jerome W.	Foundation		American Heart Association	0835388N		HIV Infection in Women During Pregnancy and the Postpartum Period
Breslin,Jerome W.	Foundation		Alcoholic Beverage Medical Research Fndt	Alcoholic Beverage M		HIV Infection in Women During Pregnancy and the Postpartum Period
Breslin,Jerome W.	Federal		NIH, National Heart Lung & Blood Inst	1R01HL098215-01A1		Novel Cellular & Genetic Analyses using a New Chlamydia Pentrant Peptide
Breslin,Jerome W.	Federal		NIH, National Inst. on Alcohol Abuse	1R21AA020049-01A1		Pharmaceutical Correction of Innate Immune Defects in Cystic Fibrosis
Breslin,Mary B	State		Board of Regents	LEQSF(2007-10)RD-A16		Antigen expressed on Pill of Lactococcus as an Oral Vaccine for HIV
Byerley,Lauri O.	Foundation		American Institute for Cancer Research	Amer Inst Cancer Res		Spermatogonial Stem Cell Transplantation in the Domestic Cat
Byerley,Lauri O.	Foundation		American Institute for Cancer Research	MG11A001		Derivation of Induced Pluripotent Stem-like Cells from Felid Somatic Cells
Canavier,Carmen C	Federal		NIH, National Institute of Mental Health	1R01MH085387-01		A New Class of Broad Spectrum Antifungal Agents
Canavier,Carmen C	Federal		NIH, Nat Inst of Neurological Disorders	1R01NS061097-01A2		VAGAL INTERGRATION OF LOWER ESOPHAGEAL SPHINCTER FUNCTION
Canavier,Carmen C	Federal		NIH, Nat Inst of Neurological Disorders	2R01NS054281-05		EFFECTS OF CHRONIC THC IN ADOLESCENCE
Canavier,Carmen C	Federal		NIH, National Institute of Mental Health	1R01MH085387-01		COMBUSTION GENERATED PMO.1 AND PREDISPOSITION TO ASTHMA
Canavier,Carmen C	Federal		NIH, Nat Inst of Neurological Disorders	NINDS - NS061097-01A		MENTORING IN CARDIOVASCULAR BIOLOGY-CORE A-ADMINISTRATION CORE
Canavier,Carmen C	Federal		NIH, Nat Inst of Neurological Disorders	2R01NS054281-05		MENTORING IN CARDIOVASCULAR BIOLOGY-CORE A-SUBAWARD WITH TULANE - DR PATRICE DELAFONTAINE
Canavier,Carmen C	Federal		NIH, Nat Inst of Neurological Disorders	2R01NS054281-05		MENTORING IN CARDIOVASCULAR BIOLOGY-CORE B-CELL AND MOLECULAR ANALYSIS CORE
Cassidy,William Morgan	Business		Pharmanet, Inc.	051-002		MENTORING IN CARDIOVASCULAR BIOLOGY-CORE C-IMAGING AND HISTOLOGY CORE
Cassidy,William Morgan	Business		Roche Laboratories Inc.	NR16172		MENTORING IN CARDIOVASCULAR BIOLOGY-CORE D-VASCULAR AND CARDIAC FUNCTION CORE
Cassidy,William Morgan	Business		Roche Laboratories Inc.	NR16161		MENTORING IN CARDIOVASCULAR BIOLOGY-PROJECT 4-MECHANISMS INVOLVED IN THE INTRACELLULAR
Castaneda-Zuniga,Wilfrido	Business		Abbott Laboratories	M97-642		MENTORING IN CARDIOVASCULAR BIOLOGY-PROJECT 5-REGULATION OF ENDOTHELIAL CELL PERMEABILITY
Cefalu,Charles A	Business		Merck & Co., Inc.	EPO8011-011		MENTORING IN CARDIOVASCULAR BIOLOGY- Sergiy Sukhanov
Cefalu,William T	Business		Johnson & Johnson	JNJ-28431754DIA3009		MENTORING IN CARDIOVASCULAR BIOLOGY-Dr. Wainford
Cefalu,William T	Business		Lilly Research Laboratories	Lilly USA LY2189265		MENTORING IN CARDIOVASCULAR BIOLOGY- Jason Gardner
Cefalu,William T	Business		Johnson & Johnson	2843175D1A3002		MENTORING IN CARDIOVASCULAR BIOLOGY - Xiping Yue
Chen,Chu	Federal		NIH, Nat Inst of Neurological Disorders	R01NS054886-01		MENTORING IN CARDIOVASCULAR BIOLOGY - Lisa Harrison-Bernard
Chen,Chu	Federal		NIH, National Institute on Aging	1R21AG039669-01		CNS G ALPHA-SUBUNIT PROTEIN CONTROL OF PLASMA AVP AND URINE OUTPUT - MODULATION BY HIGH NACL
Chen,Chu	Federal		NIH, National Institute on Aging	1R21AG039669-01		BRAIN-TARGETED ACE2 OVER-EXPRESSION ON ANGIOTENSIN-II-MEDIATED HYPERTENSION
Chen,Chu	Federal		NIH, Nat Inst of Neurological Disorders	NINDS-1R01NS076815-0		TRAVEL GRANT-XXXVI INTERNATIONAL CONGRESS OF PHYSIOLOGICAL SCIENCES-KYOTO, JAPAN
Chen,Vivien Wai-Mei	Federal		NIH, National Cancer Institute	1N01PC54402-01		TOXICOLOGICAL SIGNIFICANCE OF ALKYL BENZENE METABOLISM
Chen,Vivien Wai-Mei	Local Govt		LSUHSC, McIno Charly, No	CFMS# 716379		PREVENTION OF ASTHMA BY ALDOSE REDUCTASE INHIBITION
Chen,Vivien Wai-Mei	Local Govt		LSUHSC, McIno Charly, No	CFMS# 716379		Brain G-alpha-subunit mediated regulation of blood pressure
Chen,Vivien Wai-Mei	Local Govt		LSUHSC, McIno Charly, No	CFMS# 716379		Combining Mammalian and Drosophila Systems to Study Neuropsychiatric Disorders
Chen,Vivien Wai-Mei	Local Govt		LSUHSC, McIno Charly, No	CFMS# 716379		Brain-Targeted ACE2 over-expression on angiotensin-II-mediated hypertension
Chen,Vivien Wai-Mei	Federal		HHS, Ctr for Disease Control & Preventio	1U58DP000769-01		Regulation of IL4 signal transduction on poly (ADP-ribose) polymerase-1
Chen,Vivien Wai-Mei	Federal		HHS, Ctr for Disease Control & Preventio	1U58DP000769-01		Regulation of IL4 signal transduction by poly (ADP-ribose) polymerase-1
Chen,Vivien Wai-Mei	Federal		HHS, Ctr for Disease Control & Preventio	1U58DP000769-01		Health Impacts of Toxic Combustion By-Products - Admin.
Chen,Vivien Wai-Mei	Federal		HHS, Ctr for Disease Control & Preventio	1U58DP000769-01		Health Impacts of Toxic Combustion By-Products - Project 4
Chen,Vivien Wai-Mei	Federal		HHS, Ctr for Disease Control & Preventio	1U58DP000769-01		Health impacts of Toxic Combustion By-Products - Project 5
Chen,Vivien Wai-Mei	Federal		HHS, Ctr for Disease Control & Preventio	1U58DP000769-01		Health Impacts of Toxic Combustion By-Products - Project 6
Chen,Vivien Wai-Mei	Federal		NIH, National Cancer Institute	HHSN261201000030C		Sodium Channels, Sodium Pumps, Inflammation and Diabetic Neuropathy
Chen,Vivien Wai-Mei	Federal		NIH, National Cancer Institute	HHSN261201000030C		Effects of ACE2 gene Therapy on Diabetes
Chen,Vivien Wai-Mei	Fed Subcontract	HHS, Ctr for Disease Control & Preventio	Macro International Inc.	CDC 200-2008-27957	200-2008-27957/0008	Serotonin 5-HT2A receptor inhibition of TNF-alpha pathways and atherosclerosis
Chen,Vivien Wai-Mei	Federal		HHS, Ctr for Disease Control & Preventio	1U58DP003805-01		Preclinical evaluation of DHEA as a treatment for alcoholism
Chen,Vivien Wai-Mei	Institution				Cost Share	Preclinical evaluation of DHEA as a treatment for alcoholism
Chen,Vivien Wai-Mei	Institution				Cost Share	Balance of Angiotensin II/ Angiotensin (1-1): A target in Ischemic Stroke
Chhabra,Kavaljit	Foundation		American Heart Association	11PRE6320006		The regulation of cannabinoid receptors in microglial cells during HIV infection
Chhabra,Kavaljit	Foundation		American Heart Association	11PRE6320006		Brain G-alpha subunit protein mediated neural control of blood pressure
Chilian,William M	Fed Subcontract	NIH, National Heart Lung & Blood Inst	Tulane University	1R01HL73755-01	R01HL73755	Role of ACE2 in high fat diet-mediated dysregulation of glycemia in mice
Choi,Sun Mi	Federal		NIH, National Inst. on Alcohol Abuse	NIAAA 1F31AA021061		Role of ACE2 in high fat diet-mediated dysregulation of glycemia in mice
Choi,Sun Mi	Federal		NIH, National Inst. on Alcohol Abuse	NIAAA 1F31AA021061		The Role of IL4R Alpha in Neonatal RSV Immunopathology
Clark,Rebecca	Business		Bio-Technology General Corporation	M0225		Molecular Genetics of HSV Reactivation
Clark,Rebecca	Business		Bristol Myers Squibb	HARRT		LSU Superfund Research Center - Environmentally Persistent Free Radicals - Admin
Clark,Rebecca	Business		Discovery Life Sciences	GNPR29-US		LSU Superfund Research Center - Environmentally Persistent Free Radicals - Project 2 Cormier
Claycomb,William C	Foundation		Joe W & Dorothy Dorsett Brown Foundation			LSU Superfund Research Center - Environmentally Persistent Free Radicals - Varner
Claycomb,William C	Fed Subcontract	U.S. Army	E. Canary, LLC	W81XWH-11-1-0617	W81XWH-11-1-0617	LSU Superfund Research Center - Environmentally Persistent Free Radicals - Project 5 Backes
Conrad,Erich Josef	Business		Astra Zenca Pharmaceuticals	IRUSQUET0381		Mechanisms of ACE2 Dysregulation in Neurogenic Hypertension
Cormier,Stephanie A	Federal		NIH, Nat Inst of Environmental Health	7R01ES015050-02		ADULT STEM CELLS FOR REPAIR OF CARDIAC DAMAGE
Cormier,Stephanie A	Federal		NIH, Nat Inst on Allergy & Infec Disease	1R01AI090059-01A1		ASH 2004 YOUNG SCHOLARS AWARD
Coulter,W Alan	Fed Subcontract	U.S. Office of Education	Westat Inc	H373Y070002	H373Y070002	BIOMEDICAL ALCOHOL RESEARCH TRAINING PROGRAM - STIPENDS
Crabtree,Judy	Fed Subcontract	National Science Foundation	Board of Regents	LEQSF(2011)PFund-249	NSF: EPS-1003897	CANNABINOID EFFECTS ON HIV/AIDS
Crabtree,Judy S.	State		Pennington Biomedical Research Center	PBRC		CANNABINOID EFFECTS ON HIV/AIDS
Cui,Yan	Federal		NIH, National Cancer Institute	1R01CA112065-01		CANNABINOID EFFECTS ON HIV/AIDS

ATTACHMENT 1: LSUHSC-NO ACTIVE RESEARCH DEVELOPMENT AWARD/CONTRACT LIST

P.I. Name	Category	Primary Spnsr	Direct Sponsor	Ref Awd #	Ref Awd #2	Project Title
Cui,Yan	Federal		NIH, National Cancer Institute	1R01CA112065-01		CANNABINOID EFFECTS ON HIV/AIDS
Cui,Yan	Federal		NIH, National Cancer Institute	3R01CA112065-0551		CANNABINOID EFFECTS ON HIV/AIDS
Cui,Yan	Institution				Inst Fund	CELLULAR SIGNALING MECHANISMS IN MICROVASCULAR PERMEABILITY
Datta,Rahul	Federal		NIH, National Heart Lung & Blood Inst	1F30HL097580-01		REGULATION OF CORONARY COLLATERAL GROWTH IN THE METABOLIC SYNDROME
Datta,Rahul	Federal		NIH, National Heart Lung & Blood Inst	1F30HL097580-01		NATIONAL HISPANIC SCIENCE NETWORK ON DRUG ABUSE (NHSN) ANNUAL CONFERENCE
Deboisblanc,Bennett P	Business		Kinetic Concepts			CIRCULATING PROMOTERS OF CANCER CACHEXIA ASSOCIATED LIPOLYSIS
Deboisblanc,Bennett P	Business		Hesperion Usa Inc.	AC 052-352/PHT		National Videoconference Training Program
Deboisblanc,Bennett P	Business		Ppd Pharmaco, Inc			Mechanisms of Cardiac Damage from Inhaled Particulate Matter
Deboisblanc,Bennett P	Business		Hesperion Usa Inc.	AC-052-357		ACE-Independent Pathways in Diabetic Renal Vascular Disease
Deboisblanc,Bennett P	Business		Ppd Pharmaco, Inc	FPH01/ENCYSIVE		BIOMEDICAL ALCOHOL RESEARCH TRAINING PROGRAM - SUPPORT
Deboisblanc,Bennett P	Business		PPD Development	FPH03		BIOMEDICAL ALCOHOL RESEARCH TRAINING PROGRAM - STIPENDS
Deboisblanc,Bennett P	Business		GlaxoSmithkline Pharmaceuticals	SCO-100250		Alcohol and Sca-1; Impairment of th granulopoietic precursor cell response
Deboisblanc,Bennett P	Federal		NIH, National Heart Lung & Blood Inst	HHSN268200536172C-01		Alcohol and Sca-1; Impairment of the granulopoietic precursor cell response
Deboisblanc,Bennett P	Federal		NIH, National Heart Lung & Blood Inst	HHSN268200536172C-01		National Hispanic Science Network on Drug Abuse
Deboisblanc,Bennett P	Federal		NIH, National Heart Lung & Blood Inst	HHSN268200536172C-01		Cannabinoid Epigenomic and miRNA mechanisms impact HIV/SIV disease progression
Deboisblanc,Bennett P	Federal		NIH, National Heart Lung & Blood Inst	HHSN268200536172C-01		Cannabinoid Epigenomic and miRNA mechanisms impact HIV/SIV disease progression
Deboisblanc,Bennett P	Business		CoTherix	C200-008		Alcohol, Septicemia and LKS Cell Response
Deboisblanc,Bennett P	Business		ACTELION	AC-055-303		Alcohol intoxication & Shock; specific needs & targarted resuscitation strategies
Deboisblanc,Bennett P	Business		Gilead Sciences Inc	GS-US-235-0101		Porter Fellowship
Deboisblanc,Bennett P	Business		ACTELION	Actelion Pharma		Endocannabinoids as a Target for the Treatment of Traumatic Brain Injury
Deboisblanc,Bennett P	Business		Gilead Sciences Inc	GS-US-300-0140		Impact of alcohol intoxication on jemorrhagic shock-induced microvascular dysfunction
Deboisblanc,Bennett P	Business		Actelion	AC-065A302		Alcohol-induced Osteoimmunopathies: A Unifying Explanatory Mechanism
Deboisblanc,Bennett P	Business		ACTELION	Prospect Clinical Re		Role of Lysyl Oxidase in Heart Failure
Deboisblanc,Bennett P	Business		ACTELION	AC-063B201		Regulatory Mechanisms for Resolution of Inflammatory Microvascular Leakage
Del Valle,Luis	Federal		NIH, Nat Inst of Neurological Disorders	7R01NS05644-05		Impact of Alcohol on Hemorrhagic Shock-Induced Microvascular Dysfunction
Desai,Shyamal D.	State		Board of Regents			Post-Traumatic Stress Disorder and Alcohol Dependence
Desai,Shyamal D.	Foundation		Ataxia telangiectasia Children's Project	AT Children's Projec		Can Walnuts Slow Growth and Delay Cancer - Associated Cachexia
Desselle,Bonnie C	Private Institutions		Children's Hospital	C11-74-089		Role of Heparan Sulfate 6-O-Endosulfatase 1 and 2 in Pulmonary Fibrosis
Devier,Deirdre J	Foundation		National Alliance for Research on	NARSAD		Impact of Alcohol Intoxication on Recovery from Traumatic Brain Injury
Diaz,James H	Fed Subcontract	HHS, Ctr for Disease Control & Preventio	RTI International	CDC 200-2010-34803	200-2010-34803	Impact of Alcohol Intoxication on Lymphatic Contractile Mechanisms
Dicarlo,Richard P	Business		Vaxgen	VAX004		Impact of Alcohol Intoxication on Lymphatic Contractile Mechanisms
Dunbar,Lala Mathers	Business		GlaxoSmithkline Pharmaceuticals	265805-112		NOVEL FLUORIDE RELEASING DENTAL COMPOSITE RESIN
Dunbar,Lala Mathers	Fed Subcontract	HHS, Ctr for Disease Control & Preventio	University of California, Los Angeles	U01CI000353-03	5U01CI000353-03	SPECIAL PROJECTS OF NATIONAL SIGNIFICANCE
Dunbar,Lala Mathers	Business		Medpace, Inc	NAB-BC-3781-2001		BRPA IN VIRULENCE MODULATION OF STREPTOCOCCUS MUTANS
Dunbar,Lala Mathers	Business		Paragon Biomedical, Inc	CEM-101		Mechanisms Governing Monocyte Recruitment During Periodontal Inflammation
Eady,Tiffany Niemoller	Federal		NIH, National Institute on Aging	4F30AG032841-03		Mechanisms Governing Monocyte Recruitment during
Eady,Tiffany Niemoller	Federal		NIH, National Institute on Aging	4F30AG032841-03		Targeting Host and Fungal Eicosanoids During Candida albicans bloodstream Infections
England,John	Fed Subcontract	NIH, Nat Inst of Neurological Disorders	Tulane University	2R01NS048952-06	2R01NS048952-06	Impact of Candida Oxyliplins on Host Immunity and Fungal Biology
Erickson,Jeffrey D	Foundation		National Alliance for Research on	NARSAD		The Role of Candida Albicans Biofilms in a Novel Rat Model of Denture Stomatitis
Espinoza,Luis R	Business		Rheumatology Research International Inc	FUJI 049		A PROSPECTIVE, OBSERVATIONAL STUDY OF OSSEOTITE CERTAIN IOL IMPLANTS IN IMMEDIATE OCCLUSAL
Espinoza,Luis R	Business		Scirex	113-B02OCTR.021.TRA		TREATMENT OF GENERAL DENTAL PROCEDURES
Espinoza,Luis R	Business		Novartis Pharmaceuticals Corporation	COX189A 2335 c552		CLINICAL EVALUATION OF OSTER GRAF/CS-300
Espinoza,Luis R	Business		Tap Pharm	CO2-021		BONE RETENTION QUALITIES OF THE LASERLOK DENTAL IMPLANT
Espinoza,Luis R	Business		Pfizer Inc	A3921024		GENERAL TRAINING GRANT DONATION
Espinoza,Luis R	Business		Pfizer Inc	A3921035		Prospective Evaluation of Early Loading of Zimmer Hydroxyapatite Coated Dental Inplants
Espinoza,Luis R	Business		Roche Laboratories Inc.	ML21136		Evaluation of the stability of ,the 8 mm OsseoSpeed and OsseSpeed TM
Espinoza,Luis R	Business		Pfizer Inc	A3921032		Immediate Loading of the Nobelreplace Tapered Groovy Implant When Placed in Fresh and Healed Extraction
Espinoza,Luis R	Business		Pfizer Inc	A3921069		SINGLE TOOTH IMPLANTS SUPPORTED RESTORATION 6/31/02 Account changed to 122600019A
Espinoza,Luis R	Fed Subcontract	NIH, Inst Arthritis and Musculoskeletal	University of Alabama	5R01AR057202-02	5R01AR057202-02	BOND STRENGTH OF A NEW BONDING SYSTEM FOR PORCELAIN LAMINATE VANEERS
Espinoza,Luis R	Business		Covance	TMX-67-301		FABRICATION OF CROSS-LINKED POLYMER NANOFIBERS BY COUPLING ELECTROSPINNING IN-LINE WITH
Espinoza,Luis R	Private Institutions		Howard University	0006604-1000036762		Novel Antibacterial Fluoride-releasing Dental Materials
Estrada,John J	Fed Subcontract	NIH, Center on Minority Health and	Dillard University	1 P20MD004817-01	1P20MD004817-01	PHASE III CLINICAL TRIAL PROTOCOL 2011A-PR003
Estrada,John J	Fed Subcontract	NIH, Center on Minority Health and	Dillard University	1 P20MD004817-01	1P20MD004817-01	MENTORING ORAL HEALTH RESEARCH IN LOUISIANA-PROJECT 1
Estrada,John J	Fed Subcontract	NIH, Center on Minority Health and	Dillard University	1 P20MD004817-01	1P20MD004817-01	MENTORING ORAL HEALTH RESEARCH IN LOUISIANA-ADMIN CORE
Estrada,John J	Fed Subcontract	NIH, Center on Minority Health and	Dillard University	1 P20MD004817-01	1P20MD004817-01	MENTORING ORAL HEALTH RESEARCH IN LOUISIANA-EQUIPMENT CORE
Estrada,John J	Fed Subcontract	NIH, Center on Minority Health and	Dillard University	1 P20MD004817-01	1P20MD004817-01	MENTORING ORAL HEALTH RESEARCH IN LOUISIANA-STATISTICAL CORE
Estrada,John J	Fed Subcontract	NIH, Center on Minority Health and	Dillard University	1 P20MD004817-01	1P20MD004817-01	ROLE OF VACUOLE EXPANSION IN ORAL PATHOGEN CANDIDA ALBICANS
Estrada,John J	Fed Subcontract	NIH, Center on Minority Health and	Dillard University	1 P20MD004817-01	1P20MD004817-01	EFFECT OF AGING ON PERIODONTAL DISEASE
Estrada,John J	Fed Subcontract	NIH, Center on Minority Health and	University of Alabama	000318383-003	5P60MD0000502-09	DEVELOPMENT OF NEW ADHESIVE FLUORIDE-RELEASING MONOMERS
Fang,Zhide	Fed Subcontract	NIH, National Ctr for Research Resourc	Xavier University	OSP-11-241418-001	2P20RR016456	CX3CL1-DRIVEN MONOCYTE RECRUITMENT DURING PERIODONTITIS
Ferris,Michael J	Private Institutions		Children's Hospital, Research Institute	CHILDREN'S HOSP-RIC		MENTORING ORAL HEALTH RESEARCH IN LOUISIANA-START UP
Fidel Jr.,Paul L	Fed Subcontract	U.S. Department of Housing and Urban Dev	Board of Regents	RCEEP-02 (2007-10)	PL109-148	Mentoring Oral Health Research in Louisiana - Yuwei Fan
Fidel Jr.,Paul L	Fed Subcontract	U.S. Department of Housing and Urban Dev	Board of Regents	RCEEP-02 (2007-10)	PL109-148	MENTORING ORAL HEALTH RESEARCH IN LOUISIANA - Admin Sup Noverr Pilot Proj
Fidel Jr.,Paul L	Fed Subcontract	U.S. Department of Housing and Urban Dev	Board of Regents	RCEEP-02 (2007-10)	PL109-148	MENTORING ORAL HEALTH RESEARCH IN LOUISIANA - PALAIOLOGOU
Fidel Jr.,Paul L	Fed Subcontract	U.S. Department of Housing and Urban Dev	Board of Regents	RCEEP-02 (2007-10)	PL109-148	Partnering with Ville Ste. Marie in Linking Seniors to NLM's Consumer Health Information
Fidel Jr.,Paul L	Fed Subcontract	U.S. Department of Housing and Urban Dev	Board of Regents	RCEEP-02 (2007-10)	PL109-148	Affordable Care Act: Primary Care Residency Expansion
Fidel Jr.,Paul L	Fed Subcontract	U.S. Department of Housing and Urban Dev	Board of Regents	RCEEP-02 (2007-10)	PL109-148	Affordable Care Act: Primary Care Residency Expansion
Fidel Jr.,Paul L	Federal		NIH, National Ctr for Research Resourc	5P20RR020160-02		Gulf Coast Halth Alliance:Health Risks related to the Macondo Spill (GC-HARMS)
Fidel Jr.,Paul L	Federal		NIH, National Ctr for Research Resourc	5P20RR020160-05		DETERMINE GENETIC SUSCEPTIBILITY TO LUNG CANCER
Fidel Jr.,Paul L	Federal		NIH, National Ctr for Research Resourc	5P20RR020160-05		TAKE SAMPLES IN AN ACYCLOVIR RESISTANT HERPLEX VIRUS STUDY
Fidel Jr.,Paul L	Federal		NIH, National Ctr for Research Resourc	5P20RR020160-05		ANTHYPERTENSIVE AND LIPID-LOWERING TMT FOR HEART ATTACK
Fidel Jr.,Paul L	Federal		NIH, National Ctr for Research Resourc	5P20RR020160-05		AIDSVAX B VACCINE IF ADULTS AT RISK OF HIV-1 INFECTION
Fidel Jr.,Paul L	Federal		NIH, National Ctr for Research Resourc	5P20RR020160-05		GRANULOCYTE COLONY-STIMULATING FACTOR TO INFECTIOUS DISEASE
Fidel Jr.,Paul L	Federal		NIH, National Ctr for Research Resourc	5P20RR020160-05		PULMONARY CAPILLARY PRESSURE MEASUREMENT

ATTACHMENT 1: LSUHSC-NO ACTIVE RESEARCH DEVELOPMENT AWARD/CONTRACT LIST

P.I. Name	Category	Primary Spnser	Direct Sponsor	Ref Awd #	Ref Awd #2	Project Title
Fidel Jr.,Paul L	Federal		NIH, National Ctr for Research Resourc	5P20RR020160-05		KW2189 FOR RELAPSED GASTRIC CARCINOMA
Fidel Jr.,Paul L	Federal		NIH, National Ctr for Research Resourc	5P20RR020160-05		MOXIFLOXICIN VERSUS CEFTRAXONE IV/PO CEFUROXIME -AXETIL
Fidel Jr.,Paul L	Federal		NIH, National Ctr for Research Resourc	5P20RR020160-05		APTIMA COMBO2 ASSAY FOR CHALYDIA TRACHOMATIS
Fidel Jr.,Paul L	Federal		NIH, National Ctr for Research Resourc	3P20RR020160-0551		OPC-17116 VS DOXYCYCLINEFOR NONGONOCOCCAL IN URETHRITIS
Fidel Jr.,Paul L	Federal		NIH, National Ctr for Research Resourc	3P20RR020160-0551		PHASE I/II STUDY OF BIOLOGIC RESPONSE TO FILGRASTIM
Filipeanu,Catalin	Federal		NIH, National Institute on Drug Abuse	1R03DA031596-01		TWO CENTER DOSE-RANGING STUDY OF CP-99,219
Fisch,Bruce	Business		Hoechst Marion Roussel	071754ST1669		NORTH AMERICAN AMPLIFIED CHLAMYDIA TRACHOMATIS STUDY
Fisch,Bruce	Business		NeuroPace, Inc			BB-2516 MARIISTAT FOR MINIMAL DISEASE STAGE III NSCLC
Fisch,Bruce	Business		NeuroPace, Inc			BB-2516 MARIMASTAT IN NSCLC
Fisch,Bruce	Business		NeuroPace, Inc			EVALUATION OF DYSMORPHIA/DYSREGULATION SYNDROME
Fontham,Elizabeth T	State		LSU Pennington Biomedical Research Ctr	SPH-D012-BG-1100		STUDY OF AD1549 IN COMBINATION WITH VIRACEPT
Foster,Timothy P.	State		Board of Regents	LEQSF(2008-11)-RDA13		BD PROBE TEC ET SYSTEM
Foster,Timothy P.	Institution				Cost Share	PERFORMANCE CHARACTERISTICS FOR MALE URINE & URETHRAL SPECIM
Foundas,Anne L.	Fed Subcontract	NIH, Nat Inst of Neurological Disorders	Kessler Medical Rehab Research Center	323-02	1 R01NS055808-01A2	TREATMENT OF ACUTE EXACERBATION OF CHRONIC BRONCHITIS
Foundas,Anne L.	Federal		NIH, Inst on Deafness & Other Comm	7R03DC004957-04		BL-3 LAB SUPPORT FUNDS
Friend,Richard	Federal		HHS, Health Resources & Service Admin	1T89HP20850-01-00		REGRANEX FOR FULL THICKNESS DIABETIC NEUROPATHIC FOOT ULCERS
Friend,Richard	Federal		HHS, Health Resources & Service Admin	1T89HP20850-01-00		ASSESS EFFECTS OF R047-0203 ON EXERCISE CAPACITY IN PATIENTS
Gardner,Jason D.	State		Board of Regents	LEQSF(2009-12)RDA-10		CLINICAL VERIFICATION OF NEW WET SWAB TRANSPORT SYSTEM
Gardner,Jason D.	Foundation		American Heart Association	11GRNT7700002		INTERERON GAMMA-1B W/ANTIMYCOBACTERIALS FOR MAC INFECTION
Gardner,Jason D.	Institution				Cost Share	PHASE 3 EFFICACY TRIAL OF AZITHROMYCYLIN VE BENZTHINE PENCIL
Gasparini,Sonia	Federal		NIH, Nat Inst of Neurological Disorders	1R01NS069714-014		MODIFYING ANTIRHEUMATIC DRUGS
Gasser,Raymond F	Federal		NIH, Nat Inst Child Health & Human Dev	2 R01 HD037811-08A1		EVALUATION OF THE BIOSTAR CHLAMYDIA OIA AND GONORRHOEA OIA ASSAYS FOR IN VITRO DAIGNOSIS IF
Gasser,Raymond F	Federal		NIH, Nat Inst Child Health & Human Dev	3R01HD037811-08A1S1		STAXSENTAN SODIUM FOR PULMONARY ARTERIAL HYPERTENSION
Gee,Rebekah	Private Institutions		National Academies - Institute of Medici			MULTICENTER, OPEN-LABEL, SINGLE-ARM SAFETY STUDY OF BOSENTAN IN PATIENTS WITH PULMONARY
Giarratano,Gloria	Federal		NIH, Institute of Nursing Research	1R03NR012052-01		A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED SAFETY AND EFFICACY STUDY OF STAXSENTAN
Gilbert,Jill	Foundation		National Surgical Adjuvant Breast And Bo	PFED15-LSU-01		AMLODIPINE AND VASCULAR PROTEOGLYCAN METABOLISM
Gilbert,Jill	Foundation		Susan G Komen Breast Cancer Found			A RANDOMIZED, DOUBLE-BLIND STUDY COMPARING ARANESP (DAREPOETIN ALFA) AND RECOMBINANT
Gilbert,Jill	Foundation		CTRC Research Foundation	S0111		A PHASE III DOUBLE-BLIND, PARALLEL GROUP, MULTICENTER, PLACEBO CONTROLLED STUDY OF CICLESONIDE
Giles,Thomas D	Fed Subcontract	NIH, Nat Inst of Neurological Disorders	Univ of Medicine & Dentistry of NJ	1U01NS43975-01	U01NS43975	A DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL, MULTICENTER STUDY ON EXTENDED VTE PROPHYLAXIS
Gilpin,Nicholas	Federal		NIH, National Inst. on Alcohol Abuse	4R00AA018400-03		ASTHMA CLINICAL RESEARCH
Glynn,Gary R	Business		Pharmanet, Inc.	CAPS083		SURVEY OF THE IN-VITRO ACTIVITY OF PIPERACILLIN/TAZOBACTAM AND OTHER ANTIMICROBIAIS AGAINST
Gorman,Melissa	Private Institutions		McMaster University	EX-TIB-0907		BARF SILER COATED ENDOTRACHEAL TUBE STUDY
Gould,Harry J	Business		CV Therapeutics	CVT		A 12 WEEK, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO AND ACTIVE-CONTROLLED STUDY OF
Gould,Harry J	Business		Genzyme			A DOUBLE-BLIND, RANDOMIZED, DOSE-RANGING, PARALLEL GROUP COMPARISON OF THE EFFICACY AND
Grabczyk,Edward L	Business		Friedreich Ataxia	Friedrich's Ataxia		GEN-PROBE APTIMA COMBO ASSAY, THE APTIMA CT ASSAY, AND THE APTIMA GC ASSAY
Greenleaf,Wayne A	Fed Subcontract	HHS, Admin for Children & Families	LA, Department of Education	FEDERAL TANF FUNDS	FEDERAL TANF FUNDS	PREVENTION OF PROGRESSION OF FIBROSIS IN ADULT SUBJECTS WITH CHRONIC HEPATITIS C WITH HEPATIC
Greenleaf,Wayne A	Fed Subcontract	HHS, Admin for Children & Families	LA, Department of Education	CFMS 612291	TANF FUNDS	STAXSENTAN SODIUM TREATMENT IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION
Gregory,Paula E	Federal		NIH, National Heart Lung & Blood Inst	1 T35HL105350-01		EVALUATE ISEGANAN HC1 ORAL SOLUTION IN PREVENTING VENTILATOR-ASSOCIATED PNEUMONIA
Gregory,Paula E	Federal		NIH, National Heart Lung & Blood Inst	1 T35HL105350-01		PATIENTS WITH RHEUMATOID ARTHRITIS USING NAPROXEN
Gregory,Paula E	Federal		NIH, National Inst. on Alcohol Abuse	1R25AA021304-01		MEROPENEM, ERTAPENEM, IMIPENEM W/OTHER ANTIMICROBIALS AGAINST CLINICALLY SIGNIFICANT
Gregory,Paula E	Federal		NIH, National Inst. on Alcohol Abuse	1R25AA021304-01		ALCOHOL & REACTIVATION TB
Gregory,Paula E	Federal		NIH, National Inst. on Alcohol Abuse	1T35AA021097-01		SYMBICORT PMDI STUDY
Gutierrez,Amparo	Business		Berlex Labs	306440		BACTERIOIDES SUSCEPTIBILITY TESTING OF MOXIFLOXACIN AND OTHER AGENTS
Gutierrez,Amparo	Business		Teva Neuroscience, Inc	MS-LAQ-302		WARFIRIN VS ASPIRIN IN REDUCED CARDIAC EJECTION FRACTION
Gutierrez,Amparo	Business		Biogen	101JC402		VITECK 2 GPAC9 SUSCEPTIBILITY CARD FDA TRIA
Haas,Arthur L.	Federal		NIH, National Inst of General Med Sci	2R01GM034009-22		COMPARISON OF THE IN VITRO ACTIVITY OF MEROPENEM, ERTAPENEM, IMIPENEM WITH OTHER
Haas,Arthur L.	Federal		NIH, National Inst of General Med Sci	2R01GM034009-22		PREVALENT AND INCIDENT CARDIOVASCULAR RISK FACTORS AMONG HIV INFECTED PATIENTS INITIATING
Haas,Arthur L.	Institution				Cost Share	ALCOHOL, PULMONARY CYTOKINES AND HOST DEFENSE
Hagensee,Michael E	Business		TriPath Imaging			A PROSPECTIVE, RANDOMIZED, OPEN-LABEL STUDY COMPARING THE VIRAL KINETICS & PHARMACOKINETICS
Hagensee,Michael E	Federal		NIH, National Cancer Institute	1R01CA121979A		RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY TO COMPARE THE SAFETY AND EFFICACY OF
Hagensee,Michael E	Business		Merck & Co., Inc.	V501-042		A PHASE 2B STUDY OF MERIMEPODIB IN COMBINATION WITH PEGYLATED INTERFERON ALFA-2A AND
Hagensee,Michael E	Federal		NIH, National Cancer Institute	NCI-CA121979-0251		GULF SOUTH STI/TOPICAL MICROBICIDE COOPERATIVE RES CENT - PROJECT 1
Halabi,Anasheh	Federal		NIH, National Institute on Aging	1F30AG042263-01		GULF SOUTH STI/TOPICAL MICROBICIDE COOPERATIVE RES CENT
Happel,Kyle I	Federal		NIH, National Inst. on Alcohol Abuse	1K08AA015163-01		RANDOMIZED CLINICAL STUDY COMPARING CERVICAL COLLECTION DEVICES
Happel,Kyle I	Foundation		American Lung Association	American Lung Associ		AN 8 WEEK, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY TO ASSESS THE EFFICACY OF
Happel,Kyle I	Foundation		American Lung Association	American Lung Associ		A PHASE 3 RANDOMIZED, MULTI-CENTER, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO CONTROLLED
Happel,Kyle I	Foundation		American Lung Association	American Lung Associ		A PROSPECTIVE, MULTICENTER, OPEN-LABEL, COMPARATIVE, EFFICACY STUDY OF PEGASYS PLUS COPEGUS IN
Harris,Ronald A.	State		Governor's Office	Governor's Office		A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, 52-WEEK STUDY TO COMPARE THE EFFECT OF
Harrison,Laura M.	State		Board of Regents	LEQSF(2009-11)RD-A11		A PHASE II OPEN-LABEL STUDY TO ASSESS THE LONG-TERM SAFETY OF ORAL FEBUXOSTAT IN SUBJECTS WITH
Harrison-Bernard,Lisa M.	Foundation		Amer Society of Hypertension, Inc			CLINICAL EVALUATION OF THE BD PROBETEC ET SYSTEM AND THE BD VIPER FOR THE DIRECT QUALITATIVE
Harrison-Bernard,Lisa M.	Foundation		American Heart Association	09GRNT2250875		IN VIVO TARGETED DC VACCINE TO ACTIVATE ANTI-TUMOR CTL
Haydel,Micelle	Private Institutions		Council of Emer Med Residency Directors	Coun of Em Resi Dire		IN VIVO TARGETED DC VACCINE TO ACTIVATE ANTI-TUMOR CTL
Hill,James Milton	Business		Glaxo Wellcome, Inc.			A RANDOMIZED, DOUBLE-BLIND, CONTROLLED EVALUATION OF TENOFOVIR DF VERSUS ADEFOVIR DIPIVOXIL
Hill,James Milton	Federal		NIH, National Eye Institute	NEI-EY006311-23		HOMING AND DIFFERENTIATION OF ADULT STEM CELLS TO LUNG
Hollenbach,Andrew D.	Federal		NIH, National Cancer Institute	1R01CA138656-01A1		CLINICAL RESEARCH NETWORK FOR THE TREATMENT OF ACUTE LUNG INJURY (ALI) AND THE ACUTE
Hong,Song	Federal		NIH, Nat Inst Diabetes & Diges & Kidney	1R01DK087800-01		ACUTE LUNG INJURY & ACUTE RESPIRATORY DISTRESS SYNDROME
Hong,Song	Federal		NIH, Nat Inst Diabetes & Diges & Kidney	1R01DK087800-01		CLINICAL RESEARCH NETWORK FOR THE TREATMENT OF ACUTE LUNG INJURY (ALI) AND THE ACUTE
Hornby,Pamela	Business		Astra Hassle, Ab			ACUTE LUNG INJURY & ACUTE RESPIRATORY DISTRESS SYNDROME
Hu,Jennifer J.	Foundation		American Cancer Society	RSG-01-138-01-CNE		AN EPIDEMIOLOGIC STUDY OF XOLAIR (OMALIZUMAB): EVALUATING CLINICAL EFFECTIVENESS AND LONG-
Insler,Michael S	Business		ORA, Inc.	C-01-401-004		CPG 10103 COMBINATION THERAPY FOR THE TREATMENT OF HEPATITIS C: A PHASE II RANDOMIZED, OPEN
Iwakuma,Tomoo	Fed Subcontract	NIH, National Cancer Institute	Tulane University	TUL-HSC-100-07/08	1R01CA132603-01	ALCOHOL INFECTION AND HOST RESPONSE-ADMINISTRATIVE CORE
Iwakuma,Tomoo	Fed Subcontract	NIH, National Ctr for Research Resourc	Tulane University	2P20RR020152-06	P20RR020152	A MULTICENTER STUDY TO EVALUATE GENZYME DIAGNOSTIC'S OSOM CANDIDA RAPID TEST AS A
Iwakuma,Tomoo	Fed Subcontract	NIH, National Ctr for Research Resourc	Tulane University	2P20RR020152-06	P20RR020152	EVALUATION OF CINACALCET HCI THERAPY TO LOWER CARDIOVASCULAR EVENTS
Iwakuma,Tomoo	Foundation		American Cancer Society	RSG-09-169-01-CSM		A COMPARISON OF SAFETY AND INHALATION TIMES OF VENTAVIS (ILOPROST) DELIVERED BY I-NEB UTILIZING

ATTACHMENT 1: LSUHSC-NO ACTIVE RESEARCH DEVELOPMENT AWARD/CONTRACT LIST

P.I. Name	Category	Primary Spnsr	Direct Sponsor	Ref Awd #	Ref Awd #2	Project Title
Izumi,Tadahide	Federal		NIH, National Cancer Institute	NCI - CA098864-05A2		A COMPARISON OF IPRATROPIUM BROMIDE/SALBUTAMOL DELIVERED BY THE RESPIMAT INHALER TO
Izumi,Tadahide	Federal		NIH, National Cancer Institute	NCI - CA098864-05A2		A 26 WEEK TREATMENT, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, ADAPTIVE,
Jacob,Jean T	Business		Aton Pharma	Aton Pharma		CLINICAL EVALUATION OF THE BD VIPER FOR THE DIRECT QUALITATIVE SCREENING OF C.TRACHOMATIS AND
Jacob,Jean T	Business		Alcon Research, Ltd	Alcon Research		INHALED PREPRANDIAL HUMAN NSULIN WITH THE AERX IDIMS VERSUS SUBCUTANEOUS INJECTED INSULIN
Jacob,Jean T	Business		DSM PTG, Inc	DSM PTG, Inc		ALCOHOL INFECTION & HOST RESPONSE-ADMINISTRATIVE CORE
Jacob,Jean T	Business		Alcon Research, Ltd	Alcon Research		STUDY OF AST-120 FOR PREVENTION OF CHRONIC KIDNEY DISEASE PROGRESSION IN PATIENTS WITH
Jin,Minghao	Federal		NIH, National Eye Institute	1R01EY021208-01A1		A PROSPECTIVE OBSERVATIONAL STUDY TO EVALUATE LONG-TERM SAFETY AND FUNCTIONAL STATUS OF
Ju,Jihang	Foundation		American Heart Association	11POST8000008		A PROSPECTIVE OBSERVATIONAL STUDY TO EVALUATE LONG-TERM SAFETY AND FUNCTIONAL STATUS OF
Kantrow,Stephen P	Business		Allegro Diagnostics	ADX-0001		A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP STUDY TO EVALUATE THE SAFETY AND EFFICACY OF
Kapusta,Daniel	Federal		NIH, National Ctr for Research Resourc	2P20RR018766-06		CLINICAL EVALUATION OF THE BD VIPER SYSTEM FOR THE DIRECT QUALITATIVE SCREENING OF C
Kapusta,Daniel	Federal		NIH, National Ctr for Research Resourc	2P20RR018766-06		BOARD OF REGENTS SUBCONTRACT - THE CLINICAL AND TRANSLATIONAL RESEARCH EDUCATION AND
Kapusta,Daniel	Federal		NIH, National Ctr for Research Resourc	2P20RR018766-06		BOARD OF REGENTS SUBCONTRACT-THE CLINICAL AND TRANSLATIONAL RESEARCH EDUCATION AND
Kapusta,Daniel	Federal		NIH, National Ctr for Research Resourc	2P20RR018766-06		BOARD OF REGENTS SUBCONTRACT-THE CLINICAL AND TRANSLATIONAL RESEARCH EDUCATION AND
Kapusta,Daniel	Federal		NIH, National Ctr for Research Resourc	2P20RR018766-06		ROTAVIRUS BURDEN OF DISEASE IN THE INSTITUTIONALIZED ELDERLY
Kapusta,Daniel	Federal		NIH, National Ctr for Research Resourc	2P20RR018766-06		BIOINFORMATICS AND BIOTECHNOLOGY RESEARCH INITIATIVES: GLOBAL GENOME AND TRANSCRIPTOME
Kapusta,Daniel	Federal		NIH, National Ctr for Research Resourc	2P20RR018766-06		EMERGENCY ID NET
Kapusta,Daniel	Federal		NIH, National Ctr for Research Resourc	2P20RR018766-06		A SAFETY AND EFFICACY STUDY OF BLOOD PRESSURE CONTROL IN ACUTE HEART FAILURE-A PILOT STUDY
Kapusta,Daniel	Federal		NIH, National Ctr for Research Resourc	2P20RR018766-06		EMPIRIC THERAPY OF MUCOPURULENT CERVICITIS (MPC) FOR CHLAMYDIA AND GONORRHEA INFECTION IN
Kapusta,Daniel	Federal		NIH, National Ctr for Research Resourc	2P20RR018766-06		LONG-TERM SINGLE-ARM OPEN-LABEL EXTENSION STUDY OF THE SERAPHIN STUDY, TO ASSESS THE SAFETY
Kapusta,Daniel	Federal		NIH, National Ctr for Research Resourc	2P20RR018766-06		AN INTERNATIONAL, MULTICENTER, PROSPECTIVE OBSERVATIONAL STUDY OF THE SAFETY OF MARAVIROC
Kapusta,Daniel	Federal		NIH, National Ctr for Research Resourc	2P20RR018766-06		A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, DOSE-RANGING STUDY OF
Kapusta,Daniel	Foundation		American Heart Association	0855293E		DIAGNOSTIC TEST UTILIZING GENE EXPRESSION ANALYSIS OF AIRWAY EPITHELIAL CELLS FOR LUNG CANCER
Kaufman,Herbert Edward	Foundation		Research To Prevent Blindness			A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, STUDY OF FG-3019 IN SUBJECTS WITH
Kelly,Ben	Federal		NIH, Nat Inst on Allergy & Infec Disease	1R21AI085172-01A1		Microbial Correlates of Bacterial Vaginosis Treatment Failure and Recurrences in Heterosexual Couples
Khoobeji,Bahram	Business		Pfizer Inc	2182		Sexually Transmitted Infections Clinical Trials Group protocol entitled "Empiric Therapy of Mucopurulent
Khoobeji,Bahram	Business		Pfizer Inc			In Vivo Targeted DC Vaccine to Activate Anti-tumor CTL
Khoobeji,Bahram	Foundation		LSUHSC Foundation NO	671037		A randomized, double-blind, 3-arm Parallel-group, 2-year (104-week), multicenter study to evaluate the
Kim,Sunyoung	Federal		NIH, National Inst of General Med Sci	1R01GM097350-01		Gulf South STI/Topical Microbicide Cooperative Research Center - Quayle
Kolls,Jay Kennedy	Fed Subcontract	NIH, Nat Inst on Allergy & Infec Disease	Vanderbilt University	VANDERBILT UNIV	5 R01AI070672-02	Gulf South STI/Topical Microbicide Cooperative Research Center - Martin
Kolls,Jay Kennedy	Federal		NIH, National Inst. on Alcohol Abuse	NIAAA - AA016688-04		Gulf South STI/Topical Microbicide Cooperative Research Center - Pyles
Kolls,Jay Kennedy	Federal		NIH, National Inst. on Alcohol Abuse	NIAAA - AA016688-04		Gulf South STI/Topical Microbicide Cooperative Research Center - Kisinger
Kolls,Jay Kennedy	Federal		NIH, National Inst. on Alcohol Abuse	NIAAA - AA016688-04		Gulf South STI/Topical Microbicide Cooperative Research Center - Martin
Kolls,Jay Kennedy	Federal		NIH, National Heart Lung & Blood Inst	2 R01HL061271-10A1		Gulf South STI/Topical Microbicide Cooperative Research Center - Core B (Matrin)
Kolls,Jay Kennedy	Fed Subcontract	NIH, National Heart Lung & Blood Inst	University of Pittsburgh	PHL084932A	7P50HL084932-04	Gulf South STI/Topical Microbicide Cooperative Research Center - Core C
Kolls,Jay Kennedy	Federal		NIH, National Inst. on Alcohol Abuse	3R01AA016688-04S1		Gulf South STI/Topical Microbicide Cooperative Research Center - Core D (Myers)
Kolls,Jay Kennedy	Federal		NIH, National Inst. on Alcohol Abuse	3R01AA016688-04S1		Alcohol, HIV Infection and Host Defense
Kolls,Jay Kennedy	Federal		NIH, National Heart Lung & Blood Inst	2R01HL062052-13		ALCOHOL INFECTION & HOST RESPONSE-EDUC/TRANSLATIONAL RES
Kolls,Jay Kennedy	Federal		NIH, National Heart Lung & Blood Inst	5R37HL079142-07		A Multicenter, Retrospective of Patients with Pulmonary Arterial Hypertension Transitioned from Parenteral
Kolls,Jay Kennedy	Federal		NIH, National Heart Lung & Blood Inst	1R21HL104601-01A1		ASTHMA CLINICAL RESEARCH
Koochekpour,Shahriar	Federal		NIH, National Cancer Institute	1R21CA149137-01		ASTHMA CLINICAL RESEARCH - SOYA
Koochekpour,Shahriar	Federal		NIH, National Cancer Institute	1R21CA143589-01A1		ASTHMA CLINICAL RESEARCH - STAN
Koochekpour,Shahriar	Federal		NIH, Center on Minority Health and	NCMHHD 1R01MD005824		Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of 2 Doses of CP-
Kozlowski,Pamela A.	Fed Subcontract	NIH, Nat Inst on Allergy & Infec Disease	Emory University	1P01AI096187-01		A Randomized, Placebo-controlled Comparison of the Effects of two doses of LY2189265 or Extenate on
Kozlowski,Pamela A.	Fed Subcontract	NIH, Nat Inst on Allergy & Infec Disease	Harvard University	151128-0104	P01AI071306	Phase 3 Randomized, Double-Blind Study of the Efficacy and Safety of 2 Doses of CP-690,550 Compared to
Kozlowski,Pamela A.	Fed Subcontract	NIH, Nat Inst on Allergy & Infec Disease	Geo Vax, Inc.	Geo Vax	U19AI074073	Randomized Evaluation of efficacy and safety of ferric carboxymaltose in Patients with iron deficiency Anemia
Kozlowski,Pamela A.	Fed Subcontract	NIH, Nat Inst on Dental & Craniofacial	Children's Hospital Boston	83586	5 R01DE019060	IL-7 and Murine Pneumocystis Pneumonia
Kozlowski,Pamela A.	Fed Subcontract	NIH, Nat Inst on Dental & Craniofacial	Fred Hutchinson Cancer Research Center	0000672073	5 R01 DE019063-02	Evaluation of the performance of the cobas 4800 CT/NG test and cobas 4800 PCR collection kit for detection
Lazartigues,Eric D.	Federal		NIH, National Heart Lung & Blood Inst	1R01HL093178-01		A Menu for AIDS for AIDS Patients to EAT Safely
Lazartigues,Eric D.	State		Board of Regents	Board of Regents		Safety and Efficacy of WC2031 versus Bibra Mycin for the treatment of uncomplicated Urogenital Chlamydia
Lazartigues,Eric D.	Federal		NIH, National Heart Lung & Blood Inst	3R01HL093178-01S1		P 3 - A Randomized, Placebo-Controlled Comparison of the Effects of Two Doses of LY2189265 or Extenate
Lazartigues,Eric D.	Federal		NIH, Nat Inst Diabetes & Digest & Kidney	1R21DK084466-01A1		Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR-TIMI 53)"
Lazartigues,Eric D.	Fed Subcontract	NIH, National Heart Lung & Blood Inst	Wright State University	668046	R01HL098637	A Phase 2, multi-center, randomized, double-blind study comparing the safety and efficacy of two doses of
Lazartigues,Eric D.	Foundation		American Heart Association	12EIA0803004		Vaginitis Sample Acquisition and/or Testing
Lee,Keunbaik	Fed Subcontract	NIH, National Institute on Aging	University of Florida	UF09146	R01 AG033005	A Randomized, Double-Blind, Multi-Center Study to Evaluate the Efficacy and Safety of Oral CEM-101
Leigh,Janet E	Institution				Cost Share	A Randomized, Multicenter Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects
Li,Xiao Ching	Federal		NIH, National Institute of Mental Health	1R21MH081254-01A2		A multicenter, double-blind, placebo-controlled Phase 3 study to demonstrate the efficacy and safety of ACT
Li,Xiao Ching	Foundation		NARSAD	17989		Clinical Evaluation of the APTIMA Assay for Chlamydia trachomatis Using the Panther System
Lillis,Rebecca A.	Fed Subcontract	NIH, Nat Inst on Allergy & Infec Disease	University of Alabama	HHSN266200400073C	HHSN266200400073C	Repeated Bacterial STIS Among Heterosexual Men
Lin,Tara	Foundation		Ladies Leukemia League	Ladies Leukemia		African-American Rheumatoid Arthritis Network
Liu,Si-Qiong J.	Federal		National Science Foundation	NSF -IOS -0344559		Transcriptomics of Tuberculosis Latency and Reactivation in Primates
Liu,Si-Qiong J.	Federal		NIH, Nat Inst of Neurological Disorders	NINDS - NS058867-04		Alcohol, HIV Infection and Host Defense-ADMINISTRATIVE CORE
Liu,Si-Qiong J.	Federal		NIH, National Institute of Mental Health	1R01MH095948-01A1		Alcohol, HIV Infection and Host Defense -RES COMP 1
Liu,Wanguo	Federal		NIH, National Cancer Institute	1R01CA115555-01		ALCOHOL , HIV INFECTION & HOST RESPONSE-RES COMP 2
Liu,Wanguo	Federal		NIH, National Cancer Institute	3R01CA115555-03S1		ALCOHOL,HIV INFECTION & HOST RESPONSE-RES COMP 3
Liu,Wanguo	Fed Subcontract	NIH, National Ctr for Research Resourc	Tulane University	TUL-HSC-240-10/11	5P20RR020152-07	Alcohol, HIV Infection and Host Defense - Research Comp 4
Liu,Wanguo	Private Institutions		University Of Kansas Medical Center	Q1856050		ALCOHOL, HIV INFECTION & HOST RESPONSE - RES COMP 5
Lovera,Jesus F.	Federal		NIH, Complementary & Alternative Medicin	1K23AT004433-01		ALCOHOL, HIV INFECTION & HOST RESPONSE- ANM CORE
Lowrey,Karen A.	Institution				Cost Share	Alcohol, HIV Infection and Host Defense - Lab Core
Lu,Youming	Federal		NIH, National Institute on Aging	7R01AG033282-01		Alcohol, HIV Infection and Host Defense - Trans Res/Education Component
Lu,Youming	Federal		NIH, National Institute on Aging	7R01AG033282-01		Alcohol, HIV Infection and Host Defense - Pilot 1
Lu,Youming	Federal		NIH, Nat Inst of Neurological Disorders	7R01NS051383-03		Alcohol, HIV Infection and Host Defense - Pilot 2
Luftig,Ronald Bernard	Fed Subcontract	U.S. Department of Housing and Urban Dev	Tulane University	RCCEP-05(2007-10)	PL109-148	A Randomized, Double-Masked, Placebo-Controlled, Multicenter, Phase 2 Study to Evaluate the Safety and
Lukiw,Walter J	Foundation		Alzheimer's Assoc	IRG-09-131729		Prospective Collection of HIV Specimens
Lukiw,Walter J	Federal		NIH, National Institute on Aging	1R01AG038834-01A1		A multicenter, double-blind, placebo-controlled parallel-group study of establish proof of concept and explor

ATTACHMENT 1: LSUHSC-NO ACTIVE RESEARCH DEVELOPMENT AWARD/CONTRACT LIST

P.I. Name	Category	Primary Spnser	Direct Sponsor	Ref Awd #	Ref Awd #2	Project Title
Mandal,Diptasri	Fed Subcontract	NIH, National Cancer Institute	Univ of Cincinnati	3U01CA076293-10S1	3U01CA076293-10S1	A Three-Period, 58-Week Safety and Efficacy Trial of KRX-0502 (ferric citrate) in Patients with End-Stage Renal
Mandal,Diptasri	Fed Subcontract	National Science Foundation	Board of Regents	LEQSF(2011)-PFUND-25	EPS-1003897	A Multicenter, Double-Blind, Randomized Study to Evaluate the Efficacy and safety of Single-Dose IV
Mandal,Diptasri	Federal		NIH, National Heart Lung & Blood Inst	HHSN268201200007C		Clinical evaluation of the Xpert CT/NG assay on the GeneX-pert DX SystemDX System
Mandal,Diptasri	Federal		NIH, Human Genome Research Inst	N01HG65404		Clinical evaluation of the Xpert CT/NG assay on the GeneX-pert DX System according to protocol 73B,
Marrero,Luis	Fed Subcontract	U.S. Army	Tulane University	TUL-566-098/09	W911NF-06-1-0161	Durable-Response Therapy evaluation for Early or New Onset Type 1 Diabetes
Martin,David H	Federal		HHS, Ctr for Disease Control & Preventio	POH 9867130	POH 9867130	The Use of an Endovaginal Pelvic Model as an Adjunct in Teaching Emergency Ultrasound of GYN
Martin,David H	Business		Gen Probe Incorporated			Prospective Collection of Female First-catch Urine, Vaginal Swab, and Cervical Specimens for Testing with the
Martin,David H	Business		Otsuka America Pharmaceutical, Inc.	106-92-207 M/F		MDX-10-GSAMACQ - Collection of Clinical Specimens for General Molecular Research
Martin,David H	Business		Pfizer Inc	94-306		Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: The Occurrence
Martin,David H	Business		Roche Laboratories Inc.			Host Defense Against HIV-related Pulmonary Infections - Project 1 (Shellito)
Martin,David H	Business		Becton Dickinson Corp	99C1-017-LSU-UPP		Host Defense Against HIV-related Pulmonary Infections - Project 2 (Kolls)
Martin,David H	Business		Digene Corporation	C99-CGC-002		Host Defense Against HIV-related Pulmonary Infections - Project 2 (Norris)
Martin,David H	Business		Becton Dickinson Corp	00C2-42-LSU-WSPT		Host Defense Against HIV-related Pulmonary Infections - Core A (Admin Core)
Martin,David H	Fed Subcontract	NIH, National Institute on Aging	University of North Carolina	UNC-CH5-35002	N01-AI-75329	Host Defense Against HIV-related Pulmonary Infections - Core B (Non-Human Primate)
Martin,David H	Business		Thermo BioStar	PCL01001.01		Host Defense Against HIV-related Pulmonary Infections - Core C (Antigen)
Martin,David H	Business		Gen Probe Incorporated			A Multicenter, Randomized, Active-Control, Phase 3B Study to Evaluate the Cardiovascular Safety of
Martin,David H	Federal		NIH, Nat Inst on Allergy & Infec Disease	1U19AI061972-01		BD ProveTec Trichomonas vaginalis (TV) Qx Amplified DNA Assay, when Tested with the BD Viper System in
Martin,David H	Federal		NIH, Nat Inst on Allergy & Infec Disease	1U19AI061972-01		A Phase 3, Multicenter, Open-label Randomized, Forced-titration Clinical Trial Evaluating the Efficacy and
Martin,David H	Fed Subcontract	U.S. Department of Defense	Southern University of New Orleans	527647	W81XWH-08-1-0676	A Phase 3, Multicenter, Double-Blind, Placebo-controlled, Randomized, Clinical Trial Evaluating the Efficacy
Martin,David H	Fed Subcontract	NIH, Nat Inst on Allergy & Infec Disease	Children's Hospital	SC278658	R01AI079071	Alcohol, HIV Infection and Host Defense - Admin
Martin,David H	Federal		NIH, Nat Inst on Allergy & Infec Disease	3U19AI061972-05S1		Alcohol, HIV Infection and Host Defense - RC1
Martin,David H	Federal		NIH, Nat Inst on Allergy & Infec Disease	3U19AI061972-05S1		Alcohol, HIV Infection and Host Defense - RC2
Martin,David H	Federal		NIH, Nat Inst on Allergy & Infec Disease	3U19AI061972-05S1		Alcohol, HIV Infection and Host Defense - Admin
Martin,David H	Federal		NIH, Nat Inst on Allergy & Infec Disease	3U19AI061972-05S1		Alcohol, HIV Infection and Host Defense - RC4
Martin,David H	Federal		NIH, Nat Inst on Allergy & Infec Disease	3U19AI061972-05S1		Alcohol, HIV Infection and Host Defense - RC5
Martin,David H	Federal		NIH, Nat Inst on Allergy & Infec Disease	3U19AI061972-05S1		Alcohol, HIV Infection and Host Defense - Animal
Martin,David H	Federal		NIH, Nat Inst on Allergy & Infec Disease	3U19AI061972-05S1		Alcohol, HIV Infection and Host Defense - Lab
Martin,David H	Federal		NIH, Nat Inst on Allergy & Infec Disease	3U19AI061972-05S1		Alcohol, HIV Infection and Host Defense - Trans
Martin,David H	Fed Subcontract	NIH, Nat Inst on Allergy & Infec Disease	Tulane University	TUL-HSC-234-10/11	1R56AI085081-01A1	Drug Registry to Prospectively Describe Use of Room Temperature Stable Epoprostenol for Injection in
Mason,Carol M	Foundation		Wetmore Foundation			A Phase 2, Multi-center, Double-blind, Randomized, Placebo-Controlled Study to Evaluate the Effects of
Mason,Carol M	Federal		NIH, National Inst. on Alcohol Abuse	2R01AA011760-06		Post-FDA Approval for Clinical Trial Evaluating Bronchial Thermoplasty in Severe Persistent Asthma
Mason,Carol M	Fed Subcontract	NIH, National Heart Lung & Blood Inst	Tulane University	TUL-HSC-233-10/11	1R01HL106790-01	A Phase III, Multicenter, International, Randomized, Parallel Group, Double Blind Cardiovascular Study of BI
Maupin,Robert T	Fed Subcontract	NIH, Nat Inst Diabetes & Diges & Kidney	Tulane University	TUL-HSC-132-08/09	HHSN267200800001C	A Multi-Center Chlamydia Trachomatis, Neisseria Gonorrhoeae, and Trichomonas Vaginalis Sample Collection
McCarthy,Henry	Institution				Cost Share	Ethnic Minority Rheumatoid Arthritis Consortium Assessing Major Advancements and Outcomes of Minority
Melvan,John	Federal		NIH, National Inst. on Alcohol Abuse	NIAAA1F30AA019586-01		PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS USING TQNE
Melvan,John	Federal		NIH, National Inst. on Alcohol Abuse	NIAAA1F30AA019586-01		BOTOX PURIFIED NEUROTOXIN COMPLEX
Mercante,Donald	State		Board of Regents	LEQSF(2011-16)-GF-04		VIGABATRIM (SABRIL) 134 AND 6 G/DAY FOR PARTIAL SEIZURES
Miller,Fern T.	Foundation		Patrick F. Taylor Foundation	P. F. Taylor FDTN		VAGAS NERVE STIMULATION FOR EPILEPSY PATIENTS W/ NCP SYSTEM
Molina,Patricia E	Federal		NIH, National Institute on Drug Abuse	1R01DA020419-01		TREATMENT OF INCREASED MUSCLE TONE OF THE LOWER LIMB
Molina,Patricia E	Federal		NIH, National Institute on Drug Abuse	1R01DA020419-01		EARLIER VS LATER L-DOPA IN PARKINSON'S DISEASE
Molina,Patricia E	Federal		NIH, National Institute on Drug Abuse	1R01DA020419-01		STUDY IN PATIENTS W RELAPSING-REMITTING MULTIPLE SCLEROSIS
Molina,Patricia E	Federal		NIH, National Institute on Drug Abuse	1R01DA020419-01		KEPPRA
Molina,Patricia E	Federal		NIH, National Institute on Drug Abuse	1R01DA020419-01		PROSPECTIVE SEIZURE FREQUENCY CLINICAL INVESTIGATION
Molina,Patricia E	Federal		NIH, National Institute on Drug Abuse	NIDA - DA026647-01		RESPONSIVE NEUROSTIMULATOR SYSTEM FEASIBILITY CLINICAL INVESTIGATION
Molina,Patricia E	Fed Subcontract	HHS, Office Of Minority Health	University of Miami	66513W	6MPCMP051005-04	RESPONSIVE NEUROSTIMULATOR SYSTEM PIVOTAL
Molina,Patricia E	Fed Subcontract	NIH, National Institute Of Health	University of Miami	HHSN271200900025C	HHSN271200900025C	RESPONSIVE NEUROSTIMULATOR SYSTEM LONG-TERM TREATMENT CLINICAL INVESTIGATION
Molina,Patricia E	Federal		NIH, National Institute on Drug Abuse	1R01DA030053-01		A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP MULTICENTER STUDY TO
Molina,Patricia E	Federal		NIH, National Institute on Drug Abuse	1R01DA030053-01		A MULTICENTER, OPEN-LABEL EXTENSION TRIAL TO ASSESS THE LONG-TERM USE OF LACOSAMIDE
Molina,Patricia E	Federal		U.S. Army	W81XWH-11-2-0011		A HISTORICAL-CONTROLLED, MULTICENTER, DOUBLE-BLIND, RANDOMIZED TRIAL TO ASSESS THE EFFICACY
Molina,Patricia E	Fed Subcontract	National Science Foundation	Board of Regents	LEQSF-EPS(2012-PF283	EPS-1003897	RANOLAZINE AS AN ANALGESIC IN INFLAMMATION-INDUCED PAIN
Morse,Stephen Anthony	Business		Amgen, Inc	20050182		A MULTINATIONAL, MULTICENTER, RANDOMIZED, PARALLEL-GROUP STUDY PERFORMED IN SUBJECTS WITH
Murphy,Mary Josephine	Business		Agouron Pharmaceuticals, Inc.	AGI549		SAFETY AND NEUROPROTECTIVE EFFECTS OF POLYPHENOL E IN MULTIPLE SCLEROSIS
Muzyka,Brian Charles	Business		Daiichi Pharm	2011A-PRT003		A DOUBLE-BLIND, RANDOMIZED, MULTICENTER EFFICACY AND SAFETY STUDY OF PREGABALIN (LYRICA) AS
Nelson,Steve	Business		Amgen, Inc			BUILDING A SCIENCE FOR THE TREATMENT OF SPATIAL NEGLECT
Nelson,Steve	Business		Bayer Corporation	100244		AN OPEN-LABEL MULTICENTER EXTENSION STUDY TO DETERMINE LONG TERM SAFETY AND EFFICACY OF
Nelson,Steve	Business		Amgen, Inc	GCSF-930205		Clinical MR Indicators of Neurogenesis and Treatment Rsoponse in Depression
Nelson,Steve	Business		IntraBiotech Pharm	09-002		Multicenter, Double-Blind, Randomized, Placebo-Controlled, Three-Arm, Parallel Group Study to Evaluate the
Nelson,Steve	Federal		NIH, National Inst. on Alcohol Abuse	5P60AA009803-14		Developmental Stuttering:MRI Studies in Children
Nelson,Steve	Federal		NIH, National Inst. on Alcohol Abuse	5P60AA009803-15		Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Oxcarbazepine
Nelson,Steve	Fed Subcontract	U.S. Department of Housing and Urban Dev	Tulane University	RCEEP-06(2007-10)	PL109-148	A Phase 3, Randomized, Double Blind, Parallel, Placebo Controlled, Multicenter Study, with Optional Open
Nelson,Steve	Fed Subcontract	U.S. Department of Housing and Urban Dev	Tulane University	RCEEP-06(2007-10)	PL109-148	Lyme Neuroborreliosis Pathogenesis in th Rhesus Monkey
Nelson,Steve	Fed Subcontract	U.S. Department of Housing and Urban Dev	Tulane University	RCEEP-06(2007-10)	PL109-148	JVC Antibody Program in Patients with Relapsing Multiple Sclerosis Receiving or Considering Treatment with
Nelson,Steve	Federal		NIH, National Inst. on Alcohol Abuse	NIAAA-AA009803-16S1		Characterization of Sodium Channel of Neuroathy in the Fabry's Mouse Model
Nelson,Steve	Federal		NIH, National Inst. on Alcohol Abuse	NIAAA - AA09803-17		A PROSPECTIVE, RANDOMIZED, MULTI-CENTERED CROSSOVER STUDY TO EVALUATE SUB-THRESHOLD
Nelson,Steve	Federal		NIH, National Inst. on Alcohol Abuse	5P60AA009803-18		EFFECT OF PATIENT EDUCATION MATERIALS ON PATIENT PREFERENCE IN SPINAL CORD STIMULATION
Nelson,Steve	Federal		NIH, National Inst. on Alcohol Abuse	5P60AA009803-18		Intrathecal Pump Accuracy Study
Nelson,Steve	Federal		NIH, National Inst. on Alcohol Abuse	5P60AA009803-18		The EmPower Study: Eon Mini Study Product Options for Wellness Effectiveness and Relief; A Multi-Centered
Nelson,Steve	Federal		NIH, National Inst. on Alcohol Abuse	5P60AA009803-18		A Prospective Multi-center Randomized Evaluation of the Clinical and Radiographic Outcomes of XLIF
Nelson,Steve	Federal		NIH, National Inst. on Alcohol Abuse	5P60AA009803-18		A Retrospective Evaluation and Data Collection Study to Evaluate Patients Implanted with an ANS 16-Channel
Nelson,Steve	Federal		NIH, National Inst. on Alcohol Abuse	5P60AA009803-18		Primate Study
Nelson,Steve	Federal		NIH, National Inst. on Alcohol Abuse	5P60AA009803-18		A Retrospective Evaluation and Data Collection Study to Evaluate the Specificity of the Penta Paddle Lead in
Nelson,Steve	Federal		NIH, National Inst. on Alcohol Abuse	5P60AA009803-18		INTERNATIONAL AND DOMESTIC PEDIATRIC AND MATERNAL HIV STUDIES NETWORK
Nelson,Steve	Federal		NIH, National Inst. on Alcohol Abuse	5P60AA009803-18		SUBCONTRACT - LSOCA - PATIENT CARE
Nelson,Steve	Federal		NIH, National Inst. on Alcohol Abuse	5P60AA009803-18		UNRESTRICTED GRANT TO SUPPORT DEPARTMENTAL RESEARCH

ATTACHMENT 1: LSUHSC-NO ACTIVE RESEARCH DEVELOPMENT AWARD/CONTRACT LIST

P.I. Name	Category	Primary Spnsr	Direct Sponsor	Ref Awd #	Ref Awd #2	Project Title
Nelson,Steve	Federal		NIH, National Inst. on Alcohol Abuse	5P60AA009803-18		BIOLOGICAL COMPUTATION AND VISUALIZATION CENTER
Nelson,Steve	Federal		NIH, National Inst. on Alcohol Abuse	5P60AA009803-19		PROTEIN KINASE CB INHIBITOR - DAIBETIC RETINOPATHY STUDY
Nelson,Steve	Federal		NIH, National Inst. on Alcohol Abuse	5P60AA009803-19		RESEARCH COLLABORATION AGREEMENT
Nelson,Steve	Federal		NIH, National Inst. on Alcohol Abuse	5P60AA009803-19		COMPARISON OF HYPERSPECTRAL IMAGING AND BLOOD FLOW DETERMINATION FOR PRIMATE RETINA
Nelson,Steve	Federal		NIH, National Inst. on Alcohol Abuse	5P60AA009803-19		LASER MODEL OF CNV WITH AMERSHAM PEPTIDE
Nelson,Steve	Federal		NIH, National Inst. on Alcohol Abuse	5P60AA009803-19		A STUDY TO EVALUATE THE CLINICAL AND MICROBIAL EFFICACY AND SAFETY OF 1.0% AZASITE COMPARED
Nelson,Steve	Federal		NIH, National Inst. on Alcohol Abuse	5P60AA009803-19		RESEARCH SUPPORT - KHOOBEHI
Nelson,Steve	Federal		NIH, National Inst. on Alcohol Abuse	5P60AA009803-19		SUPPORT DEPARTMENT RESEARCH ACTIVITIES
Nelson,Steve	Federal		NIH, National Inst. on Alcohol Abuse	5P60AA009803-19		STUDIES OF THE OCULAR COMPLICATIONS
Nelson,Steve	Federal		NIH, National Inst. on Alcohol Abuse	5P60AA009803-19		Ocular HSV-Latency, Reactivation, and Recurrence
Nelson,Steve	Institution				Cost Share	Lacrisert Drug Delivery Feasibility Studies
Neumann,Donna	Fed Subcontract	NIH, Nat Inst on Allergy & Infect Disease	University of Florida	UF11185	2R01AI048633-11	Neuro-Ophthalmology Research Disease Investigator Consortium (NORDIC)
Nichols,Charles D.	Federal		NIH, National Institute of Mental Health	1R01MH083689-01A2		Bulk and Surface Characterization of Contact Lenses
Nichols,Charles D.	Federal		NIH, National Heart Lung & Blood Inst	1R21HL095961-01A2		Contact Lens Material Properties
Niemoller,Tiffany Donna	Federal		NIH, National Institute on Aging	1F30 AG032841-01A1		Effect of Specific MPs on the Hydrophobic Domains of Silicone Lenses
Noverr,Mairi C.	Foundation		American Heart Association	0835092G		Trial to Evaluate UltraSound in the Treatment of Tibial Fractures
Noverr,Mairi C.	Federal		NIH, Nat Inst on Allergy & Infect Disease	7R01AI072406-03		Cytoskeletal-Based Survival Pathways in Myocardium
Noverr,Mairi C.	Federal		NIH, Nat Inst on Dental & Craniofacial	1R56DE022069-01		PDAY Cardiovascular Specimen and Data Library
Ochoa,Augusto	State		LSUHSC, Shreveport			New methods to deliver therapeutic drugs in myocardial ischemia/reperfusion injur
Ochoa,Augusto	Private Institutions		LA Cancer Research Consortium			CHILDREN'S RESEARCH INSTITUTE DT-1 CLINICAL REIMBURSEMENTS
Ochoa,Augusto	Private Institutions		LA Cancer Research Consortium			CHILDREN'S HOSPITAL - CLINICAL TRIALS
Ochoa,Augusto	Private Institutions		LA Cancer Research Consortium			OPTIMIZING PRIMARY STROKE PREVENTION IN SC ANEMIA (2U01HL52193)
Ochoa,Augusto	Private Institutions		LA Cancer Research Consortium			ROLE OF THE TRANSCRIPTION FACTOR, INSM1 IN THE NEUROENDOCRINE PHENOTYPE OF SMALL CELL LUNG
Ochoa,Augusto	Private Institutions		LA Cancer Research Consortium			3-YEAR FELLOWSHIP AT CHILDREN'S HOSPITAL -DR CAROLINE STRAATMAN
Ochoa,Augusto	Private Institutions		LA Cancer Research Consortium			A BRIEF, CLINIC-BASED HIV PREVENTION PROGRAM FOR AFRICAN AMERICAN TEEN MALES
Ochoa,Augusto	Private Institutions		LA Cancer Research Consortium			TOMOXETINE + FLUOXETINE FOR ATTENTION AND AFFECTIVE DISORDERS
Ochoa,Augusto	Federal		NIH, National Cancer Institute	NCI - CA082689-09		STUDY OF SERTALINE IN CHILDREN & ADOLESCENT OUTPATIENTS
Ochoa,Augusto	Federal		NIH, National Ctr for Research Resourc	3P2ORR021970-551		A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, 3-MONTH CLINICAL TRIAL OF VENLAFAXINE ER AND
Ochoa,Augusto	Federal		NIH, National Ctr for Research Resourc	2P2ORR021970-06		LOUISIANA EARLY CHILDHOOD DEVELOPMENT PROGRAMS: PROGRAM EVALUATION AND RESEARCH
Ochoa,Augusto	Federal		NIH, National Ctr for Research Resourc	2P2ORR021970-06		A DOUBLE-BLIND, MULTICENTER, PLACEBO-AND -ACTIVE-CONTROLLED ACUTE AND EXTENSION STUDY OF
Ochoa,Augusto	Federal		NIH, National Ctr for Research Resourc	2P2ORR021970-06		A DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP EVALUATION OF THE LONG TERM SAFETY,
Ochoa,Augusto	Federal		NIH, National Ctr for Research Resourc	2P2ORR021970-06		DEPAKOTE ER FOR TREATMENT OF MANIA W/BIPOLAR DISORDER IN CHILDREN AND ADOLESCENTS
Ochoa,Augusto	Federal		NIH, National Ctr for Research Resourc	2P2ORR021970-06		TREATMENT OF ADHD/MORNING-DOSED OR EVENING-DOSED STRATTERA
Ochoa,Augusto	Federal		NIH, National Ctr for Research Resourc	2P2ORR021970-06		A STUDY OF SERTALINE AND PLACEBO IN CHILDREN AND ADOLESCENTS WITH POSTTRAUMATIC STRESS
Ochoa,Augusto	Federal		NIH, National Ctr for Research Resourc	2P2ORR021970-06		LA EARLY CHILDHOOD DEVELOPMENT PROGRAM LA 4 PRE-KINDERGARTEN: PROGRAM EVALUATION &
Ochoa,Augusto	Federal		NIH, National Ctr for Research Resourc	2P2ORR021970-06		STUDY OF ARIPIPRAZOLE IN TREATMENT OF PATIENTS WITH BIOPOLAR I DISORDER WITH A MOJOR
Ochoa,Augusto	Federal		NIH, National Ctr for Research Resourc	2P2ORR021970-06		SAFETY, TOLERABILITY AND EFFECTIVENESS OF ATOMOXETINE IN PRESCHOOLERS (AGES 3-6) WITH ADHD - A
Ochoa,Augusto	Federal		NIH, National Ctr for Research Resourc	2P2ORR021970-06		A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP PHASE 2 STUDY TO EVALUATE
Ochoa,Augusto	Federal		NIH, National Ctr for Research Resourc	2P2ORR021970-06		A COMPARISON OF DUOLOXETINE DOSING IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSION
Ochoa,Augusto	Federal		NIH, National Ctr for Research Resourc	2P2ORR021970-06		COMPARISON OF A STANDARD PSYCHIATRIC DIAGNOSTIC EVALUATION TO A QUANTITATIVE
Ochoa,Augusto	Federal		NIH, National Ctr for Research Resourc	2P2ORR021970-06		AN OPEN-LABEL LONG-TERM STUDY TO EVALUATE THE SAFETY OF DEPAKOTE EXTENDED RELEASE TABLETS IN
Ochoa,Augusto	Federal		NIH, National Ctr for Research Resourc	2P2ORR021970-06		A 12-MONTH, OPEN-LABEL, FLEXIBLE-DOSEAGE STUDY TO EVALUATE THE SAFETY AND EFFICACY OF GABITRIL
Ochoa,Augusto	Federal		NIH, National Ctr for Research Resourc	2P2ORR021970-06		A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY
Ochoa,Augusto	Federal		NIH, National Ctr for Research Resourc	2P2ORR021970-06		QUETIAPINE MONOTHERAPY FOR OBSESSIVE-COMPULSIVE DISORDER, A COUBLE-BLIND, FLEXIBLE-DOSE,
Ochoa,Augusto	Federal		NIH, National Ctr for Research Resourc	2P2ORR021970-06		A MULTI-CENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, PARALLEL GROUP, PHASE IIB
Ochoa,Augusto	Federal		NIH, National Ctr for Research Resourc	2P2ORR021970-06		A Fifteen-month, Prospective, Randomized, Active-controlled, Open-label, Flexible-dose Study of Paliperidone
Ochoa,Augusto	Federal		NIH, National Ctr for Research Resourc	2P2ORR021970-06		MODIFIED NEIGHBORHOOD LEVEL FACTORS AND LOW BIRTH RATE
Ochoa,Augusto	Federal		NIH, National Cancer Institute	2 R01CA107974-06A1		IOXILAN WITH IOHEXOL IN PATIENTS UNDERGOING CEREBRAL ANGIOGR
Ochoa,Augusto	Private Institutions		LA Cancer Research Consortium	LCRC		PROUROKINASE FOR PERIPHERAL ARTERIAL THROMBOEMBOLIC OCCL
Ochoa,Augusto	Private Institutions		LA Cancer Research Consortium	LCRC		USE OF AN IN VITRO MODEL TO CHARACTERIZE THE ANTIANGIOGENIC ACTIVITY OF EPALHILONE
Ochoa,Augusto	Private Institutions		LA Cancer Research Consortium	LCRC		A Multicenter, Prospective, Randomized Controlled, Single Blinded Study of Strattice Reconstructive Tissue
Ochoa,Augusto	Private Institutions		LA Cancer Research Consortium	LCRC		Modulation of Angiogenic Gene Expression by Black Raspberry Extract
Ochoa,Augusto	Private Institutions		LA Cancer Research Consortium	LCRC		TRANSFER OF GRANT BALANCE-SERUM SAMPLE DEMOGRAPHIC DATA
Ochoa,Augusto	Private Institutions		LA Cancer Research Consortium	LCRC		P2 STAR CLINICAL TRIAL
Ochoa,Augusto	Private Institutions		LA Cancer Research Consortium	LCRC		PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOGENOUS LEUKEM
Ochoa,Augusto	Private Institutions		LA Cancer Research Consortium	LCRC		SUPPORT STAR CLINICAL TRIAL
Ochoa,Augusto	Private Institutions		LA Cancer Research Consortium	LCRC		PER CASE AND SPECIMEN REIMBURSEMENT AGREEMENT
Ochoa,Augusto	Private Institutions		LA Cancer Research Consortium	LCRC		RESEARCH SUPPORT
Ochoa,Augusto	Private Institutions		LA Cancer Research Consortium	LCRC		LOUISIANA CANCER RESEARCH CONSORTIUM
Ochoa,Augusto	Private Institutions		LA Cancer Research Consortium	LCRC		LOUISIANA CANCER RESEARCH CONSORTIUM - OTOLARYNGOLOGY ALLOC
Ochoa,Augusto	Private Institutions		LA Cancer Research Consortium	LCRC		LOUISIANA CANCER RESEARCH CONSORTIUM-TISSUE BANKING CORE
Ochoa,Augusto	Private Institutions		LA Cancer Research Consortium	LCRC		LOUISIANA CANCER RESEARCH CONSORTIUM-GENETICS CORE
Ochoa,Augusto	Private Institutions		LA Cancer Research Consortium	LCRC		LOUISIANA CANCER RESEARCH CONSORTIUM-PROTEOMICS CORE
Ochoa,Augusto	Private Institutions		LA Cancer Research Consortium	LCRC		LOUISIANA CANCER RESEARCH CONSORTIUM-BIOSTATISTICS CORE
Ochoa,Augusto	Private Institutions		LA Cancer Research Consortium	LCRC		LOUISIANA CANCER RESEARCH CONSORTIUM-CENTRAL SCIENTIFIC ADMINISTRATION
Ochoa,Augusto	Private Institutions		LA Cancer Research Consortium	LCRC		AN OPEN-LABEL PHASE II STUDY EVALUATING THE SAFETY AND EFFICACY OF DAILY DOSING OF PTK787/ZK
Ochoa,Augusto	Private Institutions		LA Cancer Research Consortium	LCRC		MOHAMED ABDRAHOM FELLOWSHIP AWARD - EQUIPMENT & SUPPLIES FROM THE EGYPTIAN CULTURAL &
Ochoa,Augusto	Private Institutions		LA Cancer Research Consortium	LCRC		A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER, PHASE III STUDY IN PATIENTS WITH
Ode,David L	Fed Subcontract	NIH, National Heart Lung & Blood Inst	Med College of Georgia	U01HL52193	U01HL52193	DNA DAMAGE-RESPONSE DEFECTS IN PROSTATE CANCER RISK
Olejniczak,Piotr	Business		Cyberonics	PMS-01		INTERACTION OF EBV AND HPV IN THE DEVELOPMENT OF CERVICAL DYSPLASIA IN HIV+ WOMEN
Olejniczak,Piotr	Business		NeuroPace, Inc	RNS		A STUDY TO EVALUATE METHODS FOR MEASUREMENT OF ORAL HUMAN PAPILLOMAVIRUS (HPV) INFECTION
Olejniczak,Piotr	Business		Johnson & Johnson	RWJ-333369		ARGININE AVAILABILITY, MODULATED BY MDC, REGULATES T CELL FUNCTION IN CANCER
Olejniczak,Piotr	Business		Schwarz Biosciences	SP904		PHASE 2, MULTICENTER, TWO-TIER STUDY OF IMC-A12 IN COMBINATION WITH DEPOT OCTREOTIDE
Olejniczak,Piotr	Business		Schwarz Biosciences	SP902		UNCOVERING THE MECHANISMS OF OSTEOSARCOMA METASTASIS SUPPRESSION BY MTBP

ATTACHMENT 1: LSUHSC-NO ACTIVE RESEARCH DEVELOPMENT AWARD/CONTRACT LIST

P.I. Name	Category	Primary Spnser	Direct Sponsor	Ref Awd #	Ref Awd #2	Project Title
Olejniczak,Piotr	Business		Pfizer Inc	A0081047		REPAIR OF OXIDATIVE DNA DAMAGE IN MAMMALIAN CELLS
Olejniczak,Piotr	Business		Pfizer Inc	A0081160		REPAIR OF OXIDATIVE DNA DAMAGE IN MAMMALIAN CELLS
Olejniczak,Piotr	Business		Parexel International Corp	804P301		LSUHSC Minority Based Community Clinical Oncology
Olejniczak,Piotr	Business		Parexel International Corp	804P302		LSUHSC Minority Based Community Clinical Oncology
Olejniczak,Piotr	Business		King Pharmaceuticals	King - K826-05-3001		LSUHSC Minority Based Community Clinical Oncology Program
Ouhitit,Alla	Private Institutions		Embassy Of The Arab Republic Of Egypt			Immunotherapy for RCC
Palmer,Glen	Federal		NIH, Nat Inst on Allergy & Infec Disease	1R21AI097664-01		DNA Damage-Response Defects in Prostate Cancer Risk
Pandey,Udai	Foundation		Robert Packard Center	2000950964		Mentoring Translational Researchers in Louisiana
Pandey,Udai B.	Foundation		Amyotrophic Lateral Sclerosis Assn	30RJOH		Interaction of EBV and HPV in the development of cervical dysplasia in HIV + women
Pasternak,Ryan H	Fed Subcontract	NIH, National Institute of Mental Health	University of Kentucky	3048105243-09-293	1 R01 MH083621-01	Phase III Study of Chimeric Antibody 14.18 with GM-CSF, IL-2 and Isotretinoin in High-Risk Neuroblastoma
Paul,Dennis J	Foundation		Neuropathy Association			Significance of a novel germline AR mutation in black men with prostate cancer
Peruzzi,Francesca	Federal		NIH, National Institute of Mental Health	7 R01MH079751-05		Dillard-LSUHSC Minority Health and Health Disparities Research Center - Administrative
Peruzzi,Francesca	Fed Subcontract	NIH, National Institute on Drug Abuse	Temple University Health System, Inc.	36069304400-02	1R01DA033213-01A1	Dillard-LSUHSC Minority Health and Health Disparities Research Center - Training Core
Peters,Edward S.	Fed Subcontract	NIH, National Cancer Institute	University of Southern California	H47343	1R01CA134786-01A2	Dillard-LSUHSC Minority Health and Health Disparities Research Center - Community Core
Phillippi Jr,Stephen W	Foundation		Youth Empowerment Project	Youth Empowerment Pr		Dillard-LSUHSC Minority Health and Health Disparities Research Center - Research Core
Phillips-Savoy,Amanda	Fed Subcontract	NIH, Nat Inst of Environmental Health	University of Texas, Galveston	11-088	1U19E5020676-01	Dillard-LSUHSC Minority Health and Health Disparities Research Center - Research Project 1
Pincus,Seth H	Private Institutions		Children's Hospital, Research Insitute	Ryan Craig		Dillard-LSUHSC Minority Health and Health Disparities Research Center - Research Project 2
Pociask,Derek	State		Board of Regents	LEQSF2010-13-RD-AD7		Dillard-LSUHSC Minority Health and Health Disparities Research Center - Research Project 3
Potter,Barry J	Fed Subcontract	NIH, National Heart Lung & Blood Inst	University of South Alabama	09-0802258-01	1 R01-HL093052-01	Involvement of Survivin in the Development of PML
Prakash,Om	Business		Cytrx Corporation	Cytrx Corporation		Prognostic value of AR mutation in primary African American prostate cancer
Prakash,Om	Fed Subcontract	NIH, National Institute on Drug Abuse	University of Minnesota	N647688701	5R01DA012104-12	Nuclear IRS-1-DNA repair and mutagenesis in medulloblastoma
Quayle,Alison Jane	Fed Subcontract	NIH, Nat Inst on Dental & Craniofacial	Case Western Reserve University	RES504092/RES505082A	P01 DE019759-01	Project 1: Mentoring Translational Reseachers in Louisiana
Quayle,Alison Jane	Fed Subcontract	NIH, Nat Inst on Allergy & Infec Disease	Univ of Medicine & Dentistry of NJ	UMDNJ	1R01AI081559-01A1	Project 2: Mentoring Translational Researchers in Louisiana
Quayle,Alison Jane	Fed Subcontract	NIH, Nat Inst on Allergy & Infec Disease	University of Missouri-Kansas City	C00026076-1	1R21AI087899	Project 3: Mentoring Translational Researchers in Louisiana
Quintana,Humberto	Business		Eli Lilly And Company	B4Z-MC-LYAQ		Project 4: Mentoring Translational Reseachers in Louisiana
Quintana,Humberto	Business		Pfizer Inc	050-1015		Project 5: Mentoring Translational Researchers in Louisiana
Quintana,Humberto	Business		Abbott Laboratories	M01-342/MDS PHARMA		COBRE Core1: Mentoring Translational Researchers in Louisiana
Quintana,Humberto	Business		Eli Lilly And Company	B4Z-US-LYCC		COBRE Core 2: Mentoring Translational Researchers in Louisiana
Quintana,Humberto	Business		Pfizer Inc	A0501061		COBRE Core 3: Mentoring Translational Researchers in Louisiana
Quintana,Humberto	Business		Eli Lilly And Company	B4Z-US-X022		COBRE Core4: Mentoring Translational Researchers in Louisiana
Quintana,Humberto	Business		Lexicor Medical Tech, Inc			COBRE Core 5: Mentoring Translational Researchers in Louisiana
Quintana,Humberto	Business		Abbott Laboratories	M02-555		Core 6: Mentoring Translational Researchers in Louisiana
Ramsay,Alistair J	Business		LA Gene Therapy Research Consortium Inc	GENE THERAPY FY07-08		Tier 2 Pilot Project 1: Mentoring Translational Researchers in Louisiana
Ramsay,Alistair J	State		Board of Regents	ENH-PKSFI-PRS-02		Tier 2 Pilot Project 2: Mentoring Translational Researchers in Louisiana
Ramsay,Alistair J	State		Board of Regents	ENH-PKSFI-PRS-02		Tier 2 Pilot Project 3: Mentoring Translational Researchers in Louisiana
Ramsay,Alistair J	State		Board of Regents	ENH-PKSFI-PRS-02		Mentoring Translational Reseachers in Louisiana - Del Valle
Ramsay,Alistair J	State		Board of Regents	ENH-PKSFI-PRS-02		Mentoring Translational Reseachers in Louisiana - Reiss
Ramsay,Alistair J	State		Board of Regents	ENH-PKSFI-PRS-02		Mentoring Translational Reseachers in Louisiana - Qin
Ramsay,Alistair J	State		Board of Regents	ENH-PKSFI-PRS-02		Mentoring Translational Reseachers in Louisiana - Naura
Ramsay,Alistair J	State		Board of Regents	ENH-PKSFI-PRS-02		Mentoring Translational Reseachers in Louisiana - Cameron
Ramsay,Alistair J	State		Board of Regents	ENH-PKSFI-PRS-02		Prosaoposin: A Novel Biomarker of Prostate a Cancer Progression in African Americans
Ramsay,Alistair J	State		Board of Regents	ENH-PKSFI-PRS-02		Mentoring a Cancer Genetics Program
Ramsay,Alistair J	State		Board of Regents	ENH-PKSFI-PRS-02		p66/Insulin Like Growth Factor-1 Reno-Protection in Diabetes
Ramsay,Alistair J	State		Board of Regents	ENH-PKSFI-PRS-02		Mechanisms involved in HIV-1 Tat mediated neuronal damage
Ramsay,Alistair J	Federal		NIH, Nat Inst on Allergy & Infec Disease	NIAID -A1058810-0652		Molecular Basis of DNA Repair and Protection from Apoptosis in Neuronal Progenitors Exposed to Space
Ramsay,Alistair J	Institution				Cost Share	Preclinical Evaluation of Bafetinib for the Treatment of Glioblastoma Multiforme
Rao,Jayaraman	Fed Subcontract	NIH, Nat Inst of Neurological Disorders	Columbia University	R01NS34796	R01NS34796	Roles of DFF and PARP-1 in colon carcinogenesis
Reisin,Efrain	Business		Amgen, Inc	20010125		Participation of PARP-1 in the Pathogenesis of Asthma
Reisin,Efrain	Business		Pharmanet, Inc.	KRM-307		Arginase Production in Cancer: Evading Immune Response
Reisin,Efrain	Business		FibroGen	FDG-3019		Chemotherapy resistance in Acute Lymphocytic Leukemia: The role of Hedgehop pathway signaling
Reisin,Efrain	Business		Luitpold Pharm	1VIT090030		Regulation of VCAM-1 Expression by DNA-PK and Its Implication in Atherosclerosis
Reisin,Efrain	Business	Eli Lilly And Company	Icon Clinical Research, Inc.	H9V-MC-GFRF	H9V-MC-GFRF	Role of Epigenetics in Glutamate Transporter EAAT2 Regulation in Neuroaids
Reisin,Efrain	Business		KERYX BIOPHARMA	KRX-0502-304		Role of Bin1 in Cancer Chemosensitization
Reisin,Efrain	Business		Reata Pharmaceuticals, Inc	RTA 402-C-0903		Opioid Abuse, Opportunistic Infection and NeuroAIDS
Reiss,Krzysztof	Federal		NIH, National Cancer Institute	7 R01CA095518-08		Comprehensive Minority and Health Disparities Research Center - Community Engagement Core
Reiss,Krzysztof	Fed Subcontract	NIH, Nat Inst Diabetes & Diges & Kidney	Alton Ochsner Medical Foundation	R01DK073793-04	R01DK073793-04	Uncovering the Mechanisms of Osteosarcoma Metastasis Suppression by MTBP
Reiss,Krzysztof	Fed Subcontract	National Aeronautics & Space Administrat	Emory University	S496274	NNX088A08G	Notch-1 in T Cells: A Central Mediator of Tumor induced Energy
Richter,Erich O.	Private Institutions		St. Jude Medical	ADV NEUROMODULATION		LOUISIANA CANCER RESEARCH CONSORTIUM-ZEA START UP
Richter,Erich O.	Private Institutions		St. Jude Medical	ADV NEUROMODULATION		LOUISIANA CANCER RESEARCH CONSORTIUM-KOOCHKPOUR START UP
Richter,Erich O.	Foundation		Joe W & Dorothy Dorsett Brown Foundation	PRH09-209		LOUISIANA CANCER RESEARCH CONSORTIUM-SAKAMURO LIU START UP
Richter,Erich O.	Private Institutions		St. Jude Medical	C-09-04		LOUISIANA CANCER RESEARCH CONSORTIUM-OUHITIT START UP
Richter,Erich O.	Private Institutions		St. Jude Medical	C-10-05		LOUISIANA CANCER RESEARCH CONSORTIUM-IMMUNOLOGY CORE
Richter,Erich O.	Private Institutions		St. Jude Medical	C-11-04		LOUISIANA CANCER RESEARCH CONSORTIUM-RECRUITING
Richter,Erich O.	Private Institutions		St. Jude Medical	C-11-04		LOUISIANA CANCER RESEARCH CONSORTIUM-IWAKUMA SEED FUNDS - MULTIPOTENTIAL STROMAL CELLS
Robertson,Nancy	Business		Cook Imaging	IOX-C1001C-88		LOUISIANA CANCER RESEARCH CONSORTIUM-WANGUO LIU START UP
Rodriguez,Paulo Cesar	Federal		NIH, National Cancer Institute	NCI -1R21CA162133-01		LOUISIANA CANCER RESEARCH CONSORTIUM-OCHOA-CLINICAL CORE
Sakamuro,Daitoku	Federal		NIH, National Cancer Institute	1R01CA140379-01A1		LOUISIANA CANCER RESEARCH CONSORTIUM - "PARP-1, DFF AND GENOMIC INSTABILITY IN COLON CANCER
Sakauye,Kenneth M	Business		Fujisawa Health Care Inc	03-0-189		LCRC- Startup Package- Dr. Paulo Rodriguez
Salinas,Thomas J	Business		Steri-Oss	LSU-196		LCRC Startup Package- Dr. Zabaleta
Schwarzenberger,Paul	Foundation		Janssen Pharmaceutica Research Found	KW-USA-4		LCRC STARTUP PACKAGE -DR. LIN
Schwarzenberger,Paul	Business		British Biotech Pharmaceuticals Ltd.	C03-173-20		LCRC STARTUP- DR. DEL VALLE
Schwarzenberger,Paul	Business		British Biotech Pharmaceuticals Ltd.	C03-173-20		LCRC START UP FUNDS- DR. REISS
Scribner,Richard A	Fed Subcontract	HHS, Health Resources & Service Admin	Tulane University	R40MC001296	R40MC00296	LOUISIANA CANCER RESEARCH CONSORTIUM- DR. PERUZZI'S STARTUP FUNDING
Scribner,Richard A	Federal		NIH, National Inst. on Alcohol Abuse	1R01AA015855-01		LOUISIANA CANCER RESEARCH CONSORTIUM - DR. PRAKASH'S STARTUP FUNDING.

ATTACHMENT 1: LSUHSC-NO ACTIVE RESEARCH DEVELOPMENT AWARD/CONTRACT LIST

P.I. Name	Category	Primary Spnsr	Direct Sponsor	Ref Awd #	Ref Awd #2	Project Title
Scribner, Richard A	Federal		NIH, National Inst. on Alcohol Abuse	1RC1AA019329-01		LOUISIANA CANCER RESEARCH CONSORTIUM- DR. BOULARES STARTUP FUNDING
Scribner, Richard A	Federal		NIH, National Cancer Institute	1R01CA157565-01		LOUISIANA CANCER RESEARCH CONSORTIUM- COST SHARING- MBCCOP NIH GRANT (PS# 149740201A)
Scribner, Richard A	Fed Subcontract	NIH, Nat Inst of Environmental Health	Tulane University	TUL-HSC-332-11/12	1R01ES020447-01	LOUISIANA CANCER RESEARCH CONSORTIUM- STARTUP FUNDS- DR. RESKE
Sheets, Kristopher	Federal		NIH, National Eye Institute	1 F31EY020115-01		PROTEOMIC ANALYSIS OF NICOTINIC RECEPTOR COMPLEXES ACTIVATED BY NICOTINE IN TOBACCO SMOKE
Sheets, Kristopher	Federal		NIH, National Eye Institute	1 F31EY020115-01		SCALING OF VESICULAR GLUTAMATE AND GABA STORAGE IN NEOCORTICAL SYNAPSES
Sheline, Christian T.	Federal		NIH, Nat Inst Diabetes & Diges & Kidney	7 R01 DK073446-04		ENDOCANNABINOIDS IN COX-2-MEDIATED SYNAPTIC MODIFICATION AND NEUROTOXICITY
Shellito, Judd E	Fed Subcontract	NIH, National Heart Lung & Blood Inst	Tulane University	1P01HL075161-01	P01HL075161	MENTORING NEUROSCIENCE IN LOUISIANA: A BIOMEDICAL PROGRAM TO ENHANCE NEUROSCIENCE - BAZAN
Shellito, Judd E	Business		Cytheris Inc	CYT107		MENTORING NEUROSCIENCE IN LOUISIANA: A BIOMEDICAL PROGRAM TO ENHANCE NEUROSCIENCE - FARRIS
Shellito, Judd E	Federal		NIH, National Heart Lung & Blood Inst	2P01HL076100-07A1		MENTORING NEUROSCIENCE IN LOUISIANA: A BIOMEDICAL PROGRAM TO ENHANCE NEUROSCIENCE -
Shellito, Judd E	Federal		NIH, National Heart Lung & Blood Inst	2P01HL076100-07A1		MENTORING NEUROSCIENCE IN LOUISIANA: A BIOMEDICAL PROGRAM TO ENHANCE NEUROSCIENCE -
Shellito, Judd E	Federal		NIH, National Heart Lung & Blood Inst	2P01HL076100-07A1		MENTORING NEUROSCIENCE IN LOUISIANA: A BIOMEDICAL PROGRAM TO ENHANCE NEUROSCIENCE - XIA
Shellito, Judd E	Federal		NIH, National Heart Lung & Blood Inst	2P01HL076100-07A1		MENTORING NEUROSCIENCE IN LOUISIANA: A BIOMEDICAL PROGRAM TO ENHANCE NEUROSCIENCE -
Shellito, Judd E	Federal		NIH, National Heart Lung & Blood Inst	2P01HL076100-07A1		MENTORING NEUROSCIENCE IN LOUISIANA: A BIOMEDICAL PROGRAM TO ENHANCE NEUROSCIENCE -
Shen, Li	Federal		NIH, Nat Inst on Allergy & Infec Disease	7R01AI055869-05		MENTORING NEUROSCIENCE IN LOUISIANA: A BIOMEDICAL PROGRAM TO ENHANCE NEUROSCIENCE -
Shen, Li	Federal		NIH, Nat Inst on Allergy & Infec Disease	3R01AI055869-06S1		MENTORING NEUROSCIENCE IN LOUISIANA: A BIOMEDICAL PROGRAM TO ENHANCE NEUROSCIENCE -
Sibley, Deborah H.L.	Fed Subcontract	NIH, Nat Library Of Medicine	Houston Academy of Medicine	Houston Academy	HHSN276201100007C	NEURABIN AND INHIBITOR-1 COMPETE FOR PP1 BINDING IN LTD AND LTP EXPRESSION
Siddoway, Benjamin	Foundation		Ataxia telangiectasia Children's Project	AT Children's Projec		CRCNs: PHASE RESETTING PREDICTS SYNCHRONIZATION IN HYBRID HIPPOCAMPAL CIRCUITS
Siggins, Robert	Federal		NIH, National Inst. on Alcohol Abuse	1K99AA020312-01		NEUROPROTECTIN D1 SLOWS PHOTORECEPTOR DEGENERATION
Simmons, David Earl	Business		Zimmer Dental, Inc	10014		THE ROLE OF THE RAS HOMOLOG RHES IN DOPAMINE RECEPTOR SIGNALING
Simmons, David Earl	Business		Astra Zenca Pharmaceuticals	D2009-069		DAPK1 REGULATION OF NMDA RECEPTORS IN ISCHEMIC NEURONAL DEATH
Simmons, David Earl	Business		Nobel Biocare	Nobel Biocare		DAPK1 REGULATION OF NMDA RECEPTORS IN ISCHEMIC NEURONAL DEATH
Simonsen, Neal	Fed Subcontract	NIH, National Cancer Institute	Duke University	203-0311	1R01Ca142081-01A1	RNA EDITING OF AMPA RECEPTOR SUBUNIT GLUR2 IN ISCHEMIA
Soltani, Zohreh	Private Institutions		Brigham & Womens Hsp	SAVOR-TIMI 53		Intrinsic Currents Modulate Synaptic Integration in Dopamine Neurons
Sorensen, Ricardo U	Private Institutions		Children's Hospital, Research Institute			TYPE-1 DIABETES: ZN2+ POTENTIATED BETA-CELL DEATH BY SIRTUIN-MEDIATED NAD+ LOSS
Sorensen, Ricardo U	Private Institutions		Children's Hospital			DISTINCT ROLE OF NEURABIN AND SPINOPHILIN IN SYNAPTIC TRANSMISSION AND PLASTICITY
Sothorn, Melinda S	Federal		NIH, Nat Inst Child Health & Human Dev	1R01HD049046-01		REGULATION OF NEUROPROTECTIVE LIPID SIGNALS BY SPATIALLY DISTINCT NMDA RECEPTORS
Sothorn, Melinda S	Fed Subcontract	NIH, Nat Inst Diabetes & Diges & Kidney	Pennington Medical Foundation	Pennington	1RC1DK086881-01	REGULATION OF NEUROPROTECTIVE LIPID SIGNALS BY SPATIALLY DISTINCT NMDA RECEPTORS-
Souza, Flavia	Federal		NIH, National Inst. on Alcohol Abuse	1F32AA021049-01A1		LIPID MEDIATORS IN CORNEAL NERVE REGENERATION
Souza, Flavia	Federal		NIH, National Inst. on Alcohol Abuse	1F32AA021049-01A1		Lipid Mediators in Corneal Nerve Regeneration
Stark, David Thomas	Federal		NIH, Nat Inst of Neurological Disorders	1F30NS063630-01		The Capacity to Synthesize NPD1 is Reduced in Aged Brains
Stark, David Thomas	Federal		NIH, Nat Inst of Neurological Disorders	1F30NS063630-01		CORNEAL LIPID METABOLISM AND RESPONSE TO INFLAMMATION
Steeb, Glen	Business		Lifecell Corporation	LFC2007.03.01		Characterization of microRNAs expressed in developing songbird brain
Sulzer, Jesse	Federal		NIH, National Inst. on Alcohol Abuse	1F30AA019587-01A1		RPE MESSENGERS, TRANSCRIPTION & PHOTORECEPTOR RENEWAL
Summer, Warren Richard	Fed Subcontract	NIH, National Heart Lung & Blood Inst	University of Texas Houston, Hsc	GALLH232	NO1HC35130	Micro RNA-mediated neurotrophic & synaptic networks in alzheimer's disease
Summer, Warren Richard	Business		Quintiles Pacific Inc.	XRP15268-325		Mechanism of action of omega-3 fatty acids in brain injury
Summer, Warren Richard	Business		Aventis Pharmaceuticals Inc	XRP4583C-3501		CRCNs: Analysis of Synchronization in Hybrid Neural Circuits
Summer, Warren Richard	Foundation		American Lung Association	CP-98-020 (LOCS)		CRCNs: Analysis of synchronization in hybrid neural circuits
Summer, Warren Richard	Business		C.R. Bard Inc.	5003A		Dendritic Integration in the Entorhinal Cortex
Summer, Warren Richard	Business		Astra Zenca Pharmaceuticals	DD-039-0726		The Role of Neuroprotectin D1 in Choroidal Neovascularization
Summer, Warren Richard	Business		Astra Zenca Pharmaceuticals	D-5896C00005		The Role of Neuroprotectin D1 in Choroidal Neovascularization
Summer, Warren Richard	Business		Boehringer Ingelheim Pharmaceuticals	205.294.23		NPD1 promotes survival signaling in the Ccl2-/-/Cx3cr1-/- mouse AMD model
Summer, Warren Richard	Business		Genetech Inc.	Protocol Q2948g		Neuroprotectins and Maresins for Macrophages in Diabetic Wound Healing
Summer, Warren Richard	Business		Boehringer Ingelheim Pharmaceuticals	1012.56		Neuroprotectins and Maresins for Macrophages in Diabetic Wound Healing
Summer, Warren Richard	Business		Novartis Pharmaceuticals Corporation	QAB149B23355		The Role of Highwire/DFsn Ubiquitination Complex During Synaptic Development
Summer, Warren Richard	Business		Novo Nordisk Inc	NN1998-1616		Neuroprotection Lipid Signaling in Ischemia Reperfusion
Summer, Austin J	Business		Synergen, Inc.	PROTOCOL 0604		Neuroprotection by Docosahexaenoic Acid-Albumin in Experimental Stroke
Tang, Yaping	Federal		NIH, National Institute of Mental Health	4R33MH083530-03		Neuroprotection by Docosahexaenoic Acid-Albumin in Experimental Stroke
Tang, Yaping	Foundation		American Heart Association	11GRNT7990049		MAGL Inhibition in Prevention and Treatment of Alzheimer's Disease
Taylor, Stephanie N	Business		Presutti Lab	T-500		MAGL Inhibition in Prevention and Treatment of Alzheimer's Disease
Taylor, Stephanie N	Business		Becton Dickinson Corp	05C1-001-QXVSP-LSU		Neuroprotective bioactivity of neuroprotectin-D1 with nanoparticle-enhanced delivery in experimental retinal
Taylor, Stephanie N	Business		Genzyme	CANDID00205		The Capacity to Synthesize NPD1 is Reduced in Aged Brains
Taylor, Stephanie N	Business		Becton Dickinson Corp	07C1-004-VSPQX-LSU		The Capacity to Synthesize NPD1 is Reduced in Aged Brains
Taylor, Stephanie N	Business		Becton Dickinson Corp	6918		Micro RNA-146a (miRNA-146a) signaling in Alzheimer's disease (AD)
Taylor, Stephanie N	Fed Subcontract	NIH, Nat Inst on Allergy & Infec Disease	University of Alabama	NO1-AI40073	HHSN266200400073C	Roles of miRNAs in Regulation of Foxp2 and in Autism
Taylor, Stephanie N	Business		Roche Palo Alto	Roche - COB-CTNG-187		Regulation of normal and leber congenital amaurosis-associated RPE65s
Taylor, Stephanie N	Business		Warner Chilcott	PR04809		RPE Messengers, Transcription and Photoreceptor Renewal
Taylor, Stephanie N	Business		Becton Dickinson Corp	MDX-10-VVAGSC		Addressing Neurological Dysfunction in Ataxia Telangiectasia: Investigation into Novel, physiologic ATM
Taylor, Stephanie N	Business		Gen Probe Incorporated	ACTPS-US10-001		Endocannabinoids in Neurodegenerative Diseases
Taylor, Stephanie N	Business		Cepheid	140		GENE THERAPY RESEARCH CONSORTIUM-VECTOR CORE
Taylor, Stephanie N	Business		Cepheid	73B		CENTER OF EXCELLENCE FOR VACCINE DEVELOPMENT
Taylor, Stephanie N	Business		Gen Probe Incorporated	ATVPS-US11-001		CENTER OF EXCELLENCE FOR VACCINE DEVELOPMENT-TULANE
Taylor, Stephanie N	Business		Becton Dickinson Corp	MDX-10-GSAMACQ		CENTER OF EXCELLENCE FOR VACCINE DEVELOPMENT - XAVIER
Taylor, Stephanie N	Business		Becton Dickinson Corp	MDX-11-VXTRTV		CENTER OF EXCELLENCE FOR VACCINE DEVELOPMENT - CRI
Taylor, Stephanie N	Business		Hologic, Inc	CSP-00029		CENTER OF EXCELLENCE FOR VACCINE DEVELOPMENT-ADMIN
Tejedor, Richard	Business		Actellon	AC-060A202		CENTER OF EXCELLENCE FOR VACCINE DEVELOPMENT - EDUCATION
Tejedor, Richard S.	Business		Boston Scientific Corp	10-02		CENTER OF EXCELLENCE FOR VACCINE DEVELOPMENT - ESIP
Tender, Gabriel	Business		NuVasive, Inc.	NuVasive, Inc		CENTER OF EXCELLENCE FOR VACCINE DEVELOPMENT-BSL-3 CORE
Thompson, Hilary W	State		LSU, Baton Rouge	R110117		CENTER OF EXCELLENCE FOR VACCINE DEVELOPMENT-WELSH
Thompson, Hilary W	Fed Subcontract	NIH, National Ctr for Research Resourc	LSU, Baton Rouge	51747	2P20RR016456-09	CENTER OF EXCELLENCE FOR VACCINE DEVELOPMENT
Thompson, Hilary W	Fed Subcontract	NIH, National Ctr for Research Resourc	LSU, Baton Rouge	51747	2P20RR016456-09	CENTER OF EXCELLENCE FOR VACCINE DEVELOPMENT
Thompson, Hilary W	Fed Subcontract	NIH, National Ctr for Research Resourc	LSU, Baton Rouge	51747	2P20RR016456-09	MECHANISMS OF PROTECTIVE IMMUNITY INDUCED BY LIVE ATTENUATED SIV VACCINES
Thompson, Hilary W	Institution				Cost Share	CFTR EXPRESSION AND FUNCTION IN HUMAN NEUTROPHILS
Tilton, Ann C Henderson	Business		Allergan Inc	191622-021		GM-CSF-ADJUVANTED CLADE C DNA/MVA & MVA/MVA VACCINES

ATTACHMENT 1: LSUHSC-NO ACTIVE RESEARCH DEVELOPMENT AWARD/CONTRACT LIST

P.I. Name	Category	Primary Spnser	Direct Sponsor	Ref Awd #	Ref Awd #2	Project Title
Tilton,Ann C Henderson	Business		Allergan Inc			DIGIT REGENERATION IN MAMMALS
Townsend,Mark H	Business		Astra Zenca Pharmaceuticals	D3690C00011		Oral Vaccination for AIDS Prevention in Rhesus Monkeys
Townsend,Mark H	Business		Ortho Pharmaceutical Corp	R092670-SCH-3006		Immunization of Oral Mucosa for Induction of Rectal and Genital Mucosal Immunity
Trapido,Edward	Federal		NIH, Nat Inst of Environmental Health	1 R21ES020061-01		Vaccination strategies against pulmonary tuberculosis
Trapido,Edward	Federal		NIH, Nat Inst of Environmental Health	1 R21ES020061-01		Arthritis Management for Primary Care 2012
Trapido,Edward J.	Federal		NIH, Nat Inst of Environmental Health	1U01ES021497-01		RECOMBIVAX HB IN HEALTHY SUBJECTS BETWEEN 16 AND 35.
Trapido,Edward J.	Federal		NIH, Nat Inst of Environmental Health	1U01ES021497-01		PEGASYS WITH RIBAVIRIN FOR CHRONIC HEPATITIS
Tuckler,Victor	Business		The Medicines Company	PRONTO-TMC-CLV-08-01		IMMUNOGENICITY OF PROCESS UPGRADE VARICELLA VACCINE
Tuckler,Victor	Business		PPD Development	TMC-ORI-10-01		PRIORIX WITH R-II VACCINE ADMINISTERED TO HEALTHY CHILDREN
Turkewitz,Lanny J	Business		UCB Pharma	IND 67,741		FROZEN MMRV GIVEN CONCOMITANTLY VE NON IN HEALTHY CHILDREN
Uwaifo,Gabriel	Business		Tolerx, Inc	TRX-DM018-US-10		PEGASYS VS W/RIBAVIRIN FOR PATIENTS WITH CHRONIC HEPATITIS
Uwaifo,Gabriel I.	Business		MannKind Corporation	MKC-TI-171		LOT-CONSISTENCY AND BRIDGE STUDY OF HCP 20/20/5/3DT-MIPV/PPR-T (PENTACEL) IN
Uwaifo,Gabriel I.	Business		MannKind Corporation	MKC-TI-175		PRE-BOOSTER CONCENTRATION OF ANTI-PRP ANTIBODIES IN SERUM SAMPLES OBTAINED FROM TODDLERS
Uwaifo,Gabriel I.	Business		Boehringer Ingelheim Pharmaceuticals	1245.25		A COMPARISON OF THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF M-M-R II MANUFACTURED FROM
Vander Heide,Richard S.	Federal		NIH, National Heart Lung & Blood Inst	7R01HL084405-04		Models of Prenatal Care and Perinatal Health Indicators in Disaster Recovery Area
Vander Heide,Richard S.	Federal		NIH, National Heart Lung & Blood Inst	1R21HL098786-01		Pennington Biomed. Research Ce
Vedeckis,Wayne V	Federal		NIH, National Cancer Institute	1R01CA116042-01		CMS Nonpayment for Nosocomial Injury and Risk of Falls in Hospitals
Vedeckis,Wayne V	Private Institutions		University of Pittsburgh	0031480		IDEA NETWORKS OF BIOMEDICAL RESEARCH EXCELLENCE (INBRE)
Vedeckis,Wayne V	Fed Subcontract	NIH, National Heart Lung & Blood Inst	University of Pittsburgh	5R01HL061271-14	5R01HL061271-14	IDEA NETWORKS OF BIOMEDICAL RESEARCH EXCELLENCE (INBRE)
Vedeckis,Wayne V	Private Institutions		University of Pittsburgh	0032257		IDEA NETWORKS OF BIOMEDICAL RESEARCH EXCELLENCE (INBRE) - Hill
Veith,Robert W	Business		Novartis Pharmaceuticals Corporation	STI 106 752		Data Quality Control through Nonlinear Association Analysis of Unknown Staged Cancer Cases
Veith,Robert W	Federal		NIH, National Cancer Institute	2U10CA063845-11		Recruitment of Superior Doctoral Students in Biostatistics
Veith,Robert W	Federal		NIH, National Cancer Institute	2U10CA063845-11		Louisiana Biomedical Research Network (LBRN)
Veith,Robert W	Federal		NIH, National Cancer Institute	3U10CA063845-11S1		DNA REPAIR IN HUMAN PROSTATE CANCER RISK
Venters,Charmaine L	Business		Pharmacia & Upjohn	051-00		SURVEILLANCE,EPIDEMIOLOGY & END RESULTS(SEER) EXPANSION PROGRAM
Venters,Charmaine L	Business		Merck & Co., Inc.			CHANGES IN ALCOHOL AVAILABILITY AND HIV RATES
Venters,Charmaine L	Business		Aventis Pasteur	EM501		PROVIDE TUMOR REGISTRY SERVICES TO MCLNO
Venters,Charmaine L	Business		Merck & Co., Inc.	010-00		PROVIDE TUMOR REGISTRY SERVICES TO MCLNO
Vijayagopal,Parakat	Business		Pfizer Inc	158809		PROVIDE TUMOR REGISTRY SERVICES TO MCLNO
Wainford,Richard D.	Foundation		American Heart Association	09BGIA2250585		PROVIDE TUMOR REGISTRY SERVICES TO MCLNO
Wainford,Richard D.	Federal		NIH, National Heart Lung & Blood Inst	1R01HL107330-01		NATIONAL COMPREHENSIVE CANCER CONTROL PROGRAM - BREAST & CERVICAL CANCER-EARLY DETECTION -
Walton,Lisa	Fed Subcontract	NIH, National Inst. on Alcohol Abuse	University of Pittsburgh	Univ of Pittsburgh	R01 AA016688	NATIONAL COMPREHENSIVE CANCER CONTROL PROGRAM - BREAST & CERVICAL CANCER-EARLY DETECTION -
Wang,Guoshun	Foundation		Acres	2010-11-05		NATIONAL COMPREHENSIVE CANCER CONTROL PROGRAM - BREAST & CERVICAL CANCER-EARLY DETECTION -
Wang,Guoshun	Business		Vertex Pharmaceutica	Vertex Pharmaceutica		NATIONAL COMPREHENSIVE CANCER CONTROL PROGRAM - BREAST & CERVICAL CANCER-EARLY DETECTION-
Wang,Guoshun	Foundation		Acres	Acres		NCCDPPH - BREAST & CERVICAL CANCER-EARLY DETECTION-COLORECTAL
Wang,Guoshun	Foundation		Acres	2011-12-06		NATIONAL COMPREHENSIVE CANCER CONTROL PROGRAM - NAT'L BREAST & CERVICAL CANCER-EARLY
Wang,Guoshun	Federal		NIH, Nat Inst on Allergy & Infec Disease	1R01AI072327-01		INCIDENCE PATTERNS OF PRIMARY EXTRANODAL NON-HODGKIN LYMPHOMA BY SITE AND HISTOLOGY
Washington,Amber	Federal		NIH, National Cancer Institute	1F31CA150442-01		Comparing the Effectiveness of City Policy and Structure in Health Disparities
Washington,Amber	Federal		NIH, National Cancer Institute	1F31CA150442-01		Validation of PROMIS in Diverse Cancer Populations
Wen,Zezhang	Federal		NIH, Nat Inst on Dental & Craniofacial	NIDCR-DE019452-01A2		SURVEILLANCE,EPIDEMIOLOGY & END RESULTS(SEER) EXPANSION PROGRAM
Whim,Matthew D.	Federal		NIH, Nat Inst Diabetes & Diges & Kidney	NIDDKD-DK080441-02		SURVEILLANCE, EPIDEMIOLOGY & END RESULTS(SEER) EXPANSION PROGRAM (Patterns of Care/Quality of
Whitaker,Annie	Foundation		American Physiological Society	APS		Epidemiology of Ovarian Cancer in African-American Women
White,Jeffrey Thomas	Federal		NIH, Nat Inst Diabetes & Diges & Kidney	1F30DK082121-01		Comparative Effectiveness of Treatment for Localized Prostate Cancer
Wilcox,Ronald Dean	Business		Pfizer Inc	A4001067		Comparative Effectiveness of Treatment for Localized Prostate Cancer
Williams,Donna L	Foundation		Susan G Komen Breast Cancer Found	Susan G. Komen		Health Effects of MC252 Gulf Incident
Williams,Donna L	Federal		HHS, Ctr for Disease Control & Preventio	1U55DP003042-01		Health Effects of MC252 Gulf Incident
Williams,Donna L	Institution				Cost Share	A Genome Wide Admixture Scan of Multiple Myeloma in African Americans
Williams,Karen Renee	Business		GlaxoSmithkline Pharmaceuticals	209762/136		Enhancing Cancer Registry Data Comparative Effectiveness Research
Williams,Karen Renee	Business		Aventis Pasteur	M5A03		Validation of Promis in Diverse Cancer: Populations
Wilson,Philip G	Institution				Cost Share	Breast Center at the Interim LSU Public Hospital
Wilson,Philip G	Institution				Cost Share	The Women and [Their] Children's Gulf Health Consortium
Winsauer,Peter J	Federal		NIH, National Institute on Drug Abuse	1R01DA019625-01		The Women and [Their] Children's Gulf Health Consortium
Winsauer,Peter J	Institution				Cost Share	Community Influences on NHANES Diet and Physical Activity
Wojcik,Edward J.	Federal		NIH, National Inst of General Med Sci	7R01GM066328-02		Enhancing Cancer Registries for Early Case Capture of Pediatric and Young Adult
Wojcik,Edward J.	Institution				Cost Share	Telomere Length as a Biological Marker of Allostatic Load in Children
Woltering,Eugene A	Business		Novartis Pharmaceuticals Corporation			Norman F. Grant/American Board of Obstetrics and Gynecology
Woltering,Eugene A	Fed Subcontract	NIH, Complementary & Alternative Medicin	Pennington Biomedical Research Center	S12-50318	P50AT002776-07	Quality of Life in Prostate Cancer Project
Worrel,Mary	Federal		NIH, National Inst. on Alcohol Abuse	1F30AA019848-01		Chronic Disease Standford Management Program
Worrel,Mary	Federal		NIH, National Inst. on Alcohol Abuse	1F30AA019848-01		Gulf Coast Children's Health Study
Worthylake,David K.	Federal		NIH, National Inst of General Med Sci	1R01GM084072-01A2		MECHANISMS FOR THE METABOLIC SYNDROME IN PREPUBERTAL AF*
Worthylake,Rebecca A.	Federal		NIH, Nat Inst on Dental & Craniofacial	1R03DE019166-01A1		Anthropometric Assessment of Abdominal Obesity and Helath Risk in Children and Adolescents
Worthylake,Rebecca A.	Federal		NIH, Nat Inst on Dental & Craniofacial	3 R03DE019166-01A1S1		Demonstrating the Capacity of Comprehensive Cancer Control Programs to Implement
Wu,Chunlai	Federal		NIH, Nat Inst of Neurological Disorders	1R01NS070962-01		Tides Foundation Award
Wu,Xiao Cheng	Private Institutions		NAACCR-CSCP	NAACCR		410130128 BIOCH-C/S 110150066A
Wu,Xiao Cheng	Fed Subcontract	NIH, Inst Arthritis and Musculoskeletal	Georgetown University	RX 4442-007-LSUHSC	U01AR057971-01	405030126 REHAB-C/S 105500008A
Wu,Xiao Cheng	Fed Subcontract	HHS, Agency Healthcare Research & Quali	Vanderbilt University	VUMC37044	ARRA: 1R01HS019356	449880126 G/T-C/S 149752505A
Wu,Xiao Cheng	Fed Subcontract	HHS, Agency Healthcare Research & Quali	Vanderbilt University	VUMC37044	ARRA: 1R01HS019356	EPIDEMIOLOGY-C/S 158070035C
Wu,Xiao Cheng	Fed Subcontract	NIH, Inst Arthritis and Musculoskeletal	Georgetown University	RX 4442-014-LSUHSC	U01AR057971-02S1	449640128 MED-C/S 149200820A
Xia,Houhui	Federal		National Science Foundation	NSF IOS-0824393		410170146 MICRO-C/S 110250089A
Xia,Houhui	Federal		NIH, Nat Inst of Neurological Disorders	1 R01 NS060879-01A2		HDC-COST SHARE 105200103A
Xu,Xiaoming	Foundation		Joe W & Dorothy Dorsett Brown Foundation			HDC-COST SHARE 105200089A
Xu,Xiaoming	Foundation		Joe W & Dorothy Dorsett Brown Foundation			PHYSIO-COST SHARE 110350068A
Xu,Xiaoming	Federal		NIH, Nat Inst on Dental & Craniofacial	1 R01 DE019203-01A1		HDC-COST SHARE 105200124A
Yu,Lolie Chua	Fed Subcontract	NIH, National Cancer Institute	Ntl Childhood Cancer Foundation	98543-1226	U10CA98543	BIOSTAT-COST SHARE 158050013A

ATTACHMENT 1: LSUHSC-NO ACTIVE RESEARCH DEVELOPMENT AWARD/CONTRACT LIST

P.I. Name	Category	Primary Spnser	Direct Sponsor	Ref Awd #	Ref Awd #2	Project Title
Yu,Lolie Chua	Fed Subcontract	NIH, National Cancer Institute	Ntl Childhood Cancer Foundation	ANBL0931	3U10CA098543-07S1	BIOCHEM-COST SHARE 110150076A
Yu,Qingzhao	Private Institutions		NAACCR-CSCP	#2011-06-01 NAACCR		BIOCHEM-COST SHARE 110150084A
Yue,Xinping	Federal		NIH, National Heart Lung & Blood Inst	NHLBI -7R21HL095865-		PHARM-COST SHARE 110300064A
Yukna, Raymond A	Business		Ibah Inc.	SEPTODONT		PHARM-COST SHARE 110300118B
Yukna, Raymond A	Business		Caramed Corporation			PHARM-COST SHARE 110300118C
Yukna, Raymond A	Business		Biolok International			EPIDEMIOLOGY-C/S 158070060A
Yukna, Raymond A	Business		Sulzer Dental			COMM&BEHAV HLTH-C/S 158130022A
Zea,Arnold	Fed Subcontract	NIH, National Cancer Institute	Dartmouth University	DARTMOUTH UNIVERSITY	R01CA095648	O D & R-COST SHARE 122500007A
Zhang, Ping	Federal		NIH, National Inst. on Alcohol Abuse	1R01AA019676-01		449900109 N/C-TRANSL RES-CUI
Zieske, Arthur W	Federal		NIH, National Heart Lung & Blood Inst	2R24HL060808-10		449900110 N/C-TRIEM-H BAZAN

ATTACHMENT 1: LSUHSC-NO ACTIVE RESEARCH DEVELOPMENT AWARD/CONTRACT LIST

P.I. Name	Category	Primary Spnser	Direct Sponsor	Ref Awd #	Ref Awd #2	Project Title
Acierno,Marie D.	Fed Subcontract	NIH, National Eye Institute	St. Luke's Roosevelt Institute	1U10 EY017281-01A1	1 U10EY017281-01A1	DATA ACCOUNTABILITY CENTER
Aiyar,Ashok	Federal		NIH, Nat Inst on Allergy & Infec Disease	1 R21AI095859-01		GENE REGULATORY NETWORK FOR PODOCYTE DEVELOPMENT - STIPENDS
Alahari,Suresh K.	Federal		NIH, National Cancer Institute	1R01CA115706-01		Completion of Human Embryo Sections on DVDS
Alahari,Suresh K.	Business		Regulus Therapeutics			Physiological Consequences of Glutamate receptor Modulation
Alahari,Suresh K.	Institution				Cost Share	Completion of Human Embryo sections on DVDS
Aldridge,Kenneth E	Business		Wyeth-Ayerst	ZOSYN 0910X-101193		Neuropeptide Y and the Control of Catecholamine Secretion from the Adrenal Gland
Aldridge,Kenneth E	Business		Astra Zenca Pharmaceuticals	MERREM		Cellular Mechanisms Underlying the Long-term Potentiation of GABA Release
Aldridge,Kenneth E	Business		Bayer Corporation	MXA03-225B		Generate and Characterize Knock-In Mice Harboring DRD2 Ser311Cys Polymorphism
Aldridge,Kenneth E	Business		Biomerieux, Inc	ZGPAC9 AST		Synaptic mechanism underlying amygdala-obesity
Aldridge,Kenneth E	Business		Pfizer Inc	M7001086		CRCNs: PHASE RESETTING PREDICTS SYNCHRONIZATION IN HYBRID HIPPOCAMPAL CIRCUITS
Ali,Juzar	Business		Clinimetrics	InterMune GIMAC-001		Intrinsic Currents Modulate Synaptic Integration in Dopamine Neurons
Amedee,Angela Martin	Fed Subcontract	National Science Foundation	Board of Regents	LEQSF-EPS(2011)-SURE	EPS-1003897	CRCNs: Analysis of Synchronization in Hybrid Neural Circuits
Amedee,Angela Martin	Fed Subcontract	National Science Foundation	Board of Regents	LEQSF-EPS(2011)-SURE	EPS-1003897	Impact of Stress on GluR2 Transcription and Learning-Induced Synaptic Plasticity
Anand,Rene	Private Institutions		Philip Morris USA Inc			DERIVATION OF HEART MUSCLE LINEAGE-IMMORTALIZED CELL LINES
Anthony,Lowell B	Business		Novartis Pharmaceuticals Corporation	PTKAU550		SCF COMPLEX AND THE DROSOPHILA CENTROSOME CYCLE
Anthony,Lowell B	Business		Novartis Pharmaceuticals Corporation	RAD 001C 2325		A NOVEL REGULATOR OF CANCER CELL MIGRATION AND INVASION
Anthony,Lowell B	Business		ImClone	CP-13-0710		GLUCOCORTICOID RECEPTOR REGULATION IN LEUKEMIA
Backes,Wayne L	Federal		NIH, Nat Inst of Environmental Health	2 R01ES004344-16A1		ATP-UBIQUITIN DEPENDENT PROTEOLYSIS
Backes,Wayne L	Fed Subcontract	NIH, Nat Inst of Environmental Health	LSU, Baton Rouge	040800	1P42E013648-01A2	ATP-Ubiquitin Dependent Proteolysis
Backes,Wayne L	Fed Subcontract	NIH, Nat Inst of Environmental Health	LSU, Baton Rouge	040800	1P42E013648-01A2	TRAVEL GRANT-2ND ANNUAL WORLD SUMMIT OF ANTIVIRALS-BEIJING CHINA
Backes,Wayne L	Fed Subcontract	NIH, Nat Inst of Environmental Health	LSU, Baton Rouge	040800	1P42E013648-01A2	IQGAP1 Structure and Function
Backes,Wayne L	Fed Subcontract	NIH, Nat Inst of Environmental Health	LSU, Baton Rouge	040800	1P42E013648-01A2	Chemistry and Energy Transduction in Kinesin Motor Proteins
Backes,Wayne L	Fed Subcontract	NIH, Nat Inst of Environmental Health	LSU, Baton Rouge	61365	P42E013648	Linking neurodegeneration to protein turnover in ataxia telangiectasia
Backes,Wayne L	Fed Subcontract	NIH, Nat Inst of Environmental Health	LSU, Baton Rouge	61365	P42E013648	Therapeutic Effects of Anti-miR-27B in Breast Cancer
Backes,Wayne L	Fed Subcontract	NIH, Nat Inst of Environmental Health	LSU, Baton Rouge	61365	P42E013648	Cell Biology Development of Nutrient Medium for Increased Cell Longevity and Hardware for Cell Culling
Backes,Wayne L	Fed Subcontract	NIH, Nat Inst of Environmental Health	LSU, Baton Rouge	61365	P42E013648	MECHANISMS OF LUNG CARCINOGENESIS INDUCED BY ASBESTOS & CIGARETTE SMOKE
Backes,Wayne L	Institution				Cost Share	THE ROLE OF IL-17 IN RSV-INDUCED MUCUS AND AIRWAY RESPONSIVENESS
Backes,Wayne L	Institution				Cost Share	ALCOHOL, ROS AND MACROPHAGE EPIGENETICS
Bagby,Gregory J	Federal		NIH, National Inst. on Alcohol Abuse	5T32AA007577-07		Alcohol, ROS, and Macrophage Epigenetics
Bagby,Gregory J	Federal		NIH, National Inst. on Alcohol Abuse	NIAAA-AA07577-11		ALCOHOL, ROS AND MACROPHAGE EPIGENETICS
Bagby,Gregory J	Federal		NIH, National Inst. on Alcohol Abuse	NIAAA-AA07577-11		Mechanism of regulation for the oncogenic Pax3-FOXO1 in Alveolar
Balart Jr.,Luis A	Business		Schering Plough Research Institute	P02570		Non-CD4 Host Defense Against P. Carinii Pneumonia
Balart Jr.,Luis A	Business		Roche Laboratories Inc.	ML17756 Protocol		Host Factors in Fungal Allergy and Fibrosis
Balart Jr.,Luis A	Business		Pharmanet, Inc.	RNA003142-302		Alcohol, ROS, and Macrophage Epigenetics
Balart Jr.,Luis A	Business		Vertex Pharmaceutica	VX03-497-205		Alcohol, ROS, and Macrophage Epigenetics
Balart Jr.,Luis A	Business		Roche Laboratories Inc.	ML 18179		Medical Research Opportunities for the Patrick F. Taylor Science and Technology Academy and Taylor Opportunity Program for Students Scholars
Balart Jr.,Luis A	Business		Gilead Sciences Inc	GU-US-174-0102		Genetic Epidemiology of Lung Cancer
Balart Jr.,Luis A	Business		Coley Pharmaceutical	CPG40101		MENTORING A CANCER GENETICS PROGRAM - DR TOMOO IWAKUMA
Barbee,James Gray	Business		Wyeth-Ayerst	0600B-100735		MENTORING A CANCER GENETICS PROGRAM - DR TOMOO IWAKUMA - Mentor
Barbee,James Gray	Business		Merck & Co., Inc.	061-00		A drosophila model to investigate the role of FUS in ALS
Barbee,James Gray	Business		Wyeth-Ayerst	0600B5-354-US		Gamma Delta T Cells are Integral Mediators of Interstitial Pulmonary Fibrosis
Barbee,James Gray	Business		Bristol Myers Squibb	CN138-146-001		T cells and P carinii Pneumonia
Barbee,James Gray	Business		Eli Lilly And Company	FJ1-US-HMDR		Progress Report: Transcription-coupled GAA-TTC expansion in human cells
Barbee,James Gray	Business		Cephalon	C6671/3033/AX/US		Th17 Cytokines and Lung Immunity
Barbee,James Gray	Business		Bristol Myers Squibb	CN138-165-002		LSUHSC Summer Internship Program
Barron,Bruce Allen	Fed Subcontract	NIH, National Eye Institute	Johns Hopkins University	2U10EY08057-11	U10EY08057	LSUHSC Summer Internship Program
Barsley,Robert E	Federal		HHS, Health Resources & Service Admin	1H97HA07512-01		Germ-line Copy Number Variation in high-risk African American families
Bazan,Haydee Elvira P	Federal		NIH, National Eye Institute	1 R01EY019465-01		Mouse xenograft model generation to support in vivo investigations of CARM1 function
Bazan,Haydee Elvira P	Federal		NIH, National Eye Institute	1 R01EY019465-01		Novel Marcolide Th17 Inhibitors
Bazan,Haydee Elvira P	Federal		NIH, National Eye Institute	2 R01EY004928-27		Molecular mechanism of FUS/TLN1 related ALS
Bazan,Haydee Elvira P	Institution				Inst Fund	Alcohol and Pulmonary Immunity to MRSA
Bazan,Nicolas G	Federal		NIH, National Ctr for Research Resourc	2P20 RR016816-06		Alcohol and Pulmonary Immunity to MRSA
Bazan,Nicolas G	Federal		NIH, National Ctr for Research Resourc	2P20 RR016816-06		Testing Lytic Peptides in a Mouse Xenograft model of Uterine Fibroids
Bazan,Nicolas G	Federal		NIH, National Ctr for Research Resourc	2P20 RR016816-06		Determination of Genetic Susceptibility to Lung Cancer in Families from Southern Louisiana
Bazan,Nicolas G	Federal		NIH, National Ctr for Research Resourc	2P20 RR016816-06		Alcohol, Ros and Macrophage Epigenetics
Bazan,Nicolas G	Federal		NIH, National Ctr for Research Resourc	2P20 RR016816-06		Targeting DNA Mismatch Repair in Age-Related Repeat Expansion
Bazan,Nicolas G	Federal		NIH, National Ctr for Research Resourc	2P20 RR016816-06		Short Term Research Training for Medical Students
Bazan,Nicolas G	Federal		NIH, National Ctr for Research Resourc	2P20 RR016816-06		Short Term Research Training for Medical Students
Bazan,Nicolas G	Federal		NIH, National Ctr for Research Resourc	2P20 RR016816-06		Louisiana Sure Program
Bazan,Nicolas G	Federal		NIH, National Ctr for Research Resourc	2P20 RR016816-06		Louisiana Sure Program
Bazan,Nicolas G	Federal		NIH, National Ctr for Research Resourc	2P20 RR016816-06		Medical Student Alcohol Research Internship
Bazan,Nicolas G	Foundation		Foundation Fighting Blindness	TA-NP-0808-0463-LSUN		Research for Nikki Nguyen
Bazan,Nicolas G	Federal		NIH, National Eye Institute	3R01EY05121-25S1		Non-CD4 Host Defense Against P. Carinii Pneumonia. Graduate Student - David Ricks
Bazan,Nicolas G	Federal		NIH, Complementary & Alternative Medicin	1RC2AT005909-01		Graduate Student Contract - Sun Mi Choi
Bazan,Nicolas G	Foundation		Amer Health Assistance Ftdn	Amer Health Asst Fdt		Characterize Reg3g as an immune-base therapy to treat alcohol related life threatening CA-MRSA
Bazan,Nicolas G	Foundation		Amer Health Assistance Ftdn	Amer Health Asst Fdt		SOUTH LOUISIANA INSTITUTE FOR INFECTIOUS DISEASE RESEARCH-EDUCATION
Bazan,Nicolas G	Private Institutions		NIH, Nat Inst of Neurological Disorders	2R01NS046741-07A1		SOUTH LA INSTITUTE INFECTIOUS DISEASE RESEARCH-RESEARCH
Bazan,Nicolas G	Private Institutions		Doheny Eye Institute	1101		SOUTH LA INSTITUTE INFECTIOUS DISEASE RES-COMMERCIALIZATION
Bazan,Nicolas G	Federal		NIH, National Eye Institute	2R01EY005121-26A1		SOUTH LA INSTITUTE INFECTIOUS DISEASE RESEARCH-ADMINISTRATION
Belayev,Ludmila S.	Federal		NIH, Nat Inst of Neurological Disorders	1R01NS065786-01A2		SOUTH LOUISIANA INSTITUTE FOR INFECTIOUS DISEASE RESEARCH-START UP FUNDS-DR LI SHEN
Belayev,Ludmila S.	Federal		NIH, Nat Inst of Neurological Disorders	1R01NS065786-01A2		LOUISIANA VACCINE CENTER AND SOUTH LOUISIANA INSTITUTE FOR INFECTIOUS DISEASE RESEARCH
Bell,Laura J	Business		Genzyme	Genzyme		ANALYSES OF SIGMA FACTOR 28 OF C TRACHOMATIS

ATTACHMENT 1: LSUHSC-NO ACTIVE RESEARCH DEVELOPMENT AWARD/CONTRACT LIST

P.I. Name	Category	Primary Spnsr	Direct Sponsor	Ref Awd #	Ref Awd #2	Project Title
Bergsma,Donald R	Business		Parexel International Corp	B7A-MC-MBCM		MECHANISMS OF HERPES VIRUS PROTEINS IN HIJACKING AND SUBVERTING HOST AND CELLULAR RESPONSE PATHWAYS
Bergsma,Donald R	Foundation		Research To Prevent Blindness	Res to Prevent Blind		GRADUATE STUDENT STIPEND-CAROLINE CHAPMAN
Bergsma,Donald R	Fed Subcontract	NIH, National Eye Institute	Johns Hopkins University	U10EY008057	U10 EY008057	GRADUATE STUDENT STIPEND-RYAN CRAIG
Besch,Ceryl Lynn	Fed Subcontract	U.S. Department Of Agriculture	University of Illinois	2009-511110-20173	2009-511110-20173	THE DESIGN, DELIVERY AND DEVELOPMENT OF THERAPEUTIC PEPTIDES: PROJECT 4. DEVELOPMENT OF
Blatz,Markus B	Business		HERAEUS KULZER			Oral Mucosal Immunity in Vulnerable HIV Infected Populations
Block,Michael S	Business		Implant Innovations	2208 Fireball		Characterization and use of a novel AT-hook protein in Leishmania
Boulares,Abdel Hamid	Private Institutions		University of Texas, Galveston	09-033		Analyses of sigma factor 28 of C. trachomatis
Boulares,Abdel Hamid	Foundation		American Cancer Society	RSG-09-279-01-CNE		EBNA1 Functions Required in Burkitt's Lymphomas and Other Immortalized B-Cells
Boulares,Abdel Hamid	Federal		NIH, National Heart Lung & Blood Inst	2R01HL072889-06A2		EBNA1 Functions Required in Burkitt's Lymphomas and Other Immortalized B-Cells
Brantley,Phillip	Federal		NIH, Nat Inst Diabetes & Diges & Kidney	1T35DK093428-01		Defensins in STI-Mediated Enhanced HIV Infectivity
Brantley,Phillip	Federal		NIH, Nat Inst Diabetes & Diges & Kidney	1T35DK093428-01		C. trachomatis increases transmission of HIV: mechanisms in the endocervix
Brennan,Christine S	Federal		NIH, National Cancer Institute	1R15CA151031-01		Isolation, characterization, and culture of domestic cat spermatogonial cells
Breslin,Jerome W.	Foundation		American Heart Association	0835388N		HIV Infection in Women During Pregnancy and the Postpartum Period
Breslin,Jerome W.	Foundation		Alcoholic Beverage Medical Research Fndt	Alcoholic Beverage M		HIV Infection in Women During Pregnancy and the Postpartum Period
Breslin,Jerome W.	Federal		NIH, National Heart Lung & Blood Inst	1R01HL098215-01A1		Novel Cellular & Genetic Analyses using a New Chlamydia Pentrant Peptide
Breslin,Jerome W.	Federal		NIH, National Inst. on Alcohol Abuse	1R21AA020049-01A1		Pharmaceutical Correction of Innate Immune Defects in Cystic Fibrosis
Breslin,Mary B	State		Board of Regents	LEQSF(2007-10)RD-A16		Antigen expressed on Pill of Lactococcus as an Oral Vaccine for HIV
Byerley,Lauri O.	Foundation		American Institute for Cancer Research	Amer Inst Cancer Res		Spermatogonial Stem Cell Transplantation in the Domestic Cat
Byerley,Lauri O.	Foundation		American Institute for Cancer Research	MG11A001		Derivation of Induced Pluripotent Stem-like Cells from Felid Somatic Cells
Canavier,Carmen C	Federal		NIH, National Institute of Mental Health	1R01MH085387-01		A New Class of Broad Spectrum Antifungal Agents
Canavier,Carmen C	Federal		NIH, Nat Inst of Neurological Disorders	1R01NS061097-01A2		VAGAL INTERGRATION OF LOWER ESOPHAGEAL SPHINCTER FUNCTION
Canavier,Carmen C	Federal		NIH, Nat Inst of Neurological Disorders	2R01NS054281-05		EFFECTS OF CHRONIC THC IN ADOLESCENCE
Canavier,Carmen C	Federal		NIH, National Institute of Mental Health	1R01MH085387-01		COMBUSTION GENERATED PMO.1 AND PREDISPOSITION TO ASTHMA
Canavier,Carmen C	Federal		NIH, Nat Inst of Neurological Disorders	NINDS - NS061097-01A		MENTORING IN CARDIOVASCULAR BIOLOGY-CORE A-ADMINISTRATION CORE
Canavier,Carmen C	Federal		NIH, Nat Inst of Neurological Disorders	2R01NS054281-05		MENTORING IN CARDIOVASCULAR BIOLOGY-CORE A-SUBAWARD WITH TULANE - DR PATRICE DELAFONTAINE
Canavier,Carmen C	Federal		NIH, Nat Inst of Neurological Disorders	2R01NS054281-05		MENTORING IN CARDIOVASCULAR BIOLOGY-CORE B-CELL AND MOLECULAR ANALYSIS CORE
Cassidy,William Morgan	Business		Pharmanet, Inc.	051-002		MENTORING IN CARDIOVASCULAR BIOLOGY-CORE C-IMAGING AND HISTOLOGY CORE
Cassidy,William Morgan	Business		Roche Laboratories Inc.	NR16172		MENTORING IN CARDIOVASCULAR BIOLOGY-CORE D-VASCULAR AND CARDIAC FUNCTION CORE
Cassidy,William Morgan	Business		Roche Laboratories Inc.	NR16161		MENTORING IN CARDIOVASCULAR BIOLOGY-PROJECT 4-MECHANISMS INVOLVED IN THE INTRACELLULAR
Castaneda-Zuniga,Wilfrido	Business		Abbott Laboratories	M97-642		MENTORING IN CARDIOVASCULAR BIOLOGY-PROJECT 5-REGULATION OF ENDOTHELIAL CELL PERMEABILITY
Cefalu,Charles A	Business		Merck & Co., Inc.	EPO8011-011		MENTORING IN CARDIOVASCULAR BIOLOGY- Sergiy Sukhanov
Cefalu,William T	Business		Johnson & Johnson	JNJ-28431754DIA3009		MENTORING IN CARDIOVASCULAR BIOLOGY-Dr. Wainford
Cefalu,William T	Business		Lilly Research Laboratories	Lilly USA LY2189265		MENTORING IN CARDIOVASCULAR BIOLOGY- Jason Gardner
Cefalu,William T	Business		Johnson & Johnson	2843175D1A3002		MENTORING IN CARDIOVASCULAR BIOLOGY - Xiping Yue
Chen,Chu	Federal		NIH, Nat Inst of Neurological Disorders	R01NS054886-01		MENTORING IN CARDIOVASCULAR BIOLOGY - Lisa Harrison-Bernard
Chen,Chu	Federal		NIH, National Institute on Aging	1R21AG039669-01		CNS G ALPHA-SUBUNIT PROTEIN CONTROL OF PLASMA AVP AND URINE OUTPUT - MODULATION BY HIGH NACL
Chen,Chu	Federal		NIH, National Institute on Aging	1R21AG039669-01		BRAIN-TARGETED ACE2 OVER-EXPRESSION ON ANGIOTENSIN-II-MEDIATED HYPERTENSION
Chen,Chu	Federal		NIH, Nat Inst of Neurological Disorders	NINDS-1R01NS076815-0		TRAVEL GRANT-XXXVI INTERNATIONAL CONGRESS OF PHYSIOLOGICAL SCIENCES-KYOTO, JAPAN
Chen,Vivien Wai-Mei	Federal		NIH, National Cancer Institute	1N01PC54402-01		TOXICOLOGICAL SIGNIFICANCE OF ALKYL BENZENE METABOLISM
Chen,Vivien Wai-Mei	Local Govt		LSUHSC, McIno Charly, No	CFMS# 716379		PREVENTION OF ASTHMA BY ALDOSE REDUCTASE INHIBITION
Chen,Vivien Wai-Mei	Local Govt		LSUHSC, McIno Charly, No	CFMS# 716379		Brain G-alpha-subunit mediated regulation of blood pressure
Chen,Vivien Wai-Mei	Local Govt		LSUHSC, McIno Charly, No	CFMS# 716379		Combining Mammalian and Drosophila Systems to Study Neuropsychiatric Disorders
Chen,Vivien Wai-Mei	Local Govt		LSUHSC, McIno Charly, No	CFMS# 716379		Brain-Targeted ACE2 over-expression on angiotensin-II-mediated hypertension
Chen,Vivien Wai-Mei	Federal		HHS, Ctr for Disease Control & Preventio	1U58DP000769-01		Regulation of IL4 signal transduction on poly (ADP-ribose) polymerase-1
Chen,Vivien Wai-Mei	Federal		HHS, Ctr for Disease Control & Preventio	1U58DP000769-01		Regulation of IL4 signal transduction by poly (ADP-ribose) polymerase-1
Chen,Vivien Wai-Mei	Federal		HHS, Ctr for Disease Control & Preventio	1U58DP000769-01		Health Impacts of Toxic Combustion By-Products - Admin.
Chen,Vivien Wai-Mei	Federal		HHS, Ctr for Disease Control & Preventio	1U58DP000769-01		Health Impacts of Toxic Combustion By-Products - Project 4
Chen,Vivien Wai-Mei	Federal		HHS, Ctr for Disease Control & Preventio	1U58DP000769-01		Health impacts of Toxic Combustion By-Products - Project 5
Chen,Vivien Wai-Mei	Federal		HHS, Ctr for Disease Control & Preventio	1U58DP000769-01		Health Impacts of Toxic Combustion By-Products - Project 6
Chen,Vivien Wai-Mei	Federal		NIH, National Cancer Institute	HHSN261201000030C		Sodium Channels, Sodium Pumps, Inflammation and Diabetic Neuropathy
Chen,Vivien Wai-Mei	Federal		NIH, National Cancer Institute	HHSN261201000030C		Effects of ACE2 gene Therapy on Diabetes
Chen,Vivien Wai-Mei	Fed Subcontract	HHS, Ctr for Disease Control & Preventio	Macro International Inc.	CDC 200-2008-27957	200-2008-27957/0008	Serotonin 5-HT2A receptor inhibition of TNF-alpha pathways and atherosclerosis
Chen,Vivien Wai-Mei	Federal		HHS, Ctr for Disease Control & Preventio	1U58DP003805-01		Preclinical evaluation of DHEA as a treatment for alcoholism
Chen,Vivien Wai-Mei	Institution				Cost Share	Preclinical evaluation of DHEA as a treatment for alcoholism
Chen,Vivien Wai-Mei	Institution				Cost Share	Balance of Angiotensin II/ Angiotensin (1-1): A target in Ischemic Stroke
Chhabra,Kavaliit	Foundation		American Heart Association	11PRE6320006		The regulation of cannabinoid receptors in microglial cells during HIV infection
Chhabra,Kavaliit	Foundation		American Heart Association	11PRE6320006		Brain G-alpha subunit protein mediated neural control of blood pressure
Chilian,William M	Fed Subcontract	NIH, National Heart Lung & Blood Inst	Tulane University	1R01HL73755-01	R01HL73755	Role of ACE2 in high fat diet-mediated dysregulation of glycemia in mice
Choi,Sun Mi	Federal		NIH, National Inst. on Alcohol Abuse	NIAAA 1F31AA021061		Role of ACE2 in high fat diet-mediated dysregulation of glycemia in mice
Choi,Sun Mi	Federal		NIH, National Inst. on Alcohol Abuse	NIAAA 1F31AA021061		The Role of IL4R Alpha in Neonatal RSV Immunopathology
Clark,Rebecca	Business		Bio-Technology General Corporation	M0225		Molecular Genetics of HSV Reactivation
Clark,Rebecca	Business		Bristol Myers Squibb	HARRT		LSU Superfund Research Center - Environmentally Persistent Free Radicals - Admin
Clark,Rebecca	Business		Discovery Life Sciences	GNPR29-US		LSU Superfund Research Center - Environmentally Persistent Free Radicals - Project 2 Cormier
Claycomb,William C	Foundation		Joe W & Dorothy Dorsett Brown Foundation			LSU Superfund Research Center - Environmentally Persistent Free Radicals - Varner
Claycomb,William C	Fed Subcontract	U.S. Army	E. Canary, LLC	W81XWH-11-1-0617	W81XWH-11-1-0617	LSU Superfund Research Center - Environmentally Persistent Free Radicals - Project 5 Backes
Conrad,Erich Josef	Business		Astra Zenca Pharmaceuticals	IRUSQUET0381		Mechanisms of ACE2 Dysregulation in Neurogenic Hypertension
Cormier,Stephanie A	Federal		NIH, Nat Inst of Environmental Health	7R01ES015050-02		ADULT STEM CELLS FOR REPAIR OF CARDIAC DAMAGE
Cormier,Stephanie A	Federal		NIH, Nat Inst on Allergy & Infec Disease	1R01AI090059-01A1		ASH 2004 YOUNG SCHOLARS AWARD
Coulter,W Alan	Fed Subcontract	U.S. Office of Education	Westat Inc	H373Y070002	H373Y070002	BIOMEDICAL ALCOHOL RESEARCH TRAINING PROGRAM - STIPENDS
Crabtree,Judy	Fed Subcontract	National Science Foundation	Board of Regents	LEQSF(2011)PFund-249	NSF: EPS-1003897	CANNABINOID EFFECTS ON HIV/AIDS
Crabtree,Judy S.	State		Pennington Biomedical Research Center	PBRC		CANNABINOID EFFECTS ON HIV/AIDS
Cui,Yan	Federal		NIH, National Cancer Institute	1R01CA112065-01		CANNABINOID EFFECTS ON HIV/AIDS

ATTACHMENT 1: LSUHSC-NO ACTIVE RESEARCH DEVELOPMENT AWARD/CONTRACT LIST

P.I. Name	Category	Primary Spnsr	Direct Sponsor	Ref Awd #	Ref Awd #2	Project Title
Cui,Yan	Federal		NIH, National Cancer Institute	1R01CA112065-01		CANNABINOID EFFECTS ON HIV/AIDS
Cui,Yan	Federal		NIH, National Cancer Institute	3R01CA112065-0551		CANNABINOID EFFECTS ON HIV/AIDS
Cui,Yan	Institution				Inst Fund	CELLULAR SIGNALING MECHANISMS IN MICROVASCULAR PERMEABILITY
Datta,Rahul	Federal		NIH, National Heart Lung & Blood Inst	1F30HL097580-01		REGULATION OF CORONARY COLLATERAL GROWTH IN THE METABOLIC SYNDROME
Datta,Rahul	Federal		NIH, National Heart Lung & Blood Inst	1F30HL097580-01		NATIONAL HISPANIC SCIENCE NETWORK ON DRUG ABUSE (NHSN) ANNUAL CONFERENCE
Deboisblanc,Bennett P	Business		Kinetic Concepts			CIRCULATING PROMOTERS OF CANCER CACHEXIA ASSOCIATED LIPOLYSIS
Deboisblanc,Bennett P	Business		Hesperion Usa Inc.	AC 052-352/PHT		National Videoconference Training Program
Deboisblanc,Bennett P	Business		Ppd Pharmaco, Inc			Mechanisms of Cardiac Damage from Inhaled Particulate Matter
Deboisblanc,Bennett P	Business		Hesperion Usa Inc.	AC-052-357		ACE-Independent Pathways in Diabetic Renal Vascular Disease
Deboisblanc,Bennett P	Business		Ppd Pharmaco, Inc	FPH01/ENCYSIVE		BIOMEDICAL ALCOHOL RESEARCH TRAINING PROGRAM - SUPPORT
Deboisblanc,Bennett P	Business		PPD Development	FPH03		BIOMEDICAL ALCOHOL RESEARCH TRAINING PROGRAM - STIPENDS
Deboisblanc,Bennett P	Business		GlaxoSmithkline Pharmaceuticals	SCO-100250		Alcohol and Sca-1; Impairment of th granulopoietic precursor cell response
Deboisblanc,Bennett P	Federal		NIH, National Heart Lung & Blood Inst	HHSN268200536172C-01		Alcohol and Sca-1; Impairment of the granulopoietic precursor cell response
Deboisblanc,Bennett P	Federal		NIH, National Heart Lung & Blood Inst	HHSN268200536172C-01		National Hispanic Science Network on Drug Abuse
Deboisblanc,Bennett P	Federal		NIH, National Heart Lung & Blood Inst	HHSN268200536172C-01		Cannabinoid Epigenomic and miRNA mechanisms impact HIV/SIV disease progression
Deboisblanc,Bennett P	Federal		NIH, National Heart Lung & Blood Inst	HHSN268200536172C-01		Cannabinoid Epigenomic and miRNA mechanisms impact HIV/SIV disease progression
Deboisblanc,Bennett P	Business		CoTherix	C200-008		Alcohol, Septicemia and LKS Cell Response
Deboisblanc,Bennett P	Business		ACTELION	AC-055-303		Alcohol intoxication & Shock; specific needs & targated resuscitation strategies
Deboisblanc,Bennett P	Business		Gilead Sciences Inc	GS-US-235-0101		Porter Fellowship
Deboisblanc,Bennett P	Business		ACTELION	Actelion Pharma		Endocannabinoids as a Target for the Treatment of Traumatic Brain Injury
Deboisblanc,Bennett P	Business		Gilead Sciences Inc	GS-US-300-0140		Impact of alcohol intoxication on jemmorrhagic shock-induced microvascular dysfunction
Deboisblanc,Bennett P	Business		Actelion	AC-065A302		Alcohol-induced Osteoimmunopathies: A Unifying Explanatory Mechanism
Deboisblanc,Bennett P	Business		ACTELION	Prospect Clinical Re		Role of Lysyl Oxidase in Heart Failure
Deboisblanc,Bennett P	Business		ACTELION	AC-063B201		Regulatory Mechanisms for Resolution of Inflammatory Microvascular Leakage
Del Valle,Luis	Federal		NIH, Nat Inst of Neurological Disorders	7R01NS05644-05		Impact of Alcohol on Hemorrhagic Shock-Induced Microvascular Dysfunction
Desai,Shyamal D.	State		Board of Regents			Post-Traumatic Stress Disorder and Alcohol Dependence
Desai,Shyamal D.	Foundation		Ataxia telangiectasia Children's Project	AT Children's Projec		Can Walnuts Slow Growth and Delay Cancer - Associated Cachexia
Desselle,Bonnie C	Private Institutions		Children's Hospital	C11-74-089		Role of Heparan Sulfate 6-O-Endosulfatase 1 and 2 in Pulmonary Fibrosis
Devier,Deirdre J	Foundation		National Alliance for Research on	NARSAD		Impact of Alcohol Intoxication on Recovery from Traumatic Brain Injury
Diaz,James H	Fed Subcontract	HHS, Ctr for Disease Control & Preventio	RTI International	CDC 200-2010-34803	200-2010-34803	Impact of Alcohol Intoxication on Lymphatic Contractile Mechanisms
Dicarlo,Richard P	Business		Vaxgen	VAX004		Impact of Alcohol Intoxication on Lymphatic Contractile Mechanisms
Dunbar,Lala Mathers	Business		GlaxoSmithkline Pharmaceuticals	265805-112		NOVEL FLUORIDE RELEASING DENTAL COMPOSITE RESIN
Dunbar,Lala Mathers	Fed Subcontract	HHS, Ctr for Disease Control & Preventio	University of California, Los Angeles	U01CI000353-03	5U01CI000353-03	SPECIAL PROJECTS OF NATIONAL SIGNIFICANCE
Dunbar,Lala Mathers	Business		Medpace, Inc	NAB-BC-3781-2001		BRPA IN VIRULENCE MODULATION OF STREPTOCOCCUS MUTANS
Dunbar,Lala Mathers	Business		Paragon Biomedical, Inc	CEM-101		Mechanisms Governing Monocyte Recruitment During Periodontal Inflammation
Eady,Tiffany Niemoller	Federal		NIH, National Institute on Aging	4F30AG032841-03		Mechanisms Governing Monocyte Recruitment during
Eady,Tiffany Niemoller	Federal		NIH, National Institute on Aging	4F30AG032841-03		Targeting Host and Fungal Eicosanoids During Candida albicans bloodstream Infections
England,John	Fed Subcontract	NIH, Nat Inst of Neurological Disorders	Tulane University	2R01NS048952-06	2R01NS048952-06	Impact of Candida Oxyliplins on Host Immunity and Fungal Biology
Erickson,Jeffrey D	Foundation		National Alliance for Research on	NARSAD		The Role of Candida Albicans Biofilms in a Novel Rat Model of Denture Stomatitis
Espinoza,Luis R	Business		Rheumatology Research International Inc	FUJI 049		A PROSPECTIVE, OBSERVATIONAL STUDY OF OSSEOTITE CERTAIN IOL IMPLANTS IN IMMEDIATE OCCLUSAL
Espinoza,Luis R	Business		Scirex	113-B02OCTR.021.TRA		TREATMENT OF GENERAL DENTAL PROCEDURES
Espinoza,Luis R	Business		Novartis Pharmaceuticals Corporation	COX189A 2335 c552		CLINICAL EVALUATION OF OSTER GRAF/CS-300
Espinoza,Luis R	Business		Tap Pharm	CO2-021		BONE RETENTION QUALITIES OF THE LASERLOK DENTAL IMPLANT
Espinoza,Luis R	Business		Pfizer Inc	A3921024		GENERAL TRAINING GRANT DONATION
Espinoza,Luis R	Business		Pfizer Inc	A3921035		Prospective Evaluation of Early Loading of Zimmer Hydroxyapatite Coated Dental Inplants
Espinoza,Luis R	Business		Roche Laboratories Inc.	ML21136		Evaluation of the stability of the 8 mm OsseoSpeed and OsseSpeed TM
Espinoza,Luis R	Business		Pfizer Inc	A3921032		Immediate Loading of the Nobelreplace Tapered Groovy Implant When Placed in Fresh and Healed Extraction
Espinoza,Luis R	Business		Pfizer Inc	A3921069		SINGLE TOOTH IMPLANTS SUPPORTED RESTORATION 6/31/02 Account changed to 122600019A
Espinoza,Luis R	Fed Subcontract	NIH, Inst Arthritis and Musculoskeletal	University of Alabama	5R01AR057202-02	5R01AR057202-02	BOND STRENGTH OF A NEW BONDING SYSTEM FOR PORCELAIN LAMINATE VANEERS
Espinoza,Luis R	Business		Covance	TMX-67-301		FABRICATION OF CROSS-LINKED POLYMER NANOFIBERS BY COUPLING ELECTROSPINNING IN-LINE WITH
Espinoza,Luis R	Private Institutions		Howard University	0006604-1000036762		Novel Antibacterial Fluoride-releasing Dental Materials
Estrada,John J	Fed Subcontract	NIH, Center on Minority Health and	Dillard University	1 P20MD004817-01	1P20MD004817-01	PHASE III CLINICAL TRIAL PROTOCOL 2011A-PR003
Estrada,John J	Fed Subcontract	NIH, Center on Minority Health and	Dillard University	1 P20MD004817-01	1P20MD004817-01	MENTORING ORAL HEALTH RESEARCH IN LOUISIANA-PROJECT 1
Estrada,John J	Fed Subcontract	NIH, Center on Minority Health and	Dillard University	1 P20MD004817-01	1P20MD004817-01	MENTORING ORAL HEALTH RESEARCH IN LOUISIANA-ADMIN CORE
Estrada,John J	Fed Subcontract	NIH, Center on Minority Health and	Dillard University	1 P20MD004817-01	1P20MD004817-01	MENTORING ORAL HEALTH RESEARCH IN LOUISIANA-EQUIPMENT CORE
Estrada,John J	Fed Subcontract	NIH, Center on Minority Health and	Dillard University	1 P20MD004817-01	1P20MD004817-01	MENTORING ORAL HEALTH RESEARCH IN LOUISIANA-STATISTICAL CORE
Estrada,John J	Fed Subcontract	NIH, Center on Minority Health and	Dillard University	1 P20MD004817-01	1P20MD004817-01	ROLE OF VACUOLE EXPANSION IN ORAL PATHOGEN CANDIDA ALBICANS
Estrada,John J	Fed Subcontract	NIH, Center on Minority Health and	Dillard University	1 P20MD004817-01	1P20MD004817-01	EFFECT OF AGING ON PERIODONTAL DISEASE
Estrada,John J	Fed Subcontract	NIH, Center on Minority Health and	University of Alabama	000318383-003	5P60MD0000502-09	DEVELOPMENT OF NEW ADHESIVE FLUORIDE-RELEASING MONOMERS
Fang,Zhide	Fed Subcontract	NIH, National Ctr for Research Resourc	Xavier University	OSP-11-241418-001	2P20RR016456	CX3CL1-DRIVEN MONOCYTE RECRUITMENT DURING PERIODONTITIS
Ferris,Michael J	Private Institutions		Children's Hospital, Research Institute	CHILDREN'S HOSP-RIC		MENTORING ORAL HEALTH RESEARCH IN LOUISIANA-START UP
Fidel Jr.,Paul L	Fed Subcontract	U.S. Department of Housing and Urban Dev	Board of Regents	RCEEP-02 (2007-10)	PL109-148	Mentoring Oral Health Research in Louisiana - Yuwei Fan
Fidel Jr.,Paul L	Fed Subcontract	U.S. Department of Housing and Urban Dev	Board of Regents	RCEEP-02 (2007-10)	PL109-148	MENTORING ORAL HEALTH RESEARCH IN LOUISIANA - Admin Sup Noverr Pilot Proj
Fidel Jr.,Paul L	Fed Subcontract	U.S. Department of Housing and Urban Dev	Board of Regents	RCEEP-02 (2007-10)	PL109-148	MENTORING ORAL HEALTH RESEARCH IN LOUISIANA - PALAIOLOGOU
Fidel Jr.,Paul L	Fed Subcontract	U.S. Department of Housing and Urban Dev	Board of Regents	RCEEP-02 (2007-10)	PL109-148	Partnering with Ville Ste. Marie in Linking Seniors to NLM's Consumer Health Information
Fidel Jr.,Paul L	Fed Subcontract	U.S. Department of Housing and Urban Dev	Board of Regents	RCEEP-02 (2007-10)	PL109-148	Affordable Care Act: Primary Care Residency Expansion
Fidel Jr.,Paul L	Fed Subcontract	U.S. Department of Housing and Urban Dev	Board of Regents	RCEEP-02 (2007-10)	PL109-148	Affordable Care Act: Primary Care Residency Expansion
Fidel Jr.,Paul L	Federal		NIH, National Ctr for Research Resourc	5P20RR020160-02		Gulf Coast Halth Alliance:Health Risks related to the Macondo Spill (GC-HARMS)
Fidel Jr.,Paul L	Federal		NIH, National Ctr for Research Resourc	5P20RR020160-05		DETERMINE GENETIC SUSCEPTIBILITY TO LUNG CANCER
Fidel Jr.,Paul L	Federal		NIH, National Ctr for Research Resourc	5P20RR020160-05		TAKE SAMPLES IN AN ACYCLOVIR RESISTANT HERPLEX VIRUS STUDY
Fidel Jr.,Paul L	Federal		NIH, National Ctr for Research Resourc	5P20RR020160-05		ANTHYPERTENSIVE AND LIPID-LOWERING TMT FOR HEART ATTACK
Fidel Jr.,Paul L	Federal		NIH, National Ctr for Research Resourc	5P20RR020160-05		AIDSVAX B VACCINE IF ADULTS AT RISK OF HIV-1 INFECTION
Fidel Jr.,Paul L	Federal		NIH, National Ctr for Research Resourc	5P20RR020160-05		GRANULOCYTE COLONY-STIMULATING FACTOR TO INFECTIOUS DISEASE
Fidel Jr.,Paul L	Federal		NIH, National Ctr for Research Resourc	5P20RR020160-05		PULMONARY CAPILLARY PRESSURE MEASUREMENT

ATTACHMENT 1: LSUHSC-NO ACTIVE RESEARCH DEVELOPMENT AWARD/CONTRACT LIST

P.I. Name	Category	Primary Spnser	Direct Sponsor	Ref Awd #	Ref Awd #2	Project Title
Fidel Jr.,Paul L	Federal		NIH, National Ctr for Research Resourc	5P20RR020160-05		KW2189 FOR RELAPSED GASTRIC CARCINOMA
Fidel Jr.,Paul L	Federal		NIH, National Ctr for Research Resourc	5P20RR020160-05		MOXIFLOXICIN VERSUS CEFTRAXONE IV/PO CEFUROXIME -AXETIL
Fidel Jr.,Paul L	Federal		NIH, National Ctr for Research Resourc	5P20RR020160-05		APTIMA COMBO2 ASSAY FOR CHALYDIA TRACHOMATIS
Fidel Jr.,Paul L	Federal		NIH, National Ctr for Research Resourc	3P20RR020160-0551		OPC-17116 VS DOXYCYCLINEFOR NONGONOCOCCAL IN URETHRITIS
Fidel Jr.,Paul L	Federal		NIH, National Ctr for Research Resourc	3P20RR020160-0551		PHASE I/II STUDY OF BIOLOGIC RESPONSE TO FILGRASTIM
Filipeanu,Catalin	Federal		NIH, National Institute on Drug Abuse	1R03DA031596-01		TWO CENTER DOSE-RANGING STUDY OF CP-99,219
Fisch,Bruce	Business		Hoechst Marion Roussel	071754ST1669		NORTH AMERICAN AMPLIFIED CHLAMYDIA TRACHOMATIS STUDY
Fisch,Bruce	Business		NeuroPace, Inc			BB-2516 MARIISTAT FOR MINIMAL DISEASE STAGE III NSCLC
Fisch,Bruce	Business		NeuroPace, Inc			BB-2516 MARIMASTAT IN NSCLC
Fisch,Bruce	Business		NeuroPace, Inc			EVALUATION OF DYSMORPHIA/DYSREGULATION SYNDROME
Fontham,Elizabeth T	State		LSU Pennington Biomedical Research Ctr	SPH-D012-BG-1100		STUDY OF AD1549 IN COMBINATION WITH VIRACEPT
Foster,Timothy P.	State		Board of Regents	LEQSF(2008-11)-RDA13		BD PROBE TEC ET SYSTEM
Foster,Timothy P.	Institution				Cost Share	PERFORMANCE CHARACTERISTICS FOR MALE URINE & URETHRAL SPECIM
Foundas,Anne L.	Fed Subcontract	NIH, Nat Inst of Neurological Disorders	Kessler Medical Rehab Research Center	323-02	1 R01NS055808-01A2	TREATMENT OF ACUTE EXACERBATION OF CHRONIC BRONCHITIS
Foundas,Anne L.	Federal		NIH, Inst on Deafness & Other Comm	7R03DC004957-04		BL-3 LAB SUPPORT FUNDS
Friend,Richard	Federal		HHS, Health Resources & Service Admin	1T89HP20850-01-00		REGRANEX FOR FULL THICKNESS DIABETIC NEUROPATHIC FOOT ULCERS
Friend,Richard	Federal		HHS, Health Resources & Service Admin	1T89HP20850-01-00		ASSESS EFFECTS OF R047-0203 ON EXERCISE CAPACITY IN PATIENTS
Gardner,Jason D.	State		Board of Regents	LEQSF(2009-12)RDA-10		CLINICAL VERIFICATION OF NEW WET SWAB TRANSPORT SYSTEM
Gardner,Jason D.	Foundation		American Heart Association	11GRNT7700002		INTERERON GAMMA-1B W/ANTIMYCOBACTERIALS FOR MAC INFECTION
Gardner,Jason D.	Institution				Cost Share	PHASE 3 EFFICACY TRIAL OF AZITHROMYCYIN VE BENZTHINE PENCIL
Gasparini,Sonia	Federal		NIH, Nat Inst of Neurological Disorders	1R01NS069714-014		MODIFYING ANTIRHEUMATIC DRUGS
Gasser,Raymond F	Federal		NIH, Nat Inst Child Health & Human Dev	2 R01 HD037811-08A1		EVALUATION OF THE BIOSTAR CHLAMYDIA OIA AND GONORRHOEA OIA ASSAYS FOR IN VITRO DAIGNOSIS IF
Gasser,Raymond F	Federal		NIH, Nat Inst Child Health & Human Dev	3R01HD037811-08A1S1		STAXSENTAN SODIUM FOR PULMONARY ARTERIAL HYPERTENSION
Gee,Rebekah	Private Institutions		National Academies - Institute of Medici			MULTICENTER, OPEN-LABEL, SINGLE-ARM SAFETY STUDY OF BOSENTAN IN PATIENTS WITH PULMONARY
Giarratano,Gloria	Federal		NIH, Institute of Nursing Research	1R03NR012052-01		A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED SAFETY AND EFFICACY STUDY OF STAXSENTAN
Gilbert,Jill	Foundation		National Surgical Adjuvant Breast And Bo	PFED15-LSU-01		AMLODIPINE AND VASCULAR PROTEOGLYCAN METABOLISM
Gilbert,Jill	Foundation		Susan G Komen Breast Cancer Found			A RANDOMIZED, DOUBLE-BLIND STUDY COMPARING ARANESP (DAREPOETIN ALFA) AND RECOMBINANT
Gilbert,Jill	Foundation		CTRC Research Foundation	S0111		A PHASE III DOUBLE-BLIND, PARALLEL GROUP, MULTICENTER, PLACEBO CONTROLLED STUDY OF CICLESONIDE
Giles,Thomas D	Fed Subcontract	NIH, Nat Inst of Neurological Disorders	Univ of Medicine & Dentistry of NJ	1U01NS43975-01	U01NS43975	A DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL, MULTICENTER STUDY ON EXTENDED VTE PROPHYLAXIS
Gilpin,Nicholas	Federal		NIH, National Inst. on Alcohol Abuse	4R00AA018400-03		ASTHMA CLINICAL RESEARCH
Glynn,Gary R	Business		Pharmanet, Inc.	CAPS083		SURVEY OF THE IN-VITRO ACTIVITY OF PIPERACILLIN/TAZOBACTAM AND OTHER ANTIMICROBIAIS AGAINST
Gorman,Melissa	Private Institutions		McMaster University	EX-TIB-0907		BARF SILER COATED ENDOTRACHEAL TUBE STUDY
Gould,Harry J	Business		CV Therapeutics	CVT		A 12 WEEK, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO AND ACTIVE-CONTROLLED STUDY OF A
Gould,Harry J	Business		Genzyme			A DOUBLE-BLIND, RANDOMIZED, DOSE-RANGING, PARALLEL GROUP COMPARISON OF THE EFFICACY AND
Grabczyk,Edward L	Business		Friedreich Ataxia	Friedrich's Ataxia		GEN-PROBE APTIMA COMBO ASSAY, THE APTIMA CT ASSAY, AND THE APTIMA GC ASSAY
Greenleaf,Wayne A	Fed Subcontract	HHS, Admin for Children & Families	LA, Department of Education	FEDERAL TANF FUNDS	FEDERAL TANF FUNDS	PREVENTION OF PROGRESSION OF FIBROSIS IN ADULT SUBJECTS WITH CHRONIC HEPATITIS C WITH HEPATIC
Greenleaf,Wayne A	Fed Subcontract	HHS, Admin for Children & Families	LA, Department of Education	CFMS 612291	TANF FUNDS	STAXSENTAN SODIUM TREATMENT IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION
Gregory,Paula E	Federal		NIH, National Heart Lung & Blood Inst	1 T35HL105350-01		EVALUATE ISEGANAN HC1 ORAL SOLUTION IN PREVENTING VENTILATOR-ASSOCIATED PNEUMONIA
Gregory,Paula E	Federal		NIH, National Heart Lung & Blood Inst	1 T35HL105350-01		PATIENTS WITH RHEUMATOID ARTHRITIS USING NAPROXEN
Gregory,Paula E	Federal		NIH, National Inst. on Alcohol Abuse	1R25AA021304-01		MEROPENEM, ERTAPENEM, IMIPENEM W/OTHER ANTIMICROBIALS AGAINST CLINICALLY SIGNIFICANT
Gregory,Paula E	Federal		NIH, National Inst. on Alcohol Abuse	1R25AA021304-01		ALCOHOL & REACTIVATION TB
Gregory,Paula E	Federal		NIH, National Inst. on Alcohol Abuse	1T35AA021097-01		SYMBICORT PMDI STUDY
Gutierrez,Amparo	Business		Berlex Labs	306440		BACTERIOIDES SUSCEPTIBILITY TESTING OF MOXIFLOXACIN AND OTHER AGENTS
Gutierrez,Amparo	Business		Teva Neuroscience, Inc	MS-LAQ-302		WARFIRIN VS ASPIRIN IN REDUCED CARDIAC EJECTION FRACTION
Gutierrez,Amparo	Business		Biogen	101JC402		VITECK 2 GPAC9 SUSCEPTIBILITY CARD FDA TRIA
Haas,Arthur L.	Federal		NIH, National Inst of General Med Sci	2R01GM034009-22		COMPARISON OF THE IN VITRO ACTIVITY OF MEROPENEM, ERTAPENEM, IMIPENEM WITH OTHER
Haas,Arthur L.	Federal		NIH, National Inst of General Med Sci	2R01GM034009-22		PREVALENT AND INCIDENT CARDIOVASCULAR RISK FACTORS AMONG HIV INFECTED PATIENTS INITIATING
Haas,Arthur L.	Institution				Cost Share	ALCOHOL, PULMONARY CYTOKINES AND HOST DEFENSE
Hagensee,Michael E	Business		TriPath Imaging			A PROSPECTIVE, RANDOMIZED, OPEN-LABEL STUDY COMPARING THE VIRAL KINETICS & PHARMACOKINETICS
Hagensee,Michael E	Federal		NIH, National Cancer Institute	1R01CA121979A		RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY TO COMPARE THE SAFETY AND EFFICACY OF
Hagensee,Michael E	Business		Merck & Co., Inc.	V501-042		A PHASE 2B STUDY OF MERIMEPODIB IN COMBINATION WITH PEGYLATED INTERFERON ALFA-2A AND
Hagensee,Michael E	Federal		NIH, National Cancer Institute	NCI-CA121979-0251		GULF SOUTH STI/TOPICAL MICROBICIDE COOPERATIVE RES CENT - PROJECT 1
Halabi,Anasheh	Federal		NIH, National Institute on Aging	1F30AG042263-01		GULF SOUTH STI/TOPICAL MICROBICIDE COOPERATIVE RES CENT
Happel,Kyle I	Federal		NIH, National Inst. on Alcohol Abuse	1K08AA015163-01		RANDOMIZED CLINICAL STUDY COMPARING CERVICAL COLLECTION DEVICES
Happel,Kyle I	Foundation		American Lung Association	American Lung Associ		AN 8 WEEK, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY TO ASSESS THE EFFICACY OF
Happel,Kyle I	Foundation		American Lung Association	American Lung Associ		A PHASE 3 RANDOMIZED, MULTI-CENTER, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO CONTROLLED
Happel,Kyle I	Foundation		American Lung Association	American Lung Associ		A PROSPECTIVE, MULTICENTER, OPEN-LABEL, COMPARATIVE, EFFICACY STUDY OF PEGASYS PLUS COPEGUS IN
Harris,Ronald A.	State		Governor's Office	Governor's Office		A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, 52-WEEK STUDY TO COMPARE THE EFFECT OF
Harrison,Laura M.	State		Board of Regents	LEQSF(2009-11)RD-A11		A PHASE II OPEN-LABEL STUDY TO ASSESS THE LONG-TERM SAFETY OF ORAL FEBUXOSTAT IN SUBJECTS WITH
Harrison-Bernard,Lisa M.	Foundation		Amer Society of Hypertension, Inc			CLINICAL EVALUATION OF THE BD PROBETEC ET SYSTEM AND THE BD VIPER FOR THE DIRECT QUALITATIVE
Harrison-Bernard,Lisa M.	Foundation		American Heart Association	09GRNT2250875		IN VIVO TARGETED DC VACCINE TO ACTIVATE ANTI-TUMOR CTL
Haydel,Micelle	Private Institutions		Council of Emer Med Residency Directors	Coun of Em Resi Dire		IN VIVO TARGETED DC VACCINE TO ACTIVATE ANTI-TUMOR CTL
Hill,James Milton	Business		Glaxo Wellcome, Inc.			A RANDOMIZED, DOUBLE-BLIND, CONTROLLED EVALUATION OF TENOFOVIR DF VERSUS ADEFOVIR DIPIVOXIL
Hill,James Milton	Federal		NIH, National Eye Institute	NEI-EY006311-23		HOMING AND DIFFERENTIATION OF ADULT STEM CELLS TO LUNG
Hollenbach,Andrew D.	Federal		NIH, National Cancer Institute	1R01CA138656-01A1		CLINICAL RESEARCH NETWORK FOR THE TREATMENT OF ACUTE LUNG INJURY (ALI) AND THE ACUTE
Hong,Song	Federal		NIH, Nat Inst Diabetes & Diges & Kidney	1R01DK087800-01		ACUTE LUNG INJURY & ACUTE RESPIRATORY DISTRESS SYNDROME
Hong,Song	Federal		NIH, Nat Inst Diabetes & Diges & Kidney	1R01DK087800-01		CLINICAL RESEARCH NETWORK FOR THE TREATMENT OF ACUTE LUNG INJURY (ALI) AND THE ACUTE
Hornby,Pamela	Business		Astra Hassle, Ab			ACUTE LUNG INJURY & ACUTE RESPIRATORY DISTRESS SYNDROME
Hu,Jennifer J.	Foundation		American Cancer Society	RSG-01-138-01-CNE		AN EPIDEMIOLOGIC STUDY OF XOLAIR (OMALIZUMAB): EVALUATING CLINICAL EFFECTIVENESS AND LONG-
Insler,Michael S	Business		ORA, Inc.	C-01-401-004		CPG 10103 COMBINATION THERAPY FOR THE TREATMENT OF HEPATITIS C: A PHASE II RANDOMIZED, OPEN
Iwakuma,Tomoo	Fed Subcontract	NIH, National Cancer Institute	Tulane University	TUL-HSC-100-07/08	1R01CA132603-01	ALCOHOL INFECTION AND HOST RESPONSE-ADMINISTRATIVE CORE
Iwakuma,Tomoo	Fed Subcontract	NIH, National Ctr for Research Resourc	Tulane University	2P20RR020152-06	P20RR020152	A MULTICENTER STUDY TO EVALUATE GENZYME DIAGNOSTIC'S OSOM CANDIDA RAPID TEST AS A
Iwakuma,Tomoo	Fed Subcontract	NIH, National Ctr for Research Resourc	Tulane University	2P20RR020152-06	P20RR020152	EVALUATION OF CINACALCET HCI THERAPY TO LOWER CARDIOVASCULAR EVENTS
Iwakuma,Tomoo	Foundation		American Cancer Society	RSG-09-169-01-CSM		A COMPARISON OF SAFETY AND INHALATION TIMES OF VENTAVIS (ILOPROST) DELIVERED BY I-NEB UTILIZING

ATTACHMENT 1: LSUHSC-NO ACTIVE RESEARCH DEVELOPMENT AWARD/CONTRACT LIST

P.I. Name	Category	Primary Spnsr	Direct Sponsor	Ref Awd #	Ref Awd #2	Project Title
Izumi,Tadahide	Federal		NIH, National Cancer Institute	NCI - CA098864-05A2		A COMPARISON OF IPRATROPIUM BROMIDE/SALBUTAMOL DELIVERED BY THE RESPIMAT INHALER TO
Izumi,Tadahide	Federal		NIH, National Cancer Institute	NCI - CA098864-05A2		A 26 WEEK TREATMENT, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, ADAPTIVE,
Jacob,Jean T	Business		Aton Pharma	Aton Pharma		CLINICAL EVALUATION OF THE BD VIPER FOR THE DIRECT QUALITATIVE SCREENING OF C.TRACHOMATIS AND
Jacob,Jean T	Business		Alcon Research, Ltd	Alcon Research		INHALED PREPRANDIAL HUMAN NSULIN WITH THE AERX IDIMS VERSUS SUBCUTANEOUS INJECTED INSULIN
Jacob,Jean T	Business		DSM PTG, Inc	DSM PTG, Inc		ALCOHOL INFECTION & HOST RESPONSE-ADMINISTRATIVE CORE
Jacob,Jean T	Business		Alcon Research, Ltd	Alcon Research		STUDY OF AST-120 FOR PREVENTION OF CHRONIC KIDNEY DISEASE PROGRESSION IN PATIENTS WITH
Jin,Minghao	Federal		NIH, National Eye Institute	1R01EY021208-01A1		A PROSPECTIVE OBSERVATIONAL STUDY TO EVALUATE LONG-TERM SAFETY AND FUNCTIONAL STATUS OF
Ju,Jihang	Foundation		American Heart Association	11POST8000008		A PROSPECTIVE OBSERVATIONAL STUDY TO EVALUATE LONG-TERM SAFETY AND FUNCTIONAL STATUS OF
Kantrow,Stephen P	Business		Allegro Diagnostics	ADX-0001		A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP STUDY TO EVALUATE THE SAFETY AND EFFICACY OF
Kapusta,Daniel	Federal		NIH, National Ctr for Research Resourc	2P20RR018766-06		CLINICAL EVALUATION OF THE BD VIPER SYSTEM FOR THE DIRECT QUALITATIVE SCREENING OF C
Kapusta,Daniel	Federal		NIH, National Ctr for Research Resourc	2P20RR018766-06		BOARD OF REGENTS SUBCONTRACT - THE CLINICAL AND TRANSLATIONAL RESEARCH EDUCATION AND
Kapusta,Daniel	Federal		NIH, National Ctr for Research Resourc	2P20RR018766-06		BOARD OF REGENTS SUBCONTRACT-THE CLINICAL AND TRANSLATIONAL RESEARCH EDUCATION AND
Kapusta,Daniel	Federal		NIH, National Ctr for Research Resourc	2P20RR018766-06		BOARD OF REGENTS SUBCONTRACT-THE CLINICAL AND TRANSLATIONAL RESEARCH EDUCATION AND
Kapusta,Daniel	Federal		NIH, National Ctr for Research Resourc	2P20RR018766-06		ROTAVIRUS BURDEN OF DISEASE IN THE INSTITUTIONALIZED ELDERLY
Kapusta,Daniel	Federal		NIH, National Ctr for Research Resourc	2P20RR018766-06		BIOINFORMATICS AND BIOTECHNOLOGY RESEARCH INITIATIVES: GLOBAL GENOME AND TRANSCRIPTOME
Kapusta,Daniel	Federal		NIH, National Ctr for Research Resourc	2P20RR018766-06		EMERGENCY ID NET
Kapusta,Daniel	Federal		NIH, National Ctr for Research Resourc	2P20RR018766-06		A SAFETY AND EFFICACY STUDY OF BLOOD PRESSURE CONTROL IN ACUTE HEART FAILURE-A PILOT STUDY
Kapusta,Daniel	Federal		NIH, National Ctr for Research Resourc	2P20RR018766-06		EMPIRIC THERAPY OF MUCOPURULENT CERVICITIS (MPC) FOR CHLAMYDIA AND GONORRHEA INFECTION IN
Kapusta,Daniel	Federal		NIH, National Ctr for Research Resourc	2P20RR018766-06		LONG-TERM SINGLE-ARM OPEN-LABEL EXTENSION STUDY OF THE SERAPHIN STUDY, TO ASSESS THE SAFETY
Kapusta,Daniel	Federal		NIH, National Ctr for Research Resourc	2P20RR018766-06		AN INTERNATIONAL, MULTICENTER, PROSPECTIVE OBSERVATIONAL STUDY OF THE SAFETY OF MARAVIROC
Kapusta,Daniel	Federal		NIH, National Ctr for Research Resourc	2P20RR018766-06		A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, DOSE-RANGING STUDY OF
Kapusta,Daniel	Foundation		American Heart Association	0855293E		DIAGNOSTIC TEST UTILIZING GENE EXPRESSION ANALYSIS OF AIRWAY EPITHELIAL CELLS FOR LUNG CANCER
Kaufman,Herbert Edward	Foundation		Research To Prevent Blindness			A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, STUDY OF FG-3019 IN SUBJECTS WITH
Kelly,Ben	Federal		NIH, Nat Inst on Allergy & Infec Disease	1R21AI085172-01A1		Microbial Correlates of Bacterial Vaginosis Treatment Failure and Recurrences in Heterosexual Couples
Khoobeji,Bahram	Business		Pfizer Inc	2182		Sexually Transmitted Infections Clinical Trials Group protocol entitled "Empiric Therapy of Mucopurulent
Khoobeji,Bahram	Business		Pfizer Inc			In Vivo Targeted DC Vaccine to Activate Anti-tumor CTL
Khoobeji,Bahram	Foundation		LSUHSC Foundation NO	671037		A randomized, double-blind, 3-arm Parallel-group, 2-year (104-week), multicenter study to evaluate the
Kim,Sunyoung	Federal		NIH, National Inst of General Med Sci	1R01GM097350-01		Gulf South STI/Topical Microbicide Cooperative Research Center - Quayle
Kolls,Jay Kennedy	Fed Subcontract	NIH, Nat Inst on Allergy & Infec Disease	Vanderbilt University	VANDERBILT UNIV	5 R01AI070672-02	Gulf South STI/Topical Microbicide Cooperative Research Center - Martin
Kolls,Jay Kennedy	Federal		NIH, National Inst. on Alcohol Abuse	NIAAA - AA016688-04		Gulf South STI/Topical Microbicide Cooperative Research Center - Pyles
Kolls,Jay Kennedy	Federal		NIH, National Inst. on Alcohol Abuse	NIAAA - AA016688-04		Gulf South STI/Topical Microbicide Cooperative Research Center - Kisinger
Kolls,Jay Kennedy	Federal		NIH, National Inst. on Alcohol Abuse	NIAAA - AA016688-04		Gulf South STI/Topical Microbicide Cooperative Research Center - Martin
Kolls,Jay Kennedy	Federal		NIH, National Heart Lung & Blood Inst	2 R01HL061271-10A1		Gulf South STI/Topical Microbicide Cooperative Research Center - Core B (Matrtin)
Kolls,Jay Kennedy	Fed Subcontract	NIH, National Heart Lung & Blood Inst	University of Pittsburgh	PHL084932A	7P50HL084932-04	Gulf South STI/Topical Microbicide Cooperative Research Center - Core C
Kolls,Jay Kennedy	Federal		NIH, National Inst. on Alcohol Abuse	3R01AA016688-04S1		Gulf South STI/Topical Microbicide Cooperative Research Center - Core D (Myers)
Kolls,Jay Kennedy	Federal		NIH, National Inst. on Alcohol Abuse	3R01AA016688-04S1		Alcohol, HIV Infection and Host Defense
Kolls,Jay Kennedy	Federal		NIH, National Heart Lung & Blood Inst	2R01HL062052-13		ALCOHOL INFECTION & HOST RESPONSE-EDUC/TRANSLATIONAL RES
Kolls,Jay Kennedy	Federal		NIH, National Heart Lung & Blood Inst	5R37HL079142-07		A Multicenter, Retrospective of Patients with Pulmonary Arterial Hypertension Transitioned from Parenteral
Kolls,Jay Kennedy	Federal		NIH, National Heart Lung & Blood Inst	1R21HL104601-01A1		ASTHMA CLINICAL RESEARCH
Koochekpour,Shahriar	Federal		NIH, National Cancer Institute	1R21CA149137-01		ASTHMA CLINICAL RESEARCH - SOYA
Koochekpour,Shahriar	Federal		NIH, National Cancer Institute	1R21CA143589-01A1		ASTHMA CLINICAL RESEARCH - STAN
Koochekpour,Shahriar	Federal		NIH, Center on Minority Health and	NCMHHD 1R01MD005824		Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of 2 Doses of CP-
Kozlowski,Pamela A.	Fed Subcontract	NIH, Nat Inst on Allergy & Infec Disease	Emory University	1P01AI096187-01		A Randomized, Placebo-controlled Comparison of the Effects of two doses of LY2189265 or Extenate on
Kozlowski,Pamela A.	Fed Subcontract	NIH, Nat Inst on Allergy & Infec Disease	Harvard University	151128-0104	P01AI071306	Phase 3 Randomized, Double-Blind Study of the Efficacy and Safety of 2 Doses of CP-690,550 Compared to
Kozlowski,Pamela A.	Fed Subcontract	NIH, Nat Inst on Allergy & Infec Disease	Geo Vax, Inc.	Geo Vax	U19AI074073	Randomized Evaluation of efficacy and safety of ferric carboxymaltose in Patients with iron deficiency Anemia
Kozlowski,Pamela A.	Fed Subcontract	NIH, Nat Inst on Dental & Craniofacial	Children's Hospital Boston	83586	5 R01DE019060	IL-7 and Murine Pneumocystis Pneumonia
Kozlowski,Pamela A.	Fed Subcontract	NIH, Nat Inst on Dental & Craniofacial	Fred Hutchinson Cancer Research Center	0000672073	5 R01 DE019063-02	Evaluation of the performance of the cobas 4800 CT/NG test and cobas 4800 PCR collection kit for detection
Lazartigues,Eric D.	Federal		NIH, National Heart Lung & Blood Inst	1R01HL093178-01		A Menu for AIDS for AIDS Patients to EAT Safely
Lazartigues,Eric D.	State		Board of Regents	Board of Regents		Safety and Efficacy of WC2031 versus Bibra Mycin for the treatment of uncomplicated Urogenital Chlamydia
Lazartigues,Eric D.	Federal		NIH, National Heart Lung & Blood Inst	3R01HL093178-01S1		P 3 - A Randomized, Placebo-Controlled Comparison of the Effects of Two Doses of LY2189265 or Extenate
Lazartigues,Eric D.	Federal		NIH, Nat Inst Diabetes & Digest & Kidney	1R21DK084466-01A1		Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR-TIMI 53)"
Lazartigues,Eric D.	Fed Subcontract	NIH, National Heart Lung & Blood Inst	Wright State University	668046	R01HL098637	A Phase 2, multi-center, randomized, double-blind study comparing the safety and efficacy of two doses of
Lazartigues,Eric D.	Foundation		American Heart Association	12EIA0803004		Vaginitis Sample Acquisition and/or Testing
Lee,Keunbaik	Fed Subcontract	NIH, National Institute on Aging	University of Florida	UF09146	R01 AG033005	A Randomized, Double-Blind, Multi-Center Study to Evaluate the Efficacy and Safety of Oral CEM-101
Leigh,Janet E	Institution				Cost Share	A Randomized, Multicenter Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects
Li,Xiao Ching	Federal		NIH, National Institute of Mental Health	1R21MH081254-01A2		A multicenter, double-blind, placebo-controlled Phase 3 study to demonstrate the efficacy and safety of ACT
Li,Xiao Ching	Foundation		NARSAD	17989		Clinical Evaluation of the APTIMA Assay for Chlamydia trachomatis Using the Panther System
Lillis,Rebecca A.	Fed Subcontract	NIH, Nat Inst on Allergy & Infec Disease	University of Alabama	HHSN266200400073C	HHSN266200400073C	Repeated Bacterial STIS Among Heterosexual Men
Lin,Tara	Foundation		Ladies Leukemia League	Ladies Leukemia		African-American Rheumatoid Arthritis Network
Liu,Si-Qiong J.	Federal		National Science Foundation	NSF -IOS -0344559		Transcriptomics of Tuberculosis Latency and Reactivation in Primates
Liu,Si-Qiong J.	Federal		NIH, Nat Inst of Neurological Disorders	NINDS - NS058867-04		Alcohol, HIV Infection and Host Defense-ADMINISTRATIVE CORE
Liu,Si-Qiong J.	Federal		NIH, National Institute of Mental Health	1R01MH095948-01A1		Alcohol, HIV Infection and Host Defense -RES COMP 1
Liu,Wanguo	Federal		NIH, National Cancer Institute	1R01CA115555-01		ALCOHOL , HIV INFECTION & HOST RESPONSE-RES COMP 2
Liu,Wanguo	Federal		NIH, National Cancer Institute	3R01CA115555-03S1		ALCOHOL, HIV INFECTION & HOST RESPONSE-RES COMP 3
Liu,Wanguo	Fed Subcontract	NIH, National Ctr for Research Resourc	Tulane University	TUL-HSC-240-10/11	5P20RR020152-07	Alcohol, HIV Infection and Host Defense - Research Comp 4
Liu,Wanguo	Private Institutions		University Of Kansas Medical Center	Q1856050		ALCOHOL, HIV INFECTION & HOST RESPONSE - RES COMP 5
Lovera,Jesus F.	Federal		NIH, Complementary & Alternative Medicin	1K23AT004433-01		ALCOHOL, HIV INFECTION & HOST RESPONSE- ANM CORE
Lowrey,Karen A.	Institution				Cost Share	Alcohol, HIV Infection and Host Defense - Lab Core
Lu,Youming	Federal		NIH, National Institute on Aging	7R01AG033282-01		Alcohol, HIV Infection and Host Defense - Trans Res/Education Component
Lu,Youming	Federal		NIH, National Institute on Aging	7R01AG033282-01		Alcohol, HIV Infection and Host Defense - Pilot 1
Lu,Youming	Federal		NIH, Nat Inst of Neurological Disorders	7R01NS051383-03		Alcohol, HIV Infection and Host Defense - Pilot 2
Luftig,Ronald Bernard	Fed Subcontract	U.S. Department of Housing and Urban Dev	Tulane University	RCCEP-05(2007-10)	PL109-148	A Randomized, Double-Masked, Placebo-Controlled, Multicenter, Phase 2 Study to Evaluate the Safety and
Lukiw,Walter J	Foundation		Alzheimer's Assoc	IRG-09-131729		Prospective Collection of HIV Specimens
Lukiw,Walter J	Federal		NIH, National Institute on Aging	1R01AG038834-01A1		A multicenter, double-blind, placebo-controlled parallel-group study of establish proof of concept and explor

ATTACHMENT 1: LSUHSC-NO ACTIVE RESEARCH DEVELOPMENT AWARD/CONTRACT LIST

P.I. Name	Category	Primary Spnser	Direct Sponsor	Ref Awd #	Ref Awd #2	Project Title
Mandal,Diptasri	Fed Subcontract	NIH, National Cancer Institute	Univ of Cincinnati	3U01CA076293-10S1	3U01CA076293-10S1	A Three-Period, 58-Week Safety and Efficacy Trial of KRX-0502 (ferric citrate) in Patients with End-Stage Renal
Mandal,Diptasri	Fed Subcontract	National Science Foundation	Board of Regents	LEQSF(2011)-PFUND-25	EPS-1003897	A Multicenter, Double-Blind, Randomized Study to Evaluate the Efficacy and safety of Single-Dose IV
Mandal,Diptasri	Federal		NIH, National Heart Lung & Blood Inst	HHSN268201200007C		Clinical evaluation of the Xpert CT/NG assay on the GeneX-pert DX SystemDX System
Mandal,Diptasri	Federal		NIH, Human Genome Research Inst	N01HG65404		Clinical evaluation of the Xpert CT/NG assay on the GeneX-pert DX System according to protocol 73B,
Marrero,Luis	Fed Subcontract	U.S. Army	Tulane University	TUL-566-098/09	W911NF-06-1-0161	Durable-Response Therapy evaluation for Early or New Onset Type 1 Diabetes
Martin,David H	Federal		HHS, Ctr for Disease Control & Preventio	POH 9867130	POH 9867130	The Use of an Endovaginal Pelvic Model as an Adjunct in Teaching Emergency Ultrasound of GYN
Martin,David H	Business		Gen Probe Incorporated			Prospective Collection of Female First-catch Urine, Vaginal Swab, and Cervical Specimens for Testing with the
Martin,David H	Business		Otsuka America Pharmaceutical, Inc.	106-92-207 M/F		MDX-10-GSAMACQ - Collection of Clinical Specimens for General Molecular Research
Martin,David H	Business		Pfizer Inc	94-306		Baradoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: The Occurrence
Martin,David H	Business		Roche Laboratories Inc.			Host Defense Against HIV-related Pulmonary Infections - Project 1 (Shellito)
Martin,David H	Business		Becton Dickinson Corp	99C1-017-LSU-UPP		Host Defense Against HIV-related Pulmonary Infections - Project 2 (Kolls)
Martin,David H	Business		Digene Corporation	C99-CGC-002		Host Defense Against HIV-related Pulmonary Infections - Project 2 (Norris)
Martin,David H	Business		Becton Dickinson Corp	00C2-42-LSU-WSPT		Host Defense Against HIV-related Pulmonary Infections - Core A (Admin Core)
Martin,David H	Fed Subcontract	NIH, National Institute on Aging	University of North Carolina	UNC-CH5-35002	N01-AI-75329	Host Defense Against HIV-related Pulmonary Infections - Core B (Non-Human Primate)
Martin,David H	Business		Thermo BioStar	PCL01001.01		Host Defense Against HIV-related Pulmonary Infections - Core C (Antigen)
Martin,David H	Business		Gen Probe Incorporated			A Multicenter, Randomized, Active-Control, Phase 3B Study to Evaluate the Cardiovascular Safety of
Martin,David H	Federal		NIH, Nat Inst on Allergy & Infec Disease	1U19AI061972-01		BD ProveTec Trichomonas vaginalis (TV) Qx Amplified DNA Assay, when Tested with the BD Viper System in
Martin,David H	Federal		NIH, Nat Inst on Allergy & Infec Disease	1U19AI061972-01		A Phase 3, Multicenter, Open-label Randomized, Forced-titration Clinical Trial Evaluating the Efficacy and
Martin,David H	Fed Subcontract	U.S. Department of Defense	Southern University of New Orleans	527647	W81XWH-08-1-0676	A Phase 3, Multicenter, Double-Blind, Placebo-controlled, Randomized, Clinical Trial Evaluating the Efficacy
Martin,David H	Fed Subcontract	NIH, Nat Inst on Allergy & Infec Disease	Children's Hospital	SC278658	R01AI079071	Alcohol, HIV Infection and Host Defense - Admin
Martin,David H	Federal		NIH, Nat Inst on Allergy & Infec Disease	3U19AI061972-05S1		Alcohol, HIV Infection and Host Defense - RC1
Martin,David H	Federal		NIH, Nat Inst on Allergy & Infec Disease	3U19AI061972-05S1		Alcohol, HIV Infection and Host Defense - RC2
Martin,David H	Federal		NIH, Nat Inst on Allergy & Infec Disease	3U19AI061972-05S1		Alcohol, HIV Infection and Host Defense - Admin
Martin,David H	Federal		NIH, Nat Inst on Allergy & Infec Disease	3U19AI061972-05S1		Alcohol, HIV Infection and Host Defense - RC4
Martin,David H	Federal		NIH, Nat Inst on Allergy & Infec Disease	3U19AI061972-05S1		Alcohol, HIV Infection and Host Defense - RC5
Martin,David H	Federal		NIH, Nat Inst on Allergy & Infec Disease	3U19AI061972-05S1		Alcohol, HIV Infection and Host Defense - Animal
Martin,David H	Federal		NIH, Nat Inst on Allergy & Infec Disease	3U19AI061972-05S1		Alcohol, HIV Infection and Host Defense - Lab
Martin,David H	Federal		NIH, Nat Inst on Allergy & Infec Disease	3U19AI061972-05S1		Alcohol, HIV Infection and Host Defense - Trans
Martin,David H	Fed Subcontract	NIH, Nat Inst on Allergy & Infec Disease	Tulane University	TUL-HSC-234-10/11	1R56AI085081-01A1	Drug Registry to Prospectively Describe Use of Room Temperature Stable Epoprostenol for Injection in
Mason,Carol M	Foundation		Wetmore Foundation			A Phase 2, Multi-center, Double-blind, Randomized, Placebo-Controlled Study to Evaluate the Effects of
Mason,Carol M	Federal		NIH, National Inst. on Alcohol Abuse	2R01AA011760-06		Post-FDA Approval for Clinical Trial Evaluating Bronchial Thermoplasty in Severe Persistent Asthma
Mason,Carol M	Fed Subcontract	NIH, National Heart Lung & Blood Inst	Tulane University	TUL-HSC-233-10/11	1R01HL106790-01	A Phase III, Multicenter, International, Randomized, Parallel Group, Double Blind Cardiovascular Study of BI
Maupin,Robert T	Fed Subcontract	NIH, Nat Inst Diabetes & Diges & Kidney	Tulane University	TUL-HSC-132-08/09	HHSN267200800001C	A Multi-Center Chlamydia Trachomatis, Neisseria Gonorrhoeae, and Trichomonas Vaginalis Sample Collection
McCarthy,Henry	Institution				Cost Share	Ethnic Minority Rheumatoid Arthritis Consortium Assessing Major Advancements and Outcomes of Minority
Melvan,John	Federal		NIH, National Inst. on Alcohol Abuse	NIAAA1F30AA019586-01		PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS USING TQNE
Melvan,John	Federal		NIH, National Inst. on Alcohol Abuse	NIAAA1F30AA019586-01		BOTOX PURIFIED NEUROTOXIN COMPLEX
Mercante,Donald	State		Board of Regents	LEQSF(2011-16)-GF-04		VIGABATRIM (SABRIL) 134 AND 6 G/DAY FOR PARTIAL SEIZURES
Miller,Fern T.	Foundation		Patrick F. Taylor Foundation	P. F. Taylor FDTN		VAGAS NERVE STIMULATION FOR EPILEPSY PATIENTS W/ NCP SYSTEM
Molina,Patricia E	Federal		NIH, National Institute on Drug Abuse	1R01DA020419-01		TREATMENT OF INCREASED MUSCLE TONE OF THE LOWER LIMB
Molina,Patricia E	Federal		NIH, National Institute on Drug Abuse	1R01DA020419-01		EARLIER VS LATER L-DOPA IN PARKINSON'S DISEASE
Molina,Patricia E	Federal		NIH, National Institute on Drug Abuse	1R01DA020419-01		STUDY IN PATIENTS W RELAPSING-REMITTING MULTIPLE SCLEROSIS
Molina,Patricia E	Federal		NIH, National Institute on Drug Abuse	1R01DA020419-01		KEPPRA
Molina,Patricia E	Federal		NIH, National Institute on Drug Abuse	1R01DA020419-01		PROSPECTIVE SEIZURE FREQUENCY CLINICAL INVESTIGATION
Molina,Patricia E	Federal		NIH, National Institute on Drug Abuse	NIDA - DA026647-01		RESPONSIVE NEUROSTIMULATOR SYSTEM FEASIBILITY CLINICAL INVESTIGATION
Molina,Patricia E	Fed Subcontract	HHS, Office Of Minority Health	University of Miami	66513W	6MPCMP051005-04	RESPONSIVE NEUROSTIMULATOR SYSTEM PIVOTAL
Molina,Patricia E	Fed Subcontract	NIH, National Institute Of Health	University of Miami	HHSN271200900025C	HHSN271200900025C	RESPONSIVE NEUROSTIMULATOR SYSTEM LONG-TERM TREATMENT CLINICAL INVESTIGATION
Molina,Patricia E	Federal		NIH, National Institute on Drug Abuse	1R01DA030053-01		A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP MULTICENTER STUDY TO
Molina,Patricia E	Federal		NIH, National Institute on Drug Abuse	1R01DA030053-01		A MULTICENTER, OPEN-LABEL EXTENSION TRIAL TO ASSESS THE LONG-TERM USE OF LACOSAMIDE
Molina,Patricia E	Federal		U.S. Army	W81XWH-11-2-0011		A HISTORICAL-CONTROLLED, MULTICENTER, DOUBLE-BLIND, RANDOMIZED TRIAL TO ASSESS THE EFFICACY
Molina,Patricia E	Fed Subcontract	National Science Foundation	Board of Regents	LEQSF-EPS(2012-PF283	EPS-1003897	RANOLAZINE AS AN ANALGESIC IN INFLAMMATION-INDUCED PAIN
Morse,Stephen Anthony	Business		Amgen, Inc	20050182		A MULTINATIONAL, MULTICENTER, RANDOMIZED, PARALLEL-GROUP STUDY PERFORMED IN SUBJECTS WITH
Murphy,Mary Josephine	Business		Agouron Pharmaceuticals, Inc.	AGI549		SAFETY AND NEUROPROTECTIVE EFFECTS OF POLYPHENOL E IN MULTIPLE SCLEROSIS
Muzyka,Brian Charles	Business		Daiichi Pharm	2011A-PRT003		A DOUBLE-BLIND, RANDOMIZED, MULTICENTER EFFICACY AND SAFETY STUDY OF PREGABALIN (LYRICA) AS
Nelson,Steve	Business		Amgen, Inc			BUILDING A SCIENCE FOR THE TREATMENT OF SPATIAL NEGLECT
Nelson,Steve	Business		Bayer Corporation	100244		AN OPEN-LABEL MULTICENTER EXTENSION STUDY TO DETERMINE LONG TERM SAFETY AND EFFICACY OF
Nelson,Steve	Business		Amgen, Inc	GCSF-930205		Clinical MR Indicators of Neurogenesis and Treatment Rsoponse in Depression
Nelson,Steve	Business		IntraBiotech Pharm	09-002		Multicenter, Double-Blind, Randomized, Placebo-Controlled, Three-Arm, Parallel Group Study to Evaluate the
Nelson,Steve	Federal		NIH, National Inst. on Alcohol Abuse	5P60AA009803-14		Developmental Stuttering:MRI Studies in Children
Nelson,Steve	Federal		NIH, National Inst. on Alcohol Abuse	5P60AA009803-15		Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Oxcarbazepine
Nelson,Steve	Fed Subcontract	U.S. Department of Housing and Urban Dev	Tulane University	RCEEP-06(2007-10)	PL109-148	A Phase 3, Randomized, Double Blind, Parallel, Placebo Controlled, Multicenter Study, with Optional Open
Nelson,Steve	Fed Subcontract	U.S. Department of Housing and Urban Dev	Tulane University	RCEEP-06(2007-10)	PL109-148	Lyme Neuroborreliosis Pathogenesis in th Rhesus Monkey
Nelson,Steve	Fed Subcontract	U.S. Department of Housing and Urban Dev	Tulane University	RCEEP-06(2007-10)	PL109-148	JVC Antibody Program in Patients with Relapsing Multiple Sclerosis Receiving or Considering Treatment with
Nelson,Steve	Federal		NIH, National Inst. on Alcohol Abuse	NIAAA-AA009803-16S1		Characterization of Sodium Channel of Neuroathy in the Fabry's Mouse Model
Nelson,Steve	Federal		NIH, National Inst. on Alcohol Abuse	NIAAA - AA09803-17		A PROSPECTIVE, RANDOMIZED, MULTI-CENTERED CROSSOVER STUDY TO EVALUATE SUB-THRESHOLD
Nelson,Steve	Federal		NIH, National Inst. on Alcohol Abuse	5P60AA009803-18		EFFECT OF PATIENT EDUCATION MATERIALS ON PATIENT PREFERENCE IN SPINAL CORD STIMULATION
Nelson,Steve	Federal		NIH, National Inst. on Alcohol Abuse	5P60AA009803-18		Intrathecal Pump Accuracy Study
Nelson,Steve	Federal		NIH, National Inst. on Alcohol Abuse	5P60AA009803-18		The EmPower Study: Eon Mini Study Product Options for Wellness Effectiveness and Relief; A Multi-Centered
Nelson,Steve	Federal		NIH, National Inst. on Alcohol Abuse	5P60AA009803-18		A Prospective Multi-center Randomized Evaluation of the Clinical and Radiographic Outcomes of XLIF
Nelson,Steve	Federal		NIH, National Inst. on Alcohol Abuse	5P60AA009803-18		A Retrospective Evaluation and Data Collection Study to Evaluate Patients Implanted with an ANS 16-Channel
Nelson,Steve	Federal		NIH, National Inst. on Alcohol Abuse	5P60AA009803-18		Primate Study
Nelson,Steve	Federal		NIH, National Inst. on Alcohol Abuse	5P60AA009803-18		A Retrospective Evaluation and Data Collection Study to Evaluate the Specificity of the Penta Paddle Lead in
Nelson,Steve	Federal		NIH, National Inst. on Alcohol Abuse	5P60AA009803-18		INTERNATIONAL AND DOMESTIC PEDIATRIC AND MATERNAL HIV STUDIES NETWORK
Nelson,Steve	Federal		NIH, National Inst. on Alcohol Abuse	5P60AA009803-18		SUBCONTRACT - LSOCA - PATIENT CARE
Nelson,Steve	Federal		NIH, National Inst. on Alcohol Abuse	5P60AA009803-18		UNRESTRICTED GRANT TO SUPPORT DEPARTMENTAL RESEARCH

ATTACHMENT 1: LSUHSC-NO ACTIVE RESEARCH DEVELOPMENT AWARD/CONTRACT LIST

P.I. Name	Category	Primary Spnser	Direct Sponsor	Ref Awd #	Ref Awd #2	Project Title
Nelson,Steve	Federal		NIH, National Inst. on Alcohol Abuse	5P60AA009803-18		BIOLOGICAL COMPUTATION AND VISULIZATION CENTER
Nelson,Steve	Federal		NIH, National Inst. on Alcohol Abuse	5P60AA009803-19		PROTEIN KINASE CB INHIBITOR - DAIBETIC RETINOPATHY STUDY
Nelson,Steve	Federal		NIH, National Inst. on Alcohol Abuse	5P60AA009803-19		RESEARCH COLLABORATION AGREEMENT
Nelson,Steve	Federal		NIH, National Inst. on Alcohol Abuse	5P60AA009803-19		COMPARISON OF HYPERSPECTRAL IMAGING AND BLOOD FLOW DETERMINATION FOR PRIMATE RETINA
Nelson,Steve	Federal		NIH, National Inst. on Alcohol Abuse	5P60AA009803-19		LASER MODEL OF CNV WITH AMERSHAM PEPTIDE
Nelson,Steve	Federal		NIH, National Inst. on Alcohol Abuse	5P60AA009803-19		A STUDY TO EVALUATE THE CLINICAL AND MICROBIAL EFFICACY AND SAFETY OF 1.0% AZASITE COMPARED
Nelson,Steve	Federal		NIH, National Inst. on Alcohol Abuse	5P60AA009803-19		RESEARCH SUPPORT - KHOOBEHI
Nelson,Steve	Federal		NIH, National Inst. on Alcohol Abuse	5P60AA009803-19		SUPPORT DEPARTMENT RESEARCH ACTIVITIES
Nelson,Steve	Federal		NIH, National Inst. on Alcohol Abuse	5P60AA009803-19		STUDIES OF THE OCULAR COMPLICATIONS
Nelson,Steve	Federal		NIH, National Inst. on Alcohol Abuse	5P60AA009803-19		Ocular HSV-Latency, Reactivation, and Recurrence
Nelson,Steve	Institution				Cost Share	Lacrisert Drug Delivery Feasibility Studies
Neumann,Donna	Fed Subcontract	NIH, Nat Inst on Allergy & Infect Disease	University of Florida	UF11185	2R01AI048633-11	Neuro-Ophthalmology Research Disease Investigator Consortium (NORDIC)
Nichols,Charles D.	Federal		NIH, National Institute of Mental Health	1R01MH083689-01A2		Bulk and Surface Characterization of Contact Lenses
Nichols,Charles D.	Federal		NIH, National Heart Lung & Blood Inst	1R21HL095961-01A2		Contact Lens Material Properties
Niemoller,Tiffany Donna	Federal		NIH, National Institute on Aging	1 F30 AG032841-01A1		Effect of Specific MPs on the Hydrophobic Domains of Silicone Lenses
Noverr,Mairi C.	Foundation		American Heart Association	0835092G		Trial to Evaluate UltraSound in the Treatment of Tibial Fractures
Noverr,Mairi C.	Federal		NIH, Nat Inst on Allergy & Infect Disease	7R01AI072406-03		Cytoskeletal-Based Survival Pathways in Myocardium
Noverr,Mairi C.	Federal		NIH, Nat Inst on Dental & Craniofacial	1R56DE022069-01		PDAY Cardiovascular Specimen and Data Library
Ochoa,Augusto	State		LSUHSC, Shreveport			New methods to deliver therapeutic drugs in myocardial ischemia/reperfusion injur
Ochoa,Augusto	Private Institutions		LA Cancer Research Consortium			CHILDREN'S RESEARCH INSTITUTE DT-1 CLINICAL REIMBURSEMENTS
Ochoa,Augusto	Private Institutions		LA Cancer Research Consortium			CHILDREN'S HOSPITAL - CLINICAL TRIALS
Ochoa,Augusto	Private Institutions		LA Cancer Research Consortium			OPTIMIZING PRIMARY STROKE PREVENTION IN SC ANEMIA (2U01HL52193)
Ochoa,Augusto	Private Institutions		LA Cancer Research Consortium			ROLE OF THE TRANSCRIPTION FACTOR, INSM1 IN THE NEUROENDOCRINE PHENOTYPE OF SMALL CELL LUNG
Ochoa,Augusto	Private Institutions		LA Cancer Research Consortium			3-YEAR FELLOWSHIP AT CHILDREN'S HOSPITAL -DR CAROLINE STRAATMAN
Ochoa,Augusto	Private Institutions		LA Cancer Research Consortium			A BRIEF, CLINIC-BASED HIV PREVENTION PROGRAM FOR AFRICAN AMERICAN TEEN MALES
Ochoa,Augusto	Private Institutions		LA Cancer Research Consortium			TOMOXETINE + FLUOXETINE FOR ATTENTION AND AFFECTIVE DISORDERS
Ochoa,Augusto	Federal		NIH, National Cancer Institute	NCI - CA082689-09		STUDY OF SERTALINE IN CHILDREN & ADOLESCENT OUTPATIENTS
Ochoa,Augusto	Federal		NIH, National Ctr for Research Resourc	3P2ORR021970-551		A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, 3-MONTH CLINICAL TRIAL OF VENLAFAXINE ER AND
Ochoa,Augusto	Federal		NIH, National Ctr for Research Resourc	2P2ORR021970-06		LOUISIANA EARLY CHILDHOOD DEVELOPMENT PROGRAMS: PROGRAM EVALUATION AND RESEARCH
Ochoa,Augusto	Federal		NIH, National Ctr for Research Resourc	2P2ORR021970-06		A DOUBLE-BLIND, MULTICENTER, PLACEBO-AND -ACTIVE-CONTROLLED ACUTE AND EXTENSION STUDY OF
Ochoa,Augusto	Federal		NIH, National Ctr for Research Resourc	2P2ORR021970-06		A DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP EVALUATION OF THE LONG TERM SAFETY,
Ochoa,Augusto	Federal		NIH, National Ctr for Research Resourc	2P2ORR021970-06		DEPAKOTE ER FOR TREATMENT OF MANIA W/BIPOLAR DISORDER IN CHILDREN AND ADOLESCENTS
Ochoa,Augusto	Federal		NIH, National Ctr for Research Resourc	2P2ORR021970-06		TREATMENT OF ADHD/MORNING-DOSED OR EVENING-DOSED STRATTERA
Ochoa,Augusto	Federal		NIH, National Ctr for Research Resourc	2P2ORR021970-06		A STUDY OF SERTALINE AND PLACEBO IN CHILDREN AND ADOLESCENTS WITH POSTTRAUMATIC STRESS
Ochoa,Augusto	Federal		NIH, National Ctr for Research Resourc	2P2ORR021970-06		LA EARLY CHILDHOOD DEVELOPMENT PROGRAM LA 4 PRE-KINDERGARTEN: PROGRAM EVALUATION &
Ochoa,Augusto	Federal		NIH, National Ctr for Research Resourc	2P2ORR021970-06		STUDY OF ARIPIPRAZOLE IN TREATMENT OF PATIENTS WITH BIOPOLAR I DISORDER WITH A MOJOR
Ochoa,Augusto	Federal		NIH, National Ctr for Research Resourc	2P2ORR021970-06		SAFETY, TOLERABILITY AND EFFECTIVENESS OF ATOMOXETINE IN PRESCHOOLERS (AGES 3-6) WITH ADHD - A
Ochoa,Augusto	Federal		NIH, National Ctr for Research Resourc	2P2ORR021970-06		A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP PHASE 2 STUDY TO EVALUATE
Ochoa,Augusto	Federal		NIH, National Ctr for Research Resourc	2P2ORR021970-06		A COMPARISON OF DUOLOXETINE DOSING IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSION
Ochoa,Augusto	Federal		NIH, National Ctr for Research Resourc	2P2ORR021970-06		COMPARISON OF A STANDARD PSYCHIATRIC DIAGNOSTIC EVALUATION TO A QUANTITATIVE
Ochoa,Augusto	Federal		NIH, National Ctr for Research Resourc	2P2ORR021970-06		AN OPEN-LABEL LONG-TERM STUDY TO EVALUATE THE SAFETY OF DEPAKOTE EXTENDED RELEASE TABLETS IN
Ochoa,Augusto	Federal		NIH, National Ctr for Research Resourc	2P2ORR021970-06		A 12-MONTH, OPEN-LABEL, FLEXIBLE-DOSEAGE STUDY TO EVALUATE THE SAFETY AND EFFICACY OF GABTRIL
Ochoa,Augusto	Federal		NIH, National Ctr for Research Resourc	2P2ORR021970-06		A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY
Ochoa,Augusto	Federal		NIH, National Ctr for Research Resourc	2P2ORR021970-06		QUETIAPINE MONOTHERAPY FOR OBSESSIVE-COMPULSIVE DISORDER, A COUBLE-BLIND, FLEXIBLE-DOSE,
Ochoa,Augusto	Federal		NIH, National Ctr for Research Resourc	2P2ORR021970-06		A MULTI-CENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, PARALLEL GROUP, PHASE IIB
Ochoa,Augusto	Federal		NIH, National Ctr for Research Resourc	2P2ORR021970-06		A Fifteen-month, Prospective, Randomized, Active-controlled, Open-label, Flexible-dose Study of Paliperidone
Ochoa,Augusto	Federal		NIH, National Ctr for Research Resourc	2P2ORR021970-06		MODIFIED NEIGHBORHOOD LEVEL FACTORS AND LOW BIRTH RATE
Ochoa,Augusto	Federal		NIH, National Cancer Institute	2 R01CA107974-06A1		IOXILAN WITH IOHEXOL IN PATIENTS UNDERGOING CEREBRAL ANGIOGR
Ochoa,Augusto	Private Institutions		LA Cancer Research Consortium	LCRC		PROUROKINASE FOR PERIPHERAL ARTERIAL THROMBOEMBOLIC OCCL
Ochoa,Augusto	Private Institutions		LA Cancer Research Consortium	LCRC		USE OF AN IN VITRO MODEL TO CHARACTERIZE THE ANTIANGIOGENIC ACTIVITY OF EPALHILONE
Ochoa,Augusto	Private Institutions		LA Cancer Research Consortium	LCRC		A Multicenter, Prospective, Randomized Controlled, Single Blinded Study of Strattice Reconstructive Tissue
Ochoa,Augusto	Private Institutions		LA Cancer Research Consortium	LCRC		Modulation of Angiogenic Gene Expression by Black Raspberry Extract
Ochoa,Augusto	Private Institutions		LA Cancer Research Consortium	LCRC		TRANSFER OF GRANT BALANCE-SERUM SAMPLE DEMOGRAPHIC DATA
Ochoa,Augusto	Private Institutions		LA Cancer Research Consortium	LCRC		P2 STAR CLINICAL TRIAL
Ochoa,Augusto	Private Institutions		LA Cancer Research Consortium	LCRC		PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOGENOUS LEUKEM
Ochoa,Augusto	Private Institutions		LA Cancer Research Consortium	LCRC		SUPPORT STAR CLINICAL TRIAL
Ochoa,Augusto	Private Institutions		LA Cancer Research Consortium	LCRC		PER CASE AND SPECIMEN REIMBURSEMENT AGREEMENT
Ochoa,Augusto	Private Institutions		LA Cancer Research Consortium	LCRC		RESEARCH SUPPORT
Ochoa,Augusto	Private Institutions		LA Cancer Research Consortium	LCRC		LOUISIANA CANCER RESEARCH CONSORTIUM
Ochoa,Augusto	Private Institutions		LA Cancer Research Consortium	LCRC		LOUISIANA CANCER RESEARCH CONSORTIUM - OTOLARYNGOLOGY ALLOC
Ochoa,Augusto	Private Institutions		LA Cancer Research Consortium	LCRC		LOUISIANA CANCER RESEARCH CONSORTIUM-TISSUE BANKING CORE
Ochoa,Augusto	Private Institutions		LA Cancer Research Consortium	LCRC		LOUISIANA CANCER RESEARCH CONSORTIUM-GENETICS CORE
Ochoa,Augusto	Private Institutions		LA Cancer Research Consortium	LCRC		LOUISIANA CANCER RESEARCH CONSORTIUM-PROTEOMICS CORE
Ochoa,Augusto	Private Institutions		LA Cancer Research Consortium	LCRC		LOUISIANA CANCER RESEARCH CONSORTIUM-BIOSTATISTICS CORE
Ochoa,Augusto	Private Institutions		LA Cancer Research Consortium	LCRC		LOUISIANA CANCER RESEARCH CONSORTIUM-CENTRAL SCIENTIFIC ADMINISTRATION
Ochoa,Augusto	Private Institutions		LA Cancer Research Consortium	LCRC		AN OPEN-LABEL PHASE II STUDY EVALUATING THE SAFETY AND EFFICACY OF DAILY DOSING OF PTK787/ZK
Ochoa,Augusto	Private Institutions		LA Cancer Research Consortium	LCRC		MOHAMED ABDRAHOM FELLOWSHIP AWARD - EQUIPMENT & SUPPLIES FROM THE EGYPTIAN CULTURAL &
Ochoa,Augusto	Private Institutions		LA Cancer Research Consortium	LCRC		A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI CENTER, PHASE III STUDY IN PATIENTS WITH
Ode,David L	Fed Subcontract	NIH, National Heart Lung & Blood Inst	Med College of Georgia	U01HL52193	U01HL52193	DNA DAMAGE-RESPONSE DEFECTS IN PROSTATE CANCER RISK
Olejniczak,Piotr	Business		Cyberonics	PMS-01		INTERACTION OF EBV AND HPV IN THE DEVELOPMENT OF CERVICAL DYSPLASIA IN HIV+ WOMEN
Olejniczak,Piotr	Business		NeuroPace, Inc	RNS		A STUDY TO EVALUATE METHODS FOR MEASUREMENT OF ORAL HUMAN PAPILLOMAVIRUS (HPV) INFECTION
Olejniczak,Piotr	Business		Johnson & Johnson	RWJ-333369		ARGININE AVAILABILITY, MODULATED BY MDC, REGULATES T CELL FUNCTION IN CANCER
Olejniczak,Piotr	Business		Schwarz Biosciences	SP904		PHASE 2, MULTICENTER, TWO-TIER STUDY OF IMC-A12 IN COMBINATION WITH DEPOT OCTREOTIDE
Olejniczak,Piotr	Business		Schwarz Biosciences	SP902		UNCOVERING THE MECHANISMS OF OSTEOSARCOMA METASTASIS SUPPRESSION BY MTBP

ATTACHMENT 1: LSUHSC-NO ACTIVE RESEARCH DEVELOPMENT AWARD/CONTRACT LIST

P.I. Name	Category	Primary Spnser	Direct Sponsor	Ref Awd #	Ref Awd #2	Project Title
Olejniczak,Piotr	Business		Pfizer Inc	A0081047		REPAIR OF OXIDATIVE DNA DAMAGE IN MAMMALIAN CELLS
Olejniczak,Piotr	Business		Pfizer Inc	A0081160		REPAIR OF OXIDATIVE DNA DAMAGE IN MAMMALIAN CELLS
Olejniczak,Piotr	Business		Parexel International Corp	804P301		LSUHSC Minority Based Community Clinical Oncology
Olejniczak,Piotr	Business		Parexel International Corp	804P302		LSUHSC Minority Based Community Clinical Oncology
Olejniczak,Piotr	Business		King Pharmaceuticals	King - K826-05-3001		LSUHSC Minority Based Community Clinical Oncology Program
Ouhitit,Alla	Private Institutions		Embassy Of The Arab Republic Of Egypt			Immunotherapy for RCC
Palmer,Glen	Federal		NIH, Nat Inst on Allergy & Infec Disease	1R21AI097664-01		DNA Damage-Response Defects in Prostate Cancer Risk
Pandey,Udai	Foundation		Robert Packard Center	2000950964		Mentoring Translational Researchers in Louisiana
Pandey,Udai B.	Foundation		Amyotrophic Lateral Sclerosis Assn	30RJOH		Interaction of EBV and HPV in the development of cervical dysplasia in HIV + women
Pasternak,Ryan H	Fed Subcontract	NIH, National Institute of Mental Health	University of Kentucky	3048105243-09-293	1 R01 MH083621-01	Phase III Study of Chimeric Antibody 14.18 with GM-CSF, IL-2 and Isotretinoin in High-Risk Neuroblastoma
Paul,Dennis J	Foundation		Neuropathy Association			Significance of a novel germline AR mutation in black men with prostate cancer
Peruzzi,Francesca	Federal		NIH, National Institute of Mental Health	7 R01MH079751-05		Dillard-LSUHSC Minority Health and Health Disparities Research Center - Administrative
Peruzzi,Francesca	Fed Subcontract	NIH, National Institute on Drug Abuse	Temple University Health System, Inc.	36069304400-02	1R01DA033213-01A1	Dillard-LSUHSC Minority Health and Health Disparities Research Center - Training Core
Peters,Edward S.	Fed Subcontract	NIH, National Cancer Institute	University of Southern California	H47343	1R01CA134786-01A2	Dillard-LSUHSC Minority Health and Health Disparities Research Center - Community Core
Phillippi Jr,Stephen W	Foundation		Youth Empowerment Project	Youth Empowerment Pr		Dillard-LSUHSC Minority Health and Health Disparities Research Center - Research Core
Phillips-Savoy,Amanda	Fed Subcontract	NIH, Nat Inst of Environmental Health	University of Texas, Galveston	11-088	1U19E5020676-01	Dillard-LSUHSC Minority Health and Health Disparities Research Center - Research Project 1
Pincus,Seth H	Private Institutions		Children's Hospital, Research Insitute	Ryan Craig		Dillard-LSUHSC Minority Health and Health Disparities Research Center - Research Project 2
Pociask,Derek	State		Board of Regents	LEQSF2010-13-RD-AD7		Dillard-LSUHSC Minority Health and Health Disparities Research Center - Research Project 3
Potter,Barry J	Fed Subcontract	NIH, National Heart Lung & Blood Inst	University of South Alabama	09-0802258-01	1 R01-HL093052-01	Involvement of Survivin in the Development of PML
Prakash,Om	Business		Cytrx Corporation	Cytrx Corporation		Prognostic value of AR mutation in primary African American prostate cancer
Prakash,Om	Fed Subcontract	NIH, National Institute on Drug Abuse	University of Minnesota	N647688701	5R01DA012104-12	Nuclear IRS-1-DNA repair and mutagenesis in medulloblastoma
Quayle,Alison Jane	Fed Subcontract	NIH, Nat Inst on Dental & Craniofacial	Case Western Reserve University	RES504092/RES505082A	P01 DE019759-01	Project 1: Mentoring Translational Reseachers in Louisiana
Quayle,Alison Jane	Fed Subcontract	NIH, Nat Inst on Allergy & Infec Disease	Univ of Medicine & Dentistry of NJ	UMDNJ	1R01AI081559-01A1	Project 2: Mentoring Translational Researchers in Louisiana
Quayle,Alison Jane	Fed Subcontract	NIH, Nat Inst on Allergy & Infec Disease	University of Missouri-Kansas City	C00026076-1	1R21AI087899	Project 3: Mentoring Translational Researchers in Louisiana
Quintana,Humberto	Business		Eli Lilly And Company	B4Z-MC-LYAQ		Project 4: Mentoring Translational Reseachers in Louisiana
Quintana,Humberto	Business		Pfizer Inc	050-1015		Project 5: Mentoring Translational Researchers in Louisiana
Quintana,Humberto	Business		Abbott Laboratories	M01-342/MDS PHARMA		COBRE Core1: Mentoring Translational Researchers in Louisiana
Quintana,Humberto	Business		Eli Lilly And Company	B4Z-US-LYCC		COBRE Core 2: Mentoring Translational Researchers in Louisiana
Quintana,Humberto	Business		Pfizer Inc	A0501061		COBRE Core 3: Mentoring Translational Researchers in Louisiana
Quintana,Humberto	Business		Eli Lilly And Company	B4Z-US-X022		COBRE Core4: Mentoring Translational Researchers in Louisiana
Quintana,Humberto	Business		Lexicor Medical Tech, Inc			COBRE Core 5: Mentoring Translational Researchers in Louisiana
Quintana,Humberto	Business		Abbott Laboratories	M02-555		Core 6: Mentoring Translational Researchers in Louisiana
Ramsay,Alistair J	Business		LA Gene Therapy Research Consortium Inc	GENE THERAPY FY07-08		Tier 2 Pilot Project 1: Mentoring Translational Researchers in Louisiana
Ramsay,Alistair J	State		Board of Regents	ENH-PKSFI-PRS-02		Tier 2 Pilot Project 2: Mentoring Translational Researchers in Louisiana
Ramsay,Alistair J	State		Board of Regents	ENH-PKSFI-PRS-02		Tier 2 Pilot Project 3: Mentoring Translational Researchers in Louisiana
Ramsay,Alistair J	State		Board of Regents	ENH-PKSFI-PRS-02		Mentoring Translational Reseachers in Louisiana - Del Valle
Ramsay,Alistair J	State		Board of Regents	ENH-PKSFI-PRS-02		Mentoring Translational Reseachers in Louisiana - Reiss
Ramsay,Alistair J	State		Board of Regents	ENH-PKSFI-PRS-02		Mentoring Translational Reseachers in Louisiana - Qin
Ramsay,Alistair J	State		Board of Regents	ENH-PKSFI-PRS-02		Mentoring Translational Reseachers in Louisiana - Naura
Ramsay,Alistair J	State		Board of Regents	ENH-PKSFI-PRS-02		Mentoring Translational Reseachers in Louisiana - Cameron
Ramsay,Alistair J	State		Board of Regents	ENH-PKSFI-PRS-02		Prosaoposin: A Novel Biomarker of Prostate a Cancer Progression in African Americans
Ramsay,Alistair J	State		Board of Regents	ENH-PKSFI-PRS-02		Mentoring a Cancer Genetics Program
Ramsay,Alistair J	State		Board of Regents	ENH-PKSFI-PRS-02		p66/Insulin Like Growth Factor-1 Reno-Protection in Diabetes
Ramsay,Alistair J	State		Board of Regents	ENH-PKSFI-PRS-02		Mechanisms involved in HIV-1 Tat mediated neuronal damage
Ramsay,Alistair J	Federal		NIH, Nat Inst on Allergy & Infec Disease	NIAID -A1058810-0652		Molecular Basis of DNA Repair and Protection from Apoptosis in Neuronal Progenitors Exposed to Space
Ramsay,Alistair J	Institution				Cost Share	Preclinical Evaluation of Bafetinib for the Treatment of Glioblastoma Multiforme
Rao,Jayaraman	Fed Subcontract	NIH, Nat Inst of Neurological Disorders	Columbia University	R01NS34796	R01NS34796	Roles of DFF and PARP-1 in colon carcinogenesis
Reisin,Efrain	Business		Amgen, Inc	20010125		Participation of PARP-1 in the Pathogenesis of Asthma
Reisin,Efrain	Business		Pharmanet, Inc.	KRM-307		Arginase Production in Cancer: Evading Immune Response
Reisin,Efrain	Business		FibroGen	FDG-3019		Chemotherapy resistance in Acute Lymphocytic Leukemia: The role of Hedgehop pathway signaling
Reisin,Efrain	Business		Luitpold Pharm	1VIT090030		Regulation of VCAM-1 Expression by DNA-PK and Its Implication in Atherosclerosis
Reisin,Efrain	Business	Eli Lilly And Company	Icon Clinical Research, Inc.	H9V-MC-GFRF	H9V-MC-GFRF	Role of Epigenetics in Glutamate Transporter EAAT2 Regulation in Neuroaids
Reisin,Efrain	Business		KERYX BIOPHARMA	KRX-0502-304		Role of Bin1 in Cancer Chemosensitization
Reisin,Efrain	Business		Reata Pharmaceuticals, Inc	RTA 402-C-0903		Opioid Abuse, Opportunistic Infection and NeuroAIDS
Reiss,Krzysztof	Federal		NIH, National Cancer Institute	7 R01CA095518-08		Comprehensive Minority and Health Disparities Research Center - Community Engagement Core
Reiss,Krzysztof	Fed Subcontract	NIH, Nat Inst Diabetes & Diges & Kidney	Alton Ochsner Medical Foundation	R01DK073793-04	R01DK073793-04	Uncovering the Mechanisms of Osteosarcoma Metastasis Suppression by MTBP
Reiss,Krzysztof	Fed Subcontract	National Aeronautics & Space Administrat	Emory University	S496274	NNX088A08G	Notch-1 in T Cells: A Central Mediator of Tumor induced Energy
Richter,Erich O.	Private Institutions		St. Jude Medical	ADV NEUROMODULATION		LOUISIANA CANCER RESEARCH CONSORTIUM-ZEA START UP
Richter,Erich O.	Private Institutions		St. Jude Medical	ADV NEUROMODULATION		LOUISIANA CANCER RESEARCH CONSORTIUM-KOOCHKEKPOUR START UP
Richter,Erich O.	Foundation		Joe W & Dorothy Dorsett Brown Foundation	PRH09-209		LOUISIANA CANCER RESEARCH CONSORTIUM-SAKAMURO LIU START UP
Richter,Erich O.	Private Institutions		St. Jude Medical	C-09-04		LOUISIANA CANCER RESEARCH CONSORTIUM-OUHITIT START UP
Richter,Erich O.	Private Institutions		St. Jude Medical	C-10-05		LOUISIANA CANCER RESEARCH CONSORTIUM-IMMUNOLOGY CORE
Richter,Erich O.	Private Institutions		St. Jude Medical	C-11-04		LOUISIANA CANCER RESEARCH CONSORTIUM-RECRUITING
Richter,Erich O.	Private Institutions		St. Jude Medical	C-11-04		LOUISIANA CANCER RESEARCH CONSORTIUM-IWAKUMA SEED FUNDS - MULTIPOTENTIAL STROMAL CELLS
Robertson,Nancy	Business		Cook Imaging	IOX-C1001C-88		LOUISIANA CANCER RESEARCH CONSORTIUM-WANGUO LIU START UP
Rodriguez,Paulo Cesar	Federal		NIH, National Cancer Institute	NCI -1R21CA162133-01		LOUISIANA CANCER RESEARCH CONSORTIUM-OCHOA-CLINICAL CORE
Sakamuro,Daitoku	Federal		NIH, National Cancer Institute	1R01CA140379-01A1		LOUISIANA CANCER RESEARCH CONSORTIUM - "PARP-1, DFF AND GENOMIC INSTABILITY IN COLON CANCER
Sakauye,Kenneth M	Business		Fujisawa Health Care Inc	03-0-189		LCRC- Startup Package- Dr. Paulo Rodriguez
Salinas,Thomas J	Business		Steri-Oss	LSU-196		LCRC Startup Package- Dr. Zabaleta
Schwarzenberger,Paul	Foundation		Janssen Pharmaceutica Research Found	KW-USA-4		LCRC STARTUP PACKAGE -DR. LIN
Schwarzenberger,Paul	Business		British Biotech Pharmaceuticals Ltd.	C03-173-20		LCRC STARTUP- DR. DEL VALLE
Schwarzenberger,Paul	Business		British Biotech Pharmaceuticals Ltd.	C03-173-20		LCRC START UP FUNDS- DR. REISS
Scribner,Richard A	Fed Subcontract	HHS, Health Resources & Service Admin	Tulane University	R40MC001296	R40MC00296	LOUISIANA CANCER RESEARCH CONSORTIUM- DR. PERUZZI'S STARTUP FUNDING
Scribner,Richard A	Federal		NIH, National Inst. on Alcohol Abuse	1R01AA015855-01		LOUISIANA CANCER RESEARCH CONSORTIUM - DR. PRAKASH'S STARTUP FUNDING.

ATTACHMENT 1: LSUHSC-NO ACTIVE RESEARCH DEVELOPMENT AWARD/CONTRACT LIST

P.I. Name	Category	Primary Spnsr	Direct Sponsor	Ref Awd #	Ref Awd #2	Project Title
Scribner, Richard A	Federal		NIH, National Inst. on Alcohol Abuse	1RC1AA019329-01		LOUISIANA CANCER RESEARCH CONSORTIUM- DR. BOULARES STARTUP FUNDING
Scribner, Richard A	Federal		NIH, National Cancer Institute	1R01CA157565-01		LOUISIANA CANCER RESEARCH CONSORTIUM- COST SHARING- MBCCOP NIH GRANT (PS# 149740201A)
Scribner, Richard A	Fed Subcontract	NIH, Nat Inst of Environmental Health	Tulane University	TUL-HSC-332-11/12	1R01ES020447-01	LOUISIANA CANCER RESEARCH CONSORTIUM- STARTUP FUNDS- DR. RESKE
Sheets, Kristopher	Federal		NIH, National Eye Institute	1 F31EY020115-01		PROTEOMIC ANALYSIS OF NICOTINIC RECEPTOR COMPLEXES ACTIVATED BY NICOTINE IN TOBACCO SMOKE
Sheets, Kristopher	Federal		NIH, National Eye Institute	1 F31EY020115-01		SCALING OF VESICULAR GLUTAMATE AND GABA STORAGE IN NEOCORTICAL SYNAPSES
Sheline, Christian T.	Federal		NIH, Nat Inst Diabetes & Diges & Kidney	7 R01 DK073446-04		ENDOCANNABINOIDS IN COX-2-MEDIATED SYNAPTIC MODIFICATION AND NEUROTOXICITY
Shellito, Judd E	Fed Subcontract	NIH, National Heart Lung & Blood Inst	Tulane University	1P01HL075161-01	P01HL075161	MENTORING NEUROSCIENCE IN LOUISIANA: A BIOMEDICAL PROGRAM TO ENHANCE NEUROSCIENCE - BAZAN
Shellito, Judd E	Business		Cytheris Inc	CYT107		MENTORING NEUROSCIENCE IN LOUISIANA: A BIOMEDICAL PROGRAM TO ENHANCE NEUROSCIENCE - FARRIS
Shellito, Judd E	Federal		NIH, National Heart Lung & Blood Inst	2P01HL076100-07A1		MENTORING NEUROSCIENCE IN LOUISIANA: A BIOMEDICAL PROGRAM TO ENHANCE NEUROSCIENCE -
Shellito, Judd E	Federal		NIH, National Heart Lung & Blood Inst	2P01HL076100-07A1		MENTORING NEUROSCIENCE IN LOUISIANA: A BIOMEDICAL PROGRAM TO ENHANCE NEUROSCIENCE -
Shellito, Judd E	Federal		NIH, National Heart Lung & Blood Inst	2P01HL076100-07A1		MENTORING NEUROSCIENCE IN LOUISIANA: A BIOMEDICAL PROGRAM TO ENHANCE NEUROSCIENCE - XIA
Shellito, Judd E	Federal		NIH, National Heart Lung & Blood Inst	2P01HL076100-07A1		MENTORING NEUROSCIENCE IN LOUISIANA: A BIOMEDICAL PROGRAM TO ENHANCE NEUROSCIENCE -
Shellito, Judd E	Federal		NIH, National Heart Lung & Blood Inst	2P01HL076100-07A1		MENTORING NEUROSCIENCE IN LOUISIANA: A BIOMEDICAL PROGRAM TO ENHANCE NEUROSCIENCE -
Shellito, Judd E	Federal		NIH, National Heart Lung & Blood Inst	2P01HL076100-07A1		MENTORING NEUROSCIENCE IN LOUISIANA: A BIOMEDICAL PROGRAM TO ENHANCE NEUROSCIENCE - CELL
Shen, Li	Federal		NIH, Nat Inst on Allergy & Infec Disease	7R01AI055869-05		MENTORING NEUROSCIENCE IN LOUISIANA: A BIOMEDICAL PROGRAM TO ENHANCE NEUROSCIENCE -
Shen, Li	Federal		NIH, Nat Inst on Allergy & Infec Disease	3R01AI055869-06S1		MENTORING NEUROSCIENCE IN LOUISIANA: A BIOMEDICAL PROGRAM TO ENHANCE NEUROSCIENCE -
Sibley, Deborah H.L.	Fed Subcontract	NIH, Nat Library Of Medicine	Houston Academy of Medicine	Houston Academy	HHSN276201100007C	NEURABIN AND INHIBITOR-1 COMPETE FOR PP1 BINDING IN LTD AND LTP EXPRESSION
Siddoway, Benjamin	Foundation		Ataxia telangiectasia Children's Project	AT Children's Projec		CRCNs: PHASE RESETTING PREDICTS SYNCHRONIZATION IN HYBRID HIPPOCAMPAL CIRCUITS
Siggins, Robert	Federal		NIH, National Inst. on Alcohol Abuse	1K99AA020312-01		NEUROPROTECTIN D1 SLOWS PHOTORECEPTOR DEGENERATION
Simmons, David Earl	Business		Zimmer Dental, Inc	10014		THE ROLE OF THE RAS HOMOLOG RHES IN DOPAMINE RECEPTOR SIGNALING
Simmons, David Earl	Business		Astra Zenca Pharmaceuticals	D2009-069		DAPK1 REGULATION OF NMDA RECEPTORS IN ISCHEMIC NEURONAL DEATH
Simmons, David Earl	Business		Nobel Biocare	Nobel Biocare		DAPK1 REGULATION OF NMDA RECEPTORS IN ISCHEMIC NEURONAL DEATH
Simonsen, Neal	Fed Subcontract	NIH, National Cancer Institute	Duke University	203-0311	1R01Ca142081-01A1	RNA EDITING OF AMPA RECEPTOR SUBUNIT GLUR2 IN ISCHEMIA
Soltani, Zohreh	Private Institutions		Brigham & Womens Hsp	SAVOR-TIMI 53		Intrinsic Currents Modulate Synaptic Integration in Dopamine Neurons
Sorensen, Ricardo U	Private Institutions		Children's Hospital, Research Institute			TYPE-1 DIABETES: ZN2+ POTENTIATED BETA-CELL DEATH BY SIRTUIN-MEDIATED NAD+ LOSS
Sorensen, Ricardo U	Private Institutions		Children's Hospital			DISTINCT ROLE OF NEURABIN AND SPINOPHILIN IN SYNAPTIC TRANSMISSION AND PLASTICITY
Sothorn, Melinda S	Federal		NIH, Nat Inst Child Health & Human Dev	1R01HD049046-01		REGULATION OF NEUROPROTECTIVE LIPID SIGNALS BY SPATIALLY DISTINCT NMDA RECEPTORS
Sothorn, Melinda S	Fed Subcontract	NIH, Nat Inst Diabetes & Diges & Kidney	Pennington Medical Foundation	Pennington	1RC1DK086881-01	REGULATION OF NEUROPROTECTIVE LIPID SIGNALS BY SPATIALLY DISTINCT NMDA RECEPTORS-
Souza, Flavia	Federal		NIH, National Inst. on Alcohol Abuse	1F32AA021049-01A1		LIPID MEDIATORS IN CORNEAL NERVE REGENERATION
Souza, Flavia	Federal		NIH, National Inst. on Alcohol Abuse	1F32AA021049-01A1		Lipid Mediators in Corneal Nerve Regeneration
Stark, David Thomas	Federal		NIH, Nat Inst of Neurological Disorders	1F30NS063630-01		The Capacity to Synthesize NPD1 is Reduced in Aged Brains
Stark, David Thomas	Federal		NIH, Nat Inst of Neurological Disorders	1F30NS063630-01		CORNEAL LIPID METABOLISM AND RESPONSE TO INFLAMMATION
Steeb, Glen	Business		Lifecell Corporation	LFC2007.03.01		Characterization of microRNAs expressed in developing songbird brain
Sulzer, Jesse	Federal		NIH, National Inst. on Alcohol Abuse	1F30AA019587-01A1		RPE MESSENGERS, TRANSCRIPTION & PHOTORECEPTOR RENEWAL
Summer, Warren Richard	Fed Subcontract	NIH, National Heart Lung & Blood Inst	University of Texas Houston, Hsc	GALLH232	NO1HC35130	Micro RNA-mediated neurotrophic & synaptic networks in alzheimer's disease
Summer, Warren Richard	Business		Quintiles Pacific Inc.	XRP15268-325		Mechanism of action of omega-3 fatty acids in brain injury
Summer, Warren Richard	Business		Aventis Pharmaceuticals Inc	XRP4583C-3501		CRCNs: Analysis of Synchronization in Hybrid Neural Circuits
Summer, Warren Richard	Foundation		American Lung Association	CP-98-020 (LOCS)		CRCNs: Analysis of synchronization in hybrid neural circuits
Summer, Warren Richard	Business		C.R. Bard Inc.	5003A		Dendritic Integration in the Entorhinal Cortex
Summer, Warren Richard	Business		Astra Zenca Pharmaceuticals	DD-039-0726		The Role of Neuroprotectin D1 in Choroidal Neovascularization
Summer, Warren Richard	Business		Astra Zenca Pharmaceuticals	D-5896C00005		The Role of Neuroprotectin D1 in Choroidal Neovascularization
Summer, Warren Richard	Business		Boehringer Ingelheim Pharmaceuticals	205.294.23		NPD1 promotes survival signaling in the Ccl2-/-/Cx3cr1-/- mouse AMD model
Summer, Warren Richard	Business		Genetech Inc.	Protocol Q2948g		Neuroprotectins and Maresins for Macrophages in Diabetic Wound Healing
Summer, Warren Richard	Business		Boehringer Ingelheim Pharmaceuticals	1012.56		Neuroprotectins and Maresins for Macrophages in Diabetic Wound Healing
Summer, Warren Richard	Business		Novartis Pharmaceuticals Corporation	QAB149B23355		The Role of Highwire/DFsn Ubiquitination Complex During Synaptic Development
Summer, Warren Richard	Business		Novo Nordisk Inc	NN1998-1616		Neuroprotection Lipid Signaling in Ischemia Reperfusion
Summer, Austin J	Business		Synergen, Inc.	PROTOCOL 0604		Neuroprotection by Docosahexaenoic Acid-Albumin in Experimental Stroke
Tang, Yaping	Federal		NIH, National Institute of Mental Health	4R33MH083530-03		Neuroprotection by Docosahexaenoic Acid-Albumin in Experimental Stroke
Tang, Yaping	Foundation		American Heart Association	11GRNT7990049		MAGL Inhibition in Prevention and Treatment of Alzheimer's Disease
Taylor, Stephanie N	Business		Presutti Lab	T-500		MAGL Inhibition in Prevention and Treatment of Alzheimer's Disease
Taylor, Stephanie N	Business		Becton Dickinson Corp	05C1-001-QXVSP-LSU		Neuroprotective bioactivity of neuroprotectin-D1 with nanoparticle-enhanced delivery in experimental retinal
Taylor, Stephanie N	Business		Genzyme	CANDID00205		The Capacity to Synthesize NPD1 is Reduced in Aged Brains
Taylor, Stephanie N	Business		Becton Dickinson Corp	07C1-004-VSPQX-LSU		The Capacity to Synthesize NPD1 is Reduced in Aged Brains
Taylor, Stephanie N	Business		Becton Dickinson Corp	6918		Micro RNA-146a (miRNA-146a) signaling in Alzheimers disease (AD)
Taylor, Stephanie N	Fed Subcontract	NIH, Nat Inst on Allergy & Infec Disease	University of Alabama	NO1-AI40073	HHSN266200400073C	Roles of miRNAs in Regulation of Foxp2 and in Autism
Taylor, Stephanie N	Business		Roche Palo Alto	Roche - COB-CTNG-187		Regulation of normal and leber congenital amaurosis-associated RPE65s
Taylor, Stephanie N	Business		Warner Chilcott	PR04809		RPE Messengers, Transcription and Photoreceptor Renewal
Taylor, Stephanie N	Business		Becton Dickinson Corp	MDX-10-VVAGSC		Addressing Neurological Dysfunction in Ataxia Telangiectasia: Investigation into Novel, physiologic ATM
Taylor, Stephanie N	Business		Gen Probe Incorporated	ACTPS-US10-001		Endocannabinoids in Neurodegenerative Diseases
Taylor, Stephanie N	Business		Cepheid	140		GENE THERAPY RESEARCH CONSORTIUM-VECTOR CORE
Taylor, Stephanie N	Business		Cepheid	73B		CENTER OF EXCELLENCE FOR VACCINE DEVELOPMENT
Taylor, Stephanie N	Business		Gen Probe Incorporated	ATVPS-US11-001		CENTER OF EXCELLENCE FOR VACCINE DEVELOPMENT-TULANE
Taylor, Stephanie N	Business		Becton Dickinson Corp	MDX-10-GSAMACQ		CENTER OF EXCELLENCE FOR VACCINE DEVELOPMENT - XAVIER
Taylor, Stephanie N	Business		Becton Dickinson Corp	MDX-11-VXTRTV		CENTER OF EXCELLENCE FOR VACCINE DEVELOPMENT - CRI
Taylor, Stephanie N	Business		Hologic, Inc	CSP-00029		CENTER OF EXCELLENCE FOR VACCINE DEVELOPMENT-ADMIN
Tejedor, Richard	Business		Actellon	AC-060A202		CENTER OF EXCELLENCE FOR VACCINE DEVELOPMENT - EDUCATION
Tejedor, Richard S.	Business		Boston Scientific Corp	10-02		CENTER OF EXCELLENCE FOR VACCINE DEVELOPMENT - ESIP
Tender, Gabriel	Business		NuVasive, Inc.	NuVasive, Inc		CENTER OF EXCELLENCE FOR VACCINE DEVELOPMENT-BSL-3 CORE
Thompson, Hilary W	State		LSU, Baton Rouge	R110117		CENTER OF EXCELLENCE FOR VACCINE DEVELOPMENT-WELSH
Thompson, Hilary W	Fed Subcontract	NIH, National Ctr for Research Resourc	LSU, Baton Rouge	51747	2P20RR016456-09	CENTER OF EXCELLENCE FOR VACCINE DEVELOPMENT
Thompson, Hilary W	Fed Subcontract	NIH, National Ctr for Research Resourc	LSU, Baton Rouge	51747	2P20RR016456-09	CENTER OF EXCELLENCE FOR VACCINE DEVELOPMENT
Thompson, Hilary W	Fed Subcontract	NIH, National Ctr for Research Resourc	LSU, Baton Rouge	51747	2P20RR016456-09	MECHANISMS OF PROTECTIVE IMMUNITY INDUCED BY LIVE ATTENUATED SIV VACCINES
Thompson, Hilary W	Institution				Cost Share	CFTR EXPRESSION AND FUNCTION IN HUMAN NEUTROPHILS
Tilton, Ann C Henderson	Business		Allergan Inc	191622-021		GM-CSF-ADJUVANTED CLADE C DNA/MVA & MVA/MVA VACCINES

ATTACHMENT 1: LSUHSC-NO ACTIVE RESEARCH DEVELOPMENT AWARD/CONTRACT LIST

P.I. Name	Category	Primary Spnsr	Direct Sponsor	Ref Awd #	Ref Awd #2	Project Title
Tilton,Ann C Henderson	Business		Allergan Inc			DIGIT REGENERATION IN MAMMALS
Townsend,Mark H	Business		Astra Zenca Pharmaceuticals	D3690C00011		Oral Vaccination for AIDS Prevention in Rhesus Monkeys
Townsend,Mark H	Business		Ortho Pharmaceutical Corp	R092670-SCH-3006		Immunization of Oral Mucosa for Induction of Rectal and Genital Mucosal Immunity
Trapido,Edward	Federal		NIH, Nat Inst of Environmental Health	1 R21ES020061-01		Vaccination strategies against pulmonary tuberculosis
Trapido,Edward	Federal		NIH, Nat Inst of Environmental Health	1 R21ES020061-01		Arthritis Management for Primary Care 2012
Trapido,Edward J.	Federal		NIH, Nat Inst of Environmental Health	1U01ES021497-01		RECOMBIVAX HB IN HEALTHY SUBJECTS BETWEEN 16 AND 35.
Trapido,Edward J.	Federal		NIH, Nat Inst of Environmental Health	1U01ES021497-01		PEGASYS WITH RIBAVIRIN FOR CHRONIC HEPATITIS
Tuckler,Victor	Business		The Medicines Company	PRONTO-TMC-CLV-08-01		IMMUNOGENICITY OF PROCESS UPGRADE VARICELLA VACCINE
Tuckler,Victor	Business		PPD Development	TMC-ORI-10-01		PRIORIX WITH R-II VACCINE ADMINISTERED TO HEALTHY CHILDREN
Turkewitz,Lanny J	Business		UCB Pharma	IND 67,741		FROZEN MMRV GIVEN CONCOMITANTLY VE NON IN HEALTHY CHILDREN
Uwaifo,Gabriel	Business		Tolerx, Inc	TRX-DM018-US-10		PEGASYS VS W/RIBAVIRIN FOR PATIENTS WITH CHRONIC HEPATITIS
Uwaifo,Gabriel I.	Business		MannKind Corporation	MKC-TI-171		LOT-CONSISTENCY AND BRIDGE STUDY OF HCP 20/20/5/3DT-MIPV/PPR-T (PENTACEL) IN
Uwaifo,Gabriel I.	Business		MannKind Corporation	MKC-TI-175		PRE-BOOSTER CONCENTRATION OF ANTI-PRP ANTIBODIES IN SERUM SAMPLES OBTAINED FROM TODDLERS
Uwaifo,Gabriel I.	Business		Boehringer Ingelheim Pharmaceuticals	1245.25		A COMPARISON OF THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF M-M-R II MANUFACTURED FROM
Vander Heide,Richard S.	Federal		NIH, National Heart Lung & Blood Inst	7R01HL084405-04		Models of Prenatal Care and Perinatal Health Indicators in Disaster Recovery Area
Vander Heide,Richard S.	Federal		NIH, National Heart Lung & Blood Inst	1R21HL098786-01		Pennington Biomed. Research Ce
Vedeckis,Wayne V	Federal		NIH, National Cancer Institute	1R01CA116042-01		CMS Nonpayment for Nosocomial Injury and Risk of Falls in Hospitals
Vedeckis,Wayne V	Private Institutions		University of Pittsburgh	0031480		IDEA NETWORKS OF BIOMEDICAL RESEARCH EXCELLENCE (INBRE)
Vedeckis,Wayne V	Fed Subcontract	NIH, National Heart Lung & Blood Inst	University of Pittsburgh	5R01HL061271-14	5R01HL061271-14	IDEA NETWORKS OF BIOMEDICAL RESEARCH EXCELLENCE (INBRE)
Vedeckis,Wayne V	Private Institutions		University of Pittsburgh	0032257		IDEA NETWORKS OF BIOMEDICAL RESEARCH EXCELLENCE (INBRE) - Hill
Veith,Robert W	Business		Novartis Pharmaceuticals Corporation	STI 106 752		Data Quality Control through Nonlinear Association Analysis of Unknown Staged Cancer Cases
Veith,Robert W	Federal		NIH, National Cancer Institute	2U10CA063845-11		Recruitment of Superior Doctoral Students in Biostatistics
Veith,Robert W	Federal		NIH, National Cancer Institute	2U10CA063845-11		Louisiana Biomedical Research Network (LBRN)
Veith,Robert W	Federal		NIH, National Cancer Institute	3U10CA063845-11S1		DNA REPAIR IN HUMAN PROSTATE CANCER RISK
Venters,Charmaine L	Business		Pharmacia & Upjohn	051-00		SURVEILLANCE,EPIDEMIOLOGY & END RESULTS(SEER) EXPANSION PROGRAM
Venters,Charmaine L	Business		Merck & Co., Inc.			CHANGES IN ALCOHOL AVAILABILITY AND HIV RATES
Venters,Charmaine L	Business		Aventis Pasteur	EM501		PROVIDE TUMOR REGISTRY SERVICES TO MCLNO
Venters,Charmaine L	Business		Merck & Co., Inc.	010-00		PROVIDE TUMOR REGISTRY SERVICES TO MCLNO
Vijayagopal,Parakat	Business		Pfizer Inc	158809		PROVIDE TUMOR REGISTRY SERVICES TO MCLNO
Wainford,Richard D.	Foundation		American Heart Association	09BGIA2250585		PROVIDE TUMOR REGISTRY SERVICES TO MCLNO
Wainford,Richard D.	Federal		NIH, National Heart Lung & Blood Inst	1R01HL107330-01		NATIONAL COMPREHENSIVE CANCER CONTROL PROGRAM - BREAST & CERVICAL CANCER-EARLY DETECTION -
Walton,Lisa	Fed Subcontract	NIH, National Inst. on Alcohol Abuse	University of Pittsburgh	Univ of Pittsburgh	R01 AA016688	NATIONAL COMPREHENSIVE CANCER CONTROL PROGRAM - BREAST & CERVICAL CANCER-EARLY DETECTION -
Wang,Guoshun	Foundation		Acres	2010-11-05		NATIONAL COMPREHENSIVE CANCER CONTROL PROGRAM - BREAST & CERVICAL CANCER-EARLY DETECTION -
Wang,Guoshun	Business		Vertex Pharmaceutica	Vertex Pharmaceutica		NATIONAL COMPREHENSIVE CANCER CONTROL PROGRAM - BREAST & CERVICAL CANCER-EARLY DETECTION-
Wang,Guoshun	Foundation		Acres	Acres		NCCDPPH - BREAST & CERVICAL CANCER-EARLY DETECTION-COLORECTAL
Wang,Guoshun	Foundation		Acres	2011-12-06		NATIONAL COMPREHENSIVE CANCER CONTROL PROGRAM - NAT'L BREAST & CERVICAL CANCER-EARLY
Wang,Guoshun	Federal		NIH, Nat Inst on Allergy & Infec Disease	1R01AI072327-01		INCIDENCE PATTERNS OF PRIMARY EXTRANODAL NON-HODGKIN LYMPHOMA BY SITE AND HISTOLOGY
Washington,Amber	Federal		NIH, National Cancer Institute	1F31CA150442-01		Comparing the Effectiveness of City Policy and Structure in Health Disparities
Washington,Amber	Federal		NIH, National Cancer Institute	1F31CA150442-01		Validation of PROMIS in Diverse Cancer Populations
Wen,Zezhang	Federal		NIH, Nat Inst on Dental & Craniofacial	NIDCR-DE019452-01A2		SURVEILLANCE,EPIDEMIOLOGY & END RESULTS(SEER) EXPANSION PROGRAM
Whim,Matthew D.	Federal		NIH, Nat Inst Diabetes & Diges & Kidney	NIDDKD-DK080441-02		SURVEILLANCE, EPIDEMIOLOGY & END RESULTS(SEER) EXPANSION PROGRAM (Patterns of Care/Quality of
Whitaker,Annie	Foundation		American Physiological Society	APS		Epidemiology of Ovarian Cancer in African-American Women
White,Jeffrey Thomas	Federal		NIH, Nat Inst Diabetes & Diges & Kidney	1F30DK082121-01		Comparative Effectiveness of Treatment for Localized Prostate Cancer
Wilcox,Ronald Dean	Business		Pfizer Inc	A4001067		Comparative Effectiveness of Treatment for Localized Prostate Cancer
Williams,Donna L	Foundation		Susan G Komen Breast Cancer Found	Susan G. Komen		Health Effects of MC252 Gulf Incident
Williams,Donna L	Federal		HHS, Ctr for Disease Control & Preventio	1U55DP003042-01		Health Effects of MC252 Gulf Incident
Williams,Donna L	Institution				Cost Share	A Genome Wide Admixture Scan of Multiple Myeloma in African Americans
Williams,Karen Renee	Business		GlaxoSmithkline Pharmaceuticals	209762/136		Enhancing Cancer Registry Data Comparative Effectiveness Research
Williams,Karen Renee	Business		Aventis Pasteur	M5A03		Validation of Promis in Diverse Cancer: Populations
Wilson,Philip G	Institution				Cost Share	Breast Center at the Interim LSU Public Hospital
Wilson,Philip G	Institution				Cost Share	The Women and [Their] Children's Gulf Health Consortium
Winsauer,Peter J	Federal		NIH, National Institute on Drug Abuse	1R01DA019625-01		The Women and [Their] Children's Gulf Health Consortium
Winsauer,Peter J	Institution				Cost Share	Community Influences on NHANES Diet and Physical Activity
Wojcik,Edward J.	Federal		NIH, National Inst of General Med Sci	7R01GM066328-02		Enhancing Cancer Registries for Early Case Capture of Pediatric and Young Adult
Wojcik,Edward J.	Institution				Cost Share	Telomere Length as a Biological Marker of Allostatic Load in Children
Woltering,Eugene A	Business		Novartis Pharmaceuticals Corporation			Norman F. Grant/American Board of Obstetrics and Gynecology
Woltering,Eugene A	Fed Subcontract	NIH, Complementary & Alternative Medicin	Pennington Biomedical Research Center	S12-50318	P50AT002776-07	Quality of Life in Prostate Cancer Project
Worrel,Mary	Federal		NIH, National Inst. on Alcohol Abuse	1F30AA019848-01		Chronic Disease Standford Management Program
Worrel,Mary	Federal		NIH, National Inst. on Alcohol Abuse	1F30AA019848-01		Gulf Coast Children's Health Study
Worthylake,David K.	Federal		NIH, National Inst of General Med Sci	1R01GM084072-01A2		MECHANISMS FOR THE METABOLIC SYNDROME IN PREPUBERTAL AF*
Worthylake,Rebecca A.	Federal		NIH, Nat Inst on Dental & Craniofacial	1R03DE019166-01A1		Anthropometric Assessment of Abdominal Obesity and Helath Risk in Children and Adolescents
Worthylake,Rebecca A.	Federal		NIH, Nat Inst on Dental & Craniofacial	3 R03DE019166-01A1S1		Demonstrating the Capacity of Comprehensive Cancer Control Programs to Implement
Wu,Chunlai	Federal		NIH, Nat Inst of Neurological Disorders	1R01NS070962-01		Tides Foundation Award
Wu,Xiao Cheng	Private Institutions		NAACCR-CSCP	NAACCR		410130128 BIOCH-C/S 110150066A
Wu,Xiao Cheng	Fed Subcontract	NIH, Inst Arthritis and Musculoskeletal	Georgetown University	RX 4442-007-LSUHSC	U01AR057971-01	405030126 REHAB-C/S 105500008A
Wu,Xiao Cheng	Fed Subcontract	HHS, Agency Healthcare Research & Quali	Vanderbilt University	VUMC37044	ARRA: 1R01HS019356	449880126 G/T-C/S 149752505A
Wu,Xiao Cheng	Fed Subcontract	HHS, Agency Healthcare Research & Quali	Vanderbilt University	VUMC37044	ARRA: 1R01HS019356	EPIDEMIOLOGY-C/S 158070035C
Wu,Xiao Cheng	Fed Subcontract	NIH, Inst Arthritis and Musculoskeletal	Georgetown University	RX 4442-014-LSUHSC	U01AR057971-02S1	449640128 MED-C/S 149200820A
Xia,Houhui	Federal		National Science Foundation	NSF IOS-0824393		410170146 MICRO-C/S 110250089A
Xia,Houhui	Federal		NIH, Nat Inst of Neurological Disorders	1 R01 NS060879-01A2		HDC-COST SHARE 105200103A
Xu,Xiaoming	Foundation		Joe W & Dorothy Dorsett Brown Foundation			HDC-COST SHARE 105200089A
Xu,Xiaoming	Foundation		Joe W & Dorothy Dorsett Brown Foundation			PHYSIO-COST SHARE 110350068A
Xu,Xiaoming	Federal		NIH, Nat Inst on Dental & Craniofacial	1 R01 DE019203-01A1		HDC-COST SHARE 105200124A
Yu,Lolie Chua	Fed Subcontract	NIH, National Cancer Institute	Ntl Childhood Cancer Foundation	98543-1226	U10CA98543	BIOSTAT-COST SHARE 158050013A

ATTACHMENT 1: LSUHSC-NO ACTIVE RESEARCH DEVELOPMENT AWARD/CONTRACT LIST

P.I. Name	Category	Primary Spnser	Direct Sponsor	Ref Awd #	Ref Awd #2	Project Title
Yu,Lolie Chua	Fed Subcontract	NIH, National Cancer Institute	Ntl Childhood Cancer Foundation	ANBL0931	3U10CA098543-07S1	BIOCHEM-COST SHARE 110150076A
Yu,Qingzhao	Private Institutions		NAACCR-CSCP	#2011-06-01 NAACCR		BIOCHEM-COST SHARE 110150084A
Yue,Xinping	Federal		NIH, National Heart Lung & Blood Inst	NHLBI -7R21HL095865-		PHARM-COST SHARE 110300064A
Yukna, Raymond A	Business		Ibah Inc.	SEPTODONT		PHARM-COST SHARE 110300118B
Yukna, Raymond A	Business		Caramed Corporation			PHARM-COST SHARE 110300118C
Yukna, Raymond A	Business		Biolok International			EPIDEMIOLOGY-C/S 158070060A
Yukna, Raymond A	Business		Sulzer Dental			COMM&BEHAV HLTH-C/S 158130022A
Zea,Arnold	Fed Subcontract	NIH, National Cancer Institute	Dartmouth University	DARTMOUTH UNIVERSITY	R01CA095648	O D & R-COST SHARE 122500007A
Zhang, Ping	Federal		NIH, National Inst. on Alcohol Abuse	1R01AA019676-01		449900109 N/C-TRANSL RES-CUI
Zieske, Arthur W	Federal		NIH, National Heart Lung & Blood Inst	2R24HL060808-10		449900110 N/C-TRIEM-H BAZAN

ATTACHMENT 2: LSUHSC-NO ORGANIZATIONAL CHART

